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Secretory mucin MUC5AC in gastrointestinal malignancies
Shiv Ram Krishn, Ph.D.
University of Nebraska, 2016
Advisor: Dr. Surinder K Batra, Ph.D.
Secretory mucin MUC5AC is an extensively glycosylated high molecular weight protein that
forms a polymeric gel layer over the epithelial layers under physiological conditions to protect
these surfaces from myriad of insults. MUC5AC is known to be implicated in various
malignancies including pancreatic cancer and colorectal cancer. It is overexpressed in pancreatic
cancer compared to no expression in the normal pancreas. However, its functional implications
and associated mechanistic basis in pancreatic cancer remain obscure. Therefore, we investigated
the role of MUC5AC in initiation and progression of pancreatic cancer. Our study showed that
MUC5AC expression is elevated during pancreatic cancer progression while it was not detected
in the normal pancreas. To elucidate the functional role of MUC5AC in pancreatic cancer, we
performed MUC5AC knockdown studies in pancreatic cancer cell lines (FG/COLO357,
SW1990). Knockdown of MUC5AC decreased pancreatic cancer cell viability, tumorigenicity,
metastasis, angiogenesis, and increased sensitivity to Gemcitabine. We observed that MUC5AC
might impact pancreatic cancer cell growth and metastasis by its interactions with E-Cadherin
and β-Catenin. To further elaborate the functional role of MUC5AC, we developed the KrasG12D;
Pdx1-Cre; Muc5ac-/- mouse model by crossing Muc5ac-/- mice with pancreatic cancer mice
model- KrasG12D; Pdx1-Cre mice. A delay in the onset as well as the progression of pancreatic
cancer was observed in KrasG12D; Pdx1-Cre; Muc5ac-/- mice as compared to the control KrasG12D;
Pdx1-Cre mice.
Further, MUC5AC is not expressed in the normal colon, but it is de novo expressed
during early stages and further increases during progression to advanced stages of colorectal
malignancy. Despite association of increased MUC5AC levels with conventional and serrated
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neoplasia pathway of colorectal carcinogenesis, the diagnostic utility of MUC5AC for predicting
future colorectal malignancy remained unexploited. Hence, we also explored the diagnostic utility
of MUC5AC in conjunction with other differentially expressed mucins and mucin-associated
glycans to predict colorectal malignancy. The study findings revealed an improved efficacy of
combined MUC2, MUC5AC, and MUC17 expression for differentiating premalignant and/or
malignant lesions from benign polyps. Furthermore, we addressed the problem of current nonavailability of specific and sensitive markers to discriminate benign hyperplastic polyps from
sessile serrated and tubular adenomas. We identified a combinatorial panel of mucins and
glycoepitope based molecular markers (CA 19-9/MUC17/MUC5AC) that could discriminate
sessile serrated adenoma/polyps and tubular adenomas from benign hyperplastic polyps with high
sensitivity and specificity.
Overall, our studies demonstrate that MUC5AC plays a key role in onset and progression
of pancreatic cancer. Further, our findings indicate that in conjunction with other differentially
expressed mucins and associated glycans, MUC5AC may significantly improve the early stage
diagnosis of colorectal cancer.
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Chapter I

Review on MUC5AC

Secretory mucin MUC5AC: molecular analysis, functional,
diagnostic, prognostic and therapeutic implications in benign
and malignant diseases

2

1. Introduction
Mucins are a family of large glycoproteins expressed by various epithelial cell types (ducts of
lacrimal glands and eye, salivary glands, the lining of the respiratory, gastrointestinal, urothelial
and reproductive tracts) [1]. All mucins are characterized by the presence of tandem repeat
regions (TRR), with a high proportion of proline, threonine and serine residues (called PTS
sequences). Mucin genes display high levels of polymorphisms, owing to the variable number of
tandem repeats [1]. The serine and threonine residues in the TRR are extensively O-glycosylated
that is post-translationally modified, as per the distinct requirements of the epithelia [2]. Mucins
have complex biophysical properties owing to the large mass, glycosylations and high ordered
structures due to polymerization. Mucins are known to play a central role in the physicochemical
protection of the epithelial cell surfaces, configure and maintain the local microenvironment and
promote cell survival by impacting overall homeostasis in adverse physiological and pathological
conditions [2, 3]. Deregulated mucins function as an important link between inflammation and
cancer [4]. In response to external stimuli, mucins communicate signals through multiple domains
present in their structure, resulting in coordinated cellular responses that include proliferation,
differentiation, apoptosis, altered cell adhesion and secretion of specialized cellular products [5].
Also, mucin-type oligosaccharides are involved in specific ligand–receptor interactions, confer
hygroscopic properties, might bind various small molecules, proteins and provide stoichiometric
amplification owing to high degree of multivalency for oligosaccharide structures [3].
Importantly, the deregulated expression of mucins and the enzymes that modify them, differential
glycosylation, and altered localization implicate in different pathologies including various
functional properties of tumor and its microenvironment [4].
To date, 21 different mucin family members have been identified. These have both
unique and shared structural features and are classified into two subfamilies-the transmembrane
mucins and secreted mucins [1]. Transmembrane mucins (MUC1, MUC3A/B, MUC4, MUC11–

3

13, MUC15–17, MUC20, and MUC21) have hydrophobic plasma membrane spanning domain
and short cytoplasmic tails that associate with proteins in different cellular compartments to
participate in signal transduction [6]. Secreted mucins include gel-forming (MUC2, MUC5AC,
MUC5B, MUC6, and MUC19) and non-gel forming (MUC7) mucins. The gel-forming mucins
form a physical barrier as a mucous gel, providing protection to epithelial surfaces of respiratory,
gastrointestinal tracts and ducts lining organs such as liver, breast, pancreas, and kidney [7]. As a
part of defense mechanism to maintain the integrity of epithelial surfaces, secretory mucins are
considered to appear early in metazoan evolution followed by transmembrane mucins [4].
Among gel forming secretory mucins, the MUC6, MUC2, MUC5AC and MUC5B genes
evolved from duplication of an MUC11p15 ancestor [8]. For the first time, MUC5AC was
identified as a tracheobronchial mucin gene MUC5 localized to chromosome 11p15 [9, 10].
Numerous genetic clones were then described and thought to encode unique mucins MUC5A,
MUC5B, and MUC5C. However, it was subsequently demonstrated that MUC5A and MUC5C
were identical, and therefore, it was designated to be MUC5AC [11]. Since then, different studies
indicated that polymeric gel forming secretory mucin MUC5AC is expressed in conjunctiva,
middle ear, nasopharynx, lungs, gall bladder and stomach providing protection to respective
epithelial surfaces from different factors under physiological and pathological conditions (Table
1) [12, 13]. In the past decade, the aberrant expression of MUC5AC has extensively been studied
and reported in various benign pathologies (Table 2). These include otitis media [14], chronic
rhinosinusitis [15], chronic obstructive pulmonary diseases [16], Helicobacter pylori infections
[17], inflammatory bowel diseases [18] and pancreatitis [19]. Besides this, evidence from
multiple investigations has concluded that alterations in expression, synthesis and secretion of
MUC5AC may have a significant association with the pathogenesis of cancers (Table 3). These
include lung cancer (LC) [20], gastric cancer (GC) [21], pancreatic cancer (PC) [22],
cholangiocarcinoma (CCA) [23, 24] and colorectal cancer (CRC) [25]. In a quest to alleviate the
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pathological implications associated with altered expression of MUC5AC in different
pathologies, multiple investigations have focused on the elucidation of factors associated with
regulation of MUC5AC. Studies regarding the impact of different therapeutics targeting these
regulators on the expression of MUC5AC coupled with overall implications on disease
progression have also been conducted [26]. However, lack of mechanistic insights associated with
exact functions of MUC5AC remained inconclusive which have hindered the progress of
successful therapeutic interventions against these pathologies.
This Review, for the first time, provides a comprehensive and updated overview of the
genomic organization, structure, expression, regulation, and functional significance of secretory
mucin MUC5AC in physiological conditions, as well as during development and progression of
different pathologies including malignant conditions. Importantly, it highlights the diagnostic
utility and possible implications associated with direct/indirect therapeutic targeting of MUC5AC
expression in various pathologies including cancers. Overall, to develop useful therapeutic
modalities against different pathologies, a thorough understanding of the role of MUC5AC in
diverse contexts necessitates extensive investigations.
2. Genomic organization and domain structure and functions
The cloning of mucin genes and the characterization of their structure and sequence have
presented significant challenges owing to their extended regions of repeated sequence (rich in
nucleotides G and C) and the similarity of the genes [27, 28]. Polymeric gel forming secretory
mucins share a similar gene structure composed of a large central exon and flanking 5’ and 3’
regions [28]. The gel-forming mucin, MUC5AC is a huge multidomain molecule made up of
thousands of amino acid residues; heavily O-glycosylated apoprotein cores; and cysteine-rich Nand C- terminal domains that permit disulfide-bond mediated oligomerization [29]. MUC5AC
gene is located within a single 400-kb genomic DNA segment in the subtelomeric,
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recombination-rich region on chromosome 11p15.5, clustered with four other mucin genes in a
sequence MUC6-MUC2-MUC5AC-MUC5B from telomere to centromere (Figure 1.1) [30].
The

completely

annotated

MUC5AC

cDNA

sequence

(~17.5

kb)

(http://www.ncbi.nlm.nih.gov/nuccore/748983075) consists of total 49 exons. The location and
sequences of the intron-exon boundaries, intron-exon sizes, and splice junction sequences have
previously been elucidated and were recently updated [30]. The ~17.5 kb c-DNA of MUC5AC,
encodes a protein of ~5654 residues. The 5’-region of MUC5AC is composed of 30 exons that
encode cysteine-rich domains- D1, D2, D’, and D3 (similar to structural domains within von
Willebrand factor (vWF)), and a short domain corresponding to the MUC11p15-type described
by Desseyn et al. [31, 32]. The 5’-region also contains a potential 19 amino acid signal sequence
and also consists of seven potential N-glycosylation sites [33]. It has been reported that CGLC
motifs in 5’-region D-domains of MUC5AC may function in disulfide-linked multimer formation
[31]. Interestingly, the presence of a putative leucine zipper repeat pattern (between residues 273
and 300) in D1-domain of MUC5AC has also been reported. It has been speculated that leucinezipper motif may be involved in non-covalent homo-oligomerization and multimerization via the
N-termini of MUC5AC dimers [33]. Overall, N-terminus domains form inter- and intra-chain
disulfide bonds resulting in assembly of MUC5AC as multimers. Further, the large central exon
(exon 31, ~10.5 kb) in MUC5AC, encompass proline, threonine, and serine-rich tandem repeats
(PTS-TR) and cysteine-rich CysD domains. The four tandem repeat regions (PTS-TR1-TR4) in
MUC5AC consists of 24 nucleotides repeated units that translate into eight-amino acid repeats
rich in proline, threonine, and serine. Although the consensus repeat sequence- TTSTTSAP is
observed more frequently, other motifs such as GTTPSPVP are also frequently observed [31]. It
has been demonstrated that the four TR regions are interspersed by a total of nine CysD domains
recently classified as Class-I, Class-II, and Class-III domains [30]. Each of these CysD domains
contains ten cysteine residues per 110 amino acids [31]. One putative C-mannosylation consensus

6

sequence is observed in the amino-terminal region of Cys-subdomain [27]. Interestingly, it has
been demonstrated that different individuals may have an extra number of CysD domains in their
central region due to segmental duplications resulting in MUC5AC structural variants [30]. The
TR domains of secretory mucin MUC5AC are known to be heavily O-glycosylated, coupled with
variable levels of sialylation and sulfation. Glycosylation leads to conformational changes and
stiffens the mucin polypeptide resulting in increased volume and formation of the mucin gel
network within mucus. It may also impact the passage of mucin macromolecules through the
secretory pathway along with packaging within secretory granules. Mucin oligosaccharides are
highly heterogeneous. For given mucins and tissues, they vary between species, and within
species, they vary even within tissues. It has been suggested that this structural diversity may
have evolved to cope with diverse and rapidly changing pathogens and other ligands in the
external environment. Further, the 3’ region of MUC5AC is composed of 18 exons, the last one
containing the 3’-untranslated region (UTR). The C-terminus exons encode MUC11p15-type
subdomain, A3uD4 subdomain, and cysteine-rich vWF-like domains (D4, B, C, and CK) [34].
Also, it has been reported that C-terminal cysteine-rich part of MUC5AC contains a GDPH (GlyAsp-Pro-His) sequence [35]. Interestingly, it has been demonstrated that MUC5AC is cleaved in
its GDPH sequence in the endoplasmic reticulum at a neutral pH, and this process of cleavage is
accelerated by a lower pH [35]. However, the exact biological implications of this cleavage are
still obscure necessitating further investigations. Interestingly, it has been demonstrated that the
C-terminus domains play a major role in MUC5AC dimerization. Studies have also shown that Cterminal dimerization in endoplasmic reticulum precedes the N-terminal multimerization in Golgi
complex.
It is very likely that other, as-yet-undescribed functionalities reside in these domains; in
particular, these domains may be sites of interaction with other components of mucus that are
essential for barrier organization or innate defense.
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3. Expression and functions of MUC5AC
3.1 MUC5AC in physiological conditions
The secretory mucin MUC5AC is synthesized under physiological conditions by various
epithelial cell surfaces. By forming a polymeric gel, MUC5AC acts as a physicochemical barrier
against multiple environmental toxins, allergens, and infectious pathogens forming the first line
of defense [12]. In humans, expression of MUC5AC has been reported in the conjunctiva [36],
eustachian tube [37] and middle ear epithelium [38], lungs, stomach, gall bladder, and endocervix
[13]. At the ocular surface, the conjunctival goblet cell–derived secretory mucin MUC5AC acts
as a component of the tear fluid providing lubrication as well as maintaining hydration of the
epithelial surface [39]. The MUC5AC multimeric networks are assumed to trap and clean the
debris and pathogens, and to remove the material from the surface of the epithelium [36]. Further,
MUC5AC may also hold eye fluids in place and harbor defense molecules secreted by the
lacrimal gland [39]. As a major secretory mucin of the middle ear epithelium, MUC5AC plays a
major role in mucosal protection from pathogen invasion, pathogen-mediated damage and their
clearance [40]. Importantly, MUC5AC is one of the major airway mucins where it is expressed
by the goblet cells [12]. In airways, MUC5AC has been assumed to play a role in mucociliary
clearance and contribute to the innate mucosal defense system. However, to date, the exact
mechanisms behind these functions are poorly understood [12]. Further, a higher level of
MUC5AC mRNA expression was detected in the stomach at 23 weeks of gestation [41]. Also, in
adults MUC5AC remained the major gel-forming mucin consistently transcribed and expressed in
both superficial foveolar epithelium of fundic and pyloric regions of the stomach [42]. As a
component of the mucus layer covering the gastric mucosa, MUC5AC functions to protect gastric
tissues, from the hazardous gastric environment and multiple infectious agents [43, 44].
Expression of MUC5AC by endocervix epithelium has also been demonstrated, however, exact
roles it plays during the reproductive process are not known [45]. Frequent expression of
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MUC5AC has also been shown in the gallbladder [46]. Interestingly, it has been demonstrated
that MUC5AC is secreted in bile [47]. Besides all these, a moderate signal of MUC5AC mRNA
was detected in primitive intestine both on villi and in crypts at eight weeks of gestation with its
inconsistent levels after that. Further, at 12 weeks, MUC5AC mRNAs were observed in the
ileum, but not in the colon with no expression of MUC5AC detected in any region of the intestine
after 12 weeks [48]. Interestingly, MUC5AC is never detected in adult bowel unless early stages
of neoplasia develop [49]. Also, expression of MUC5AC protein had been observed early in
embryonic epidermis from day 13 of gestation until seven days after birth, when the surface
epidermis became negative, and the reaction restricts to secreting sebum cells [50].
3.2 MUC5AC in Benign pathologies
3.2.A Allergic Rhinitis
Allergic rhinitis (AR) is a chronic inflammatory upper airway disease that results from an
immunoglobulin E-mediated allergy associated with nasal inflammation. It negatively impacts
patient’s quality of life due to sneezing, rhinorrhea and stuffy nose [51]. The precise pathogenesis
of AR remains uncertain. However, it is suggested that it involves goblet cell hyperplasia, mast
cell infiltration and lymphocytes disorders [51]. One of the key features of AR is airway
inflammation and mucus hypersecretion. Weak to the diffuse expression of MUC5AC in
nasopharyngeal mucosa has previously been reported. However, MUC5AC is highly expressed
during AR, causing airway obstruction and infection [52]. Different studies have focused on
understanding the mechanisms of MUC5AC regulation that may lead to new therapies for the
treatment of aberrant mucus production in AR. It has been reported that MUC5AC upregulation
during AR may be mediated by upregulation of calcium-activated chloride channel (hCLCA1)
[53, 54], activation of p38MAPK/COX-2 [55], TNF-α and IL-6 mediated NF-κB activation [56],
upregulation of IL-17A [57], and upregulation of IL-31 and IL-31RA [58, 59]. These studies

9

provide insight into the pathophysiology and potential targets for the pharmacotherapeutic
prevention and treatment of AR.
3.2.B Chronic Rhinosinusitis
Chronic rhinosinusitis (CRS) defines a group of disorders characterized by persistent
inflammation of the sinonasal tract. It is associated with goblet cell and submucosal gland cell
hyperplasia resulting in mucus production and hypersecretion and defective mucociliary
clearance [60]. The secretory mucin MUC5AC mRNA and protein levels were observed to be
significantly increased and localized to goblet cells of the epithelium in chronic rhinosinusitis
compared with those in normal sinus mucosa [60-62]. These results suggest that up-regulation of
MUC5AC may play important roles in the pathogenesis of sinus hypersecretion in chronic
rhinosinusitis. About primary mechanisms leading to MUC5AC upregulation during CRS, the
synergism of highly upregulated TGF-α with TNF-α through ERK signaling pathway [63],
human neutrophil elastase-tumor necrosis factor-α converting enzyme (HNE-TACE) signaling
pathway [15], and IL-13 mediated goblet cell hyperplasia [64] have been demonstrated. Another
study demonstrated the utility of inhibiting calcium-activated chloride channel named
transmembrane protein 16A (TMEM16A) in chronic rhinosinusitis with nasal polyps (CRSwNP)
as it plays a significant role in increased secretion of MUC5AC during this disease [65]. Further,
Ono et al. in their study concluded that increased expression of MUC5AC could play an
important role in the pathogenesis of eosinophilic chronic rhinosinusitis (ECRS). They assumed
that persistent airway inflammation characterized by infiltrating macrophages, neutrophils, and
their promotive factors, might have an association with increased MUC5AC levels [66].
3.2.C Otitis media
Mucins are important in the mucociliary transport system of the middle ear [67] and Eustachian
tube [38]. Mucin overproduction is a hallmark of otitis media (OM). The uncontrolled, excessive
mucus contributes significantly to conductive hearing loss [14]. As a primary innate defense
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mechanism for the middle ear (ME) epithelium, the secretory mucin MUC5AC is known to play
an important role in the mucociliary clearance of bacterial pathogens [68]. Further, during periods
of inflammation and goblet cell stimulation in patients with otitis media with effusion (OME)
expression of MUC5AC is significantly increased [40]. Also, the post-transcriptionally modified
longer length of MUC5AC mucin also results in the higher viscosity of mucin, leading to
abnormal mucociliary clearance, middle ear fluid stasis and ultimately chronic disease condition
[68]. Not only the properties of post-transcriptionally modified MUC5AC deserve further study
but also the impact of this polymorphism on specific pathogen-host interactions should be
explored. Further, a thorough exploration of factors affecting MUC5AC expression will provide
opportunities to develop novel interventions for the extremely common problem of OM. In this
regard, Moon et al. identified Retinoic acid and hydrocortisone as inducers of MUC5AC and
Triiodothyronine as a suppressor of its expression [69]. Besides this, Escherichia coli
lipopolysaccharides (LPS) endotoxin has also been shown to upregulate the expression of
MUC5AC mRNA during experimental OME in the rat [70]. Further, phosphodiesterase 4B
(PDE4B) mediates ERK-dependent up-regulation of mucin MUC5AC by Streptococcus
pneumoniae by inhibiting cAMP-PKA-dependent MKP-1 pathway [71]. Also, cigarette smoke
increases the expression of MUC5AC mRNAs and proteins via EGFR pathway which plays a
major role in OME [72].
3.2.D Chronic airway diseases
Chronic airway diseases, such as asthma, cystic fibrosis (CF), and chronic obstructive pulmonary
disease (COPD) are associated with mucous cell metaplasia, resulting in mucus hypersecretory
phenotype [29]. Mucus hypersecretion involves increased expression, production, and release of
mucins [73]. Induction of mucous metaplasia acts as the first line of defense to clear the airway of
toxic substances and cellular debris [12]. However, under chronic conditions the persistent
mucous metaplasia results in obstruction of airways contributing significantly to morbidity and
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mortality. Baseline levels of gel-forming mucins MUC5AC and MUC5B in the airways are
believed to contribute to the protective barrier function, rheology of airway mucus and perform
the homeostatic roles. MUC5AC has been shown to be the goblet cell mucin and widely used as a
marker for goblet cell metaplasia [74]. It is consistently reported to be induced and upregulated
during airway inflammation in humans and animals [75]. A marked increase in MUC5AC mRNA
and protein expression has been observed in goblet cells of the bronchiolar epithelium of
asthmatic patients, and patients with COPD when compared to non-diseased airways.
Confounding reports have been published about the expression of MUC5AC in the CF sputum.
Studies indicate that MUC5AC expression is elevated in CF sputum [76], especially following
exacerbations [77]. However, some recent studies show that MUC5AC and MUC5B mucins are
present in lower concentrations in CF sputum [78] thus highlighting the challenges inherent in
analyzing CF lung sputum. Interestingly, a significant association of a 6.4-kb variable number
tandem repeat region in the MUC5AC gene has been demonstrated with the severity of CF lung
disease. This suggests that MUC5AC polymeric mucin gene may be a genetic modifier for CF
lung disease [79]. The past decade has seen significant advances in the understanding of the
pathways associated with regulation of secretory mucin MUC5AC, its production, and synthesis
in the context of airway diseases [73, 80]. These advances have partially answered the questions
regarding its role in chronic lung diseases, and benefits associated with its inhibition. By blocking
mucus in exacerbations of asthma and COPD may affect morbidity, thus necessitating a focus on
inhibition of mucus and MUC5AC in particular as a therapy for chronic airway diseases.
3.2.E Barrett’s esophagus
Barrett's esophagus (BE) is a premalignant condition consisting of mucosa with a metaplastic
columnar epithelium [81]. It is associated with gastroesophageal reflux disease (GERD) in which
acid, pepsin, and other noxious materials reach the esophageal mucosa and interacts with the
luminal aspect of the squamous epithelium [81]. The esophagus under physiological conditions
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has a protective barrier of the surface-adherent mucus gel barrier. However, expression of mucins
is substantially altered in GERD patients [82]. Among mucins, the secretory mucin MUC5AC is
absent from normal squamous epithelium, while it was ectopically expressed in 100% of Barrett’s
esophagus specimens [82]. It has been demonstrated that MUC5AC expression and secretion
during Barrett’s esophagus can be attributed to the conjugated bile acids present in the refluxate
[83]. Functionally, it is assumed that MUC5AC may play a major role in the protection of the
esophageal mucosa against potential damage caused by acids, pepsin, and bile acids present in the
refluxate. Mechanistically, conjugated bile acids transcriptionally induce MUC5AC via activation
of the PI3K–AKT–AP1 pathway [83]. Interestingly, during progression from Barrett’s epithelium
to dysplasia and adenocarcinoma, expression of MUC5AC is significantly decreased [84].
Among the two pathways [adenomatous (type-1) and non-adenomatous (type-2 or
foveolar/hyperplastic type)] speculated for progression of Barrett mucosa through dysplasia to
adenocarcinoma, MUC5AC was more commonly expressed in patients with foveolar-type
dysplasia [85].
3.2.F Helicobacter pylori infections
Helicobacter pylori (H. pylori) are the gram-negative bacterium that colonizes the gastric mucosa
to induce chronic inflammation and intestinal metaplasia (IM) through genetic and epigenetic
changes. Resultant activation of intracellular signaling pathways contributes to gastritis, peptic
ulcers and gastric carcinogenesis [86]. The main mucin that protects the gastric surface
epithelium is MUC5AC. H. pylori colonize to the gastric mucosa by its adhesion via BabA and
SabA adhesins to the blood group antigens LeB and Sialyl LeX present on gastric mucin
MUC5AC [87]. Investigations regarding the relationship between H. pylori and altered mucin
expression in gastric mucosa demonstrated that number of MUC5AC expressing cells and its
staining intensity is significantly decreased in H. pylori positive patients [17, 88, 89]. Besides,
MUC5AC expression is significantly reduced in H. pylori infected GC cases compared to non-
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infected cases [90] suggesting that the reduction of the MUC5AC might be related to gastric
carcinogenesis caused by H. pylori and the progression of GC [91]. It has been reported that H.
pylori infection may decrease MUC5AC expression via inhibition of key enzyme of mucin
synthesis- UDP-galactosyltransferase [92]. Interestingly, a decrease in MUC5AC expression
impairs the gastric mucosal barrier, facilitating H. pylori swimming and attaching the epithelium,
and contribute to the mucosal injury [17].
3.2.G Pancreatitis
Pancreatitis is inflammation of the pancreas that may progress to necrosis of the pancreas or
surrounding fatty tissue. The two main types include acute and chronic pancreatitis [93].
Regarding expression, MUC5AC transcripts were observed to be undetectable in all the cell types
of the normal exocrine pancreas and low in obstructive chronic pancreatitis cases adjacent to
cancer [94]. In a case of autoimmune pancreatitis (AIP), the atypical cells were tested positive for
the MUC5AC overexpression [95]. Guppy et al. highlighted strongest expression of MUC5AC in
pancreatitis [96]. Despite the availability of information regarding MUC5AC expression during
pancreatitis, the paucity of information regarding its role in pathogenesis warrants further
investigation. It has been recently described that conditions of diabetes and chronic pancreatitis
result in the formation of pancreatic duct glands (PDGs)- a new compartment of the major
pancreatic ducts in humans and mice [97]. Utilizing mice model of diabetes and pancreatitis, it
was demonstrated that production of tumor marker Muc5ac is induced in these PDGs along with
enhanced BrdU incorporation. It was suggested that pancreatic tumors might originate from these
PDGs, underscoring these structures to be potential targets for PC therapy [97].
3.2.H Inflammatory bowel disease
Ulcerative colitis (UC) and Crohn’s disease (CD) are the two major forms of inflammatory bowel
diseases (IBD). Dysfunctional mucus barrier due to changes in mucin secretion implicated by
host immune, microbial, genetic or environmental factors is now considered critical to the
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pathogenesis of IBD [98]. In this context, increased expression of secretory mucin MUC5AC in
the ileum of patients with Crohn’s disease (CD) compared to no expression in healthy ileal
mucosa has been reported with assumptions that MUC5AC may play a critical role in mucosal
protection and wound healing during IBD [99]. In other studies, M1/MUC5AC mucin was
detected in the mucus of 70-100% UC cases and was significantly associated with inflammatory
activity and goblet cell depletion [100, 101]. Contradicting previous assumptions regarding the
role of increased MUC5AC expression in mucosal protection and wound healing during IBD, one
study demonstrated a significant association of decrease in MUC5AC expression with endoscopic
improvement (EI) and pathologic remission of UC [102]. Further, clinical remission (CR) and EI
were associated with loss of MUC5AC in MUC5AC positive CD patients undergoing
adalimumab therapy suggesting the prospective utility of determining MUC5AC expression in
intestines of CD patients after therapy, as a predictive marker of the flare up and EI [18]. About
mechanisms associated with upregulation of MUC5AC during IBD, one study on Shigella
infection-associated acute IBD, highlighted TNF-α, PKC and ERK1/2 mediated increased
MUC5AC expression thus suggesting the potential therapeutic targets for IBD [103]. Looking at
the availability of only correlative studies regarding the association of MUC5AC with IBD, more
investigations are necessitated to functionally and mechanistically characterize this molecule in
IBD. This will be critical in deciding the appropriate therapeutic approaches against IBD.
3.3 MUC5AC and malignant diseases
Expression of secretory mucin MUC5AC is deregulated in different disease conditions as
reviewed above. Also, altered expression levels of MUC5AC have been extensively reported in
various malignant conditions. Few studies conducted to functionally characterize this mucin in
gastric cancer [21], pancreatic cancer [22], and lung cancer [20] indicate both tumor suppressive
as well as oncogenic roles of this mucin, suggesting its context-dependent functions. The
mechanistic basis of these functions is still obscure. Here, we have reviewed the available
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information regarding expression, and any specific roles played by MUC5AC in different
malignant conditions.
3.3.A Salivary gland carcinomas
Immunoreactivity for MUC5AC is poorly detected in excretory ducts of normal salivary glands.
However, their expression has been reported in salivary gland tumors. Immunoreactivity of
MUC5AC was observed in differentiated glandular cells in 73% of mucoepidermoid carcinomas
[104]. The diagnostic utility of MUC5AC as a marker to differentiate different salivary gland
carcinomas types has also been suggested. The combination of MUC3-/MUC5AC+/MUC6-;
MUC3+/MUC5AC-/MUC6-; and MUC3-/MUC5AC-/MUC6- suggested the diagnosis of
mucoepidermoid carcinomas, acinic cell adenocarcinoma, and adenoid cystic carcinoma
respectively [105]. In a series of salivary mucoepidermoid carcinomas, it was further shown that
MUC5AC staining can be used to distinguish high-grade mucoepidermoid carcinoma from
squamous cell carcinoma. Additionally, MUC5AC was significantly associated with tumorassociated lymphoid infiltrates (P<0.05) [106]. In a case of Cystadenoma (a relatively rare benign
epithelial tumor of the salivary glands), the absence of MUC2, MUC5B and MUC5AC along
with expression of MUC1, MUC4 and MUC6 was reported [107]. The mucin-rich variant of
salivary duct carcinoma (mSDC) is highly aggressive and is extremely rare. Interestingly, in a
case of salivary mSDC showing predominantly signet-ring cell features, the signet ring cells were
found immunopositive for MUC5AC [108].
3.3.B Lung cancer
Variable expression pattern of MUC5AC has been observed in bronchial epithelium from normal
individuals. MUC5AC is expressed in goblet cells in the normal respiratory mucosa. Earliest
studies reported a reduced expression of MUC5AC in non-small cell carcinomas, regardless of
their histologic subtype [109]. In contrast to these, expression of MUC5AC was shown to be the
most intense in mucinous-type bronchoalveolar carcinomas [110]. In a study conducted to
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evaluate the expression of the secretory mucins (MUC2, MUC5AC, and MUC6) in 79 surgical
specimens of small adenocarcinoma of the lung (SACL) cases, 7.6% SACL cases showed
MUC5AC expression. No significant correlation was observed between MUC5AC expression
and nodal involvement in SACL [111]. In a study of the progression from adenomatous
hyperplasia (AAH) to adenocarcinoma with mixed subtypes (MX), a significant increase in the
expression of MUC5AC correlated significantly with p53 gene abnormalities, suggesting that the
expression of MUC5AC might be associated with the progression of adenocarcinoma of the lung
[112]. Also, overexpression of MUC5AC gene was significantly associated with postoperative
relapse and lung cancer metastases [113]. In non-small cell lung carcinoma (NSCLC) samples,
expression of MUC5AC was detected in 27% samples with EGFR mutations and 30% samples
with wild-type EGFR. However, regardless of EGFR mutation status, expression of MUC5AC in
NSCLC was not associated with overall and relapse-free survival [114]. As NSCLC bearing
sialomucin expression tended to relapse earlier than those without sialomucin [115], hence, Yu et
al. investigated whether the expression of sialomucin in LC is caused by an abnormal
glycosylation process or by the expression of a specific mucin gene product. Interestingly, the
significantly higher amount of MUC5AC gene expression in adenocarcinomas positively
correlated with the expression status of sialomucin (P=0.012) [116]. Further, studies conducted to
test the hypothesis that sialomucin on MUC5AC may contribute to increased metastasis of LC
cells revealed that the patients bearing co-expression of MUC5AC and sLe(x) in tumors had a
higher probability of post-operative distant metastasis, and shorter overall survival [117]. Also,
overexpression of secretory mucin MUC5AC in lung tumors of smokers has been associated with
increased probability of postoperative recurrence [113]. Interestingly, investigation of the
reversible and irreversible expression changes in lung epithelium upon smoking cessation
indicated that only partial reversal of MUC5AC on cessation of smoking may account for the
persistent lung cancer risk and/or progression to LC [118].
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3.3.C Breast cancer
Secretory mucin MUC5AC is not expressed in normal breast tissues [119], and ductal hyperplasia
of the breast without atypia [120]. However, its immunoreactivity was observed in 5% of signetring cell carcinoma [121], 4-7% invasive carcinoma [120, 122, 123], and 12% of mucinous
carcinoma [123] cases. Interestingly, all invasive carcinomas expressing MUC5AC were
observed to be positive for MUC1 [120]. Additionally, in a study of 1447 cases of invasive breast
carcinoma with a long-term follow-up, 37% of cases expressed MUC5AC with no association
with patient outcome [124]. Further, a study conducted to differentiate clinicopathological
profiles of histiocytoid carcinoma of the breast (HLC) and classical invasive lobular carcinoma
(CLC), demonstrated MUC5AC expression in 50% of HLC cases compared to none in CLC.
Importantly, the presence of MUC2 and MUC5AC in HLC was significantly associated with
shorter disease-free survival time than lobular carcinomas without the expressions of MUC2 and
MUC5AC (p=0.0055 and p=0.0060) [125]. In another study conducted to compare expression of
MUC5AC between the mismatch repair-deficient and mismatch repair-proficient breast cancers
revealed no significant difference [126]. About mechanisms associated with expression of
MUC5AC in breast cancer cells, MUC5AC expression was correlated with DNA methylation
pattern in breast cancer cell lines. While the promoter of MUC5AC negative cells (MDA-MB453) were methylated in the distal region (-3718 to -3670), the MUC5AC positive cells (MCF-7)
had low methylation levels. The histone H3-K9 modification was also closely related to
MUC5AC expression [127].
3.3.D Gastric cancer
The normal adult stomach is characterized by strong expression of MUC5AC in the foveolar
epithelium [128, 129]. However, the expression rate of MUC5AC is decreased with the loss of
tumor differentiation, an increase in the tumor invasion depth, and with an increase in the number
of metastatic lymph nodes [128]. An overall reduction in expression of MUC5AC in GC has been
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reported, with 38-42% of gastric carcinomas expressing MUC5AC [130-132]. Reduction of
MUC5AC immunoreactivity reflects the significant reduction of gastric differentiation, represents
a marker of worse survival probability in GC, and a high-risk subgroup of pTNM stage-I patients
[133]. Interestingly, MUC5AC expression was inversely associated with tumor stage, depth of
invasion, lymphovascular invasion, lymph node and liver metastasis [21, 131, 134]. The patients
with MUC1+/MUC5AC- antigen staining in gastric carcinoma tissues showed the lowest survival
rate in contrast to the patients with MUC1-/MUC5AC+ staining pattern [131]. Further, MUC5AC
expression was negative in mucinous gastric carcinomas having a deeper invasion, more frequent
lymph node metastasis, more advanced pathologic state, lower survival rates than patients with
non-mucinous gastric carcinoma [135]. In eleven retrospective cohort studies comprising 2135
patients conducted to assess the association between MUC5AC expression and overall survival
and clinicopathological characteristics revealed that decreased MUC5AC expression was
significantly correlated with poor overall survival of GC patients. Moreover, decreased MUC5AC
expression was also significantly associated with tumor invasion depth and lymph node
metastasis in GC [136].
3.3.E Gallbladder adenocarcinoma
Expression of MUC5AC has been reported in the fetal gallbladder [137]. MUC5AC is weakly
and diffusely expressed at mRNA and protein level in normal gallbladder biliary epithelial cells
and intrahepatic bile ducts [138]. While in adenomas, dysplasias, and carcinomas of gallbladder
the expression of MUC5AC was reported to be decreased [139]. In another study, the positive
rate of MUC5AC expression was significantly lower in gallbladder adenocarcinomas than that in
peritumoral tissues (p<0.01), adenomas (p<0.05), and chronic cholecystitis (p<0.01) [140]. The
highly differentiated adenocarcinoma had significantly higher positivity rate of MUC5AC
compared to low differentiated adenocarcinomas [140]. Further, decreased expression of
MUC5AC was significantly associated with decreased overall survival (p=0.017), and was a
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significant independent prognostic predictor of gallbladder adenocarcinoma [140]. Contrary to
these, expression of MUC5AC was observed in carcinoma cells at deeply invasive sites [46]. A
rare case of minute subserosal adenocarcinoma of the gallbladder which arose in RokitanskyAschoff sinus (RAS) was found to be positive for MUC5AC expression [141]. Interestingly,
MUC5AC was expressed in 86% of mucinous carcinomas of the gallbladder (large and advanced
tumors exhibiting more aggressive behavior than ordinary gallbladder carcinomas) [142].
3.3.F Cholangiocarcinoma
Cholangiocarcinoma (CCA) is a highly malignant epithelial cancer of the biliary tract that
presents with metastatic disease [143]. The cellular and molecular pathogenesis of CCA remains
unclear [143]. Multistep progression of CCA has been suggested from biliary intraepithelial
neoplasia (BilIN) and intraductal papillary neoplasm of the bile duct (IPN-B). Among mucins,
expression of MUC5AC has been demonstrated in intrahepatic (biliary) intraductal papillary
mucinous neoplasia (b-IPMN) [144]. Extensive expression of MUC5AC (>50%) in CCAs have
previously been reported [145, 146]. Interestingly, MUC5AC expression was significantly
associated with more advanced tumors [146] and poor prognosis [147]. Also, a significant
association of the increased expression of MUC5AC with neural invasion (p=0.022) and
advanced intrahepatic cholangiocarcinoma (ICC) stage (p=0.008) has been demonstrated for liver
fluke-associated ICC [148]. In patients with intrahepatic cholangiocarcinoma mass-forming type
(ICC-MF), following curative intent hepatectomy, the expression of secretory mucin MUC5AC
was significantly related to aggressive tumor development, lymph node metastasis and
independently predicted poor prognosis [23]. Moreover, MUC5AC expression was significantly
more often (p<0.0001) observed in hilar CCAs compared with peripheral CCAs [149].
Early and specific diagnosis may aid in the effective and timely treatment of CCA [143].
Currently, there is no powerful marker for the diagnosis of CCA, which has led to the late
diagnosis and poor patient outcome [143]. Interestingly, determination of serum MUC5AC could
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discriminate CCA patients from controls with 71% sensitivity and 90% specificity [150].
Investigation of the diagnostic performance of MUC5AC in both bile and serum samples for
differentiating CCA and benign biliary disorders (biliary stones and cholangitis) revealed that
expression of data in terms of serum to bile ratio showed the improved diagnostic performance of
MUC5AC over quantification in serum alone [24]. MUC5AC as a new serum marker for biliary
tract cancer has also been proposed. Significantly greater levels of serum MUC5AC in BTC
patients compared to benign biliary disorders and healthy controls had a significant association
with lymph-node metastasis (P= 0.05) and stage-IVb disease (P=0.047). Interestingly, in patients
who underwent an operation with curative intent, the serum levels of MUC5AC ≥ 14 ng/mL
correlated to poor prognosis (3-year survival rate of 21.5%) in comparison to the patients with
lesser levels of serum MUC5AC (3-year survival rate of 59.3%) [151]. Further, it has been
demonstrated that CA-S27, a novel Lewis-a [Le (a)] associated modification of MUC5AC is
involved in promoting CCA cell growth, adhesion, migration, and invasion. The higher levels of
CA-S27 in the serum of CCA patients was significantly associated with shorter survival and
could differentiate CCA patients from different malignancies and controls with high sensitivity
and negative predictive value [152]. Another study demonstrated that MUC5AC is a core
glycoprotein for the S121 epitope that distinguishes patients with CCA from other pathologies
and normal controls with 89.58% specificity, 87.63% sensitivity, 80.95% positive predictive
value and 93.47% negative predictive value. Further, serum S121 levels were related to poor
patient outcome [153].
3.3.G Pancreatic cancer
Earliest report about the expression of MUC5AC transcripts suggests that it is undetectable in all
cells of normal pancreas tissue and chronic pancreatitis adjacent to PC. However, MUC5AC
transcript expression was observed in the areas of papillary hyperplasia and PC [154]. MUC5AC
mRNA was expressed in 83% of intraductal papillary mucinous tumors (IPMT) versus only 13%
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of invasive ductal carcinomas (IDC) [155]. All the three subtypes of IPMT (villous dark cell type,
papillary clear cell type, and compact cell type) expressed MUC5AC [155]. Interestingly, patients
expressing MUC5AC mRNA had a significantly better survival compared to the cases with no
MUC5AC expression (p<0.005) [155]. Immunohistochemically, expression of MUC5AC was
observed in 100% of intraductal papillary mucinous adenomas (IPMAs) compared to only
33.33% of benign mucinous cystadenomas of the pancreas [156]. Besides this, expression of
MUC5AC was demonstrated in all the cases of gastric and intestinal type of intraductal papillary
mucinous neoplasm (IPMN) [157]. Meta-analysis of 39 studies having 1235 IPMN samples
revealed that expression of Kras and MUC5AC is common in IPMN samples, but not strongly
associated with histologic progression of IPMN to malignancy [158]. Also, pancreatic mucinous
cysts without histologic characteristics of neoplasia and noninvasive mucinous cystic neoplasms
were observed to be expressing MUC5AC [159, 160].
MUC5AC is maximally expressed amongst all the mucins in all the histologically welldefined precursor ductal lesions of PC called Pancreatic intraepithelial neoplasia (PanIN-1A, -1B,
-2, -3) and PC compared to its rare expression in normal pancreas [161]. Matsuyama et al.
examined the differences in mucin expression between normal PanIN lesions and PanINs in
PDACs (PDAC-PanINs). MUC5AC expression was observed in 41%, 65.7% and 36.4% of
normal PanIN-1A, PanIN-1B and PanIN-2 specimens respectively. However, it was increased to
80.9%, 75.8% and 78.3% of PDAC PanIN-1A, PanIN-1B and PanIN-2 specimens respectively.
Particularly, significant differences were observed in the frequency of MUC5AC expression
between normal and PDAC-PanIN-1A (p<0.0001) and PanIN-2 (p<0.05) lesions [162].
Among pancreatic tumors, expression of MUC5AC was observed in all 100% cases of
well-differentiated pancreatic tumors, 96% moderately differentiated and 59% of poorlydifferentiated tumors [161]. One study reported the expression of MUC5AC in 73.9% of
cancerous regions, 48.7% of the dysplastic regions, and 72% of the hyperplastic regions but not in
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the normal pancreatic duct. Notably, stromal expression of MUC5AC was observed in 60.9% of
the cancerous regions with no such observation in stromal regions associated with hyperplasia
[111]. Further, expression of MUC5AC was reported in 63.6% of IDC cases of the pancreas.
MUC5AC-negative expression was significantly associated with lymphatic invasion, venous
invasion, lymph node metastasis, and MUC5AC positive patients showed significantly better
survival than MUC5AC-negative patients [163]. Contrary to this, in an important study done on
161 pancreatic tumors, the authors observed and presented a statistically significant association
between expression of MUC5AC and shorter survival time of patients after adjusting for different
covariates. This association was further strengthened in well to moderately differentiated ductal
adenocarcinomas. Authors highlighted that tumor histologies differed in this study compared to
Japanese cohorts and suggested that pancreatic tumor types differ across populations and that
interpretation of biomarkers may also vary by pancreatic tumors lineages [164]. Takano et al.
classified PDAC samples by metaplastic changes and heterogeneous gastric and intestinal
elements. Tissues expressing MUC5AC were classified gastric type PDAC accounting for
approximately 25.4% of such cases. Interestingly PDAC with gastric elements were welldifferentiated types with the significantly higher rate of lymph node metastasis [165]. In
endoscopic ultrasound-guided fine needle aspiration specimens from 114 PDAC patients,
expression of MUC5AC was observed in 78.9% cases. Interestingly, advanced stage PDAC
patients with MUC5AC expression had a significantly better outcome than those who were
MUC5AC-negative (p=0.002) [166]. Overall, observations from different studies lack clarity
regarding the association of MUC5AC to PC patient prognosis as it might be impacted by sample
type, population cohort and stage at which samples were collected.
3.3.G.a Pancreatic cancer diagnosis
One of the biggest challenges associated with PC are lack of early stage diagnostic markers. By
the time patient is diagnosed the disease is in its advanced stages or cancer has metastasized to
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distant locales. In an attempt to find solution to this problem it was demonstrated that analysis of
upregulated MUC1 and MUC5AC mRNA in pancreatic juice is a better diagnostic modality than
that of MUC4 and MUC6 mRNA during the development of high-grade PanIN lesions to IDC
[167]. In the nonneoplastic endoscopic ultrasound-guided fine needle aspirations (EUS-FNA) of
the pancreas MUC5AC was observed to be absent. Interestingly, the MUC1/MUC2/MUC5AC
panel was considered to be the most optimum for the diagnosis of ductal adenocarcinoma [168].
Further, in EUS-FNA specimens, higher specificity of the panel MUC1-/MUC2-/MUC5AC+ and
MUC1-/MUC2+/MUC5AC+ were highlighted to diagnose PC and pancreatic mucinous
neoplasms respectively [169]. In a study conducted on sera of PC patients, MUC5AC was found
to be elevated at the protein level (in 35% of the patients) and had the most glycan alterations.
The most frequent elevations involved fucose, the CA 19-9, and terminal mannose. It was
suggested that N-glycans, as well as O-glycans, may play important roles in modifying the
behaviors of MUC5AC in disease [170]. Hence, identification and functional characterization of
MUC5AC specific glycan alterations during PC are necessitated. In fact detection of glycan
variants on MUC5AC utilizing antibody-lectin sandwich microarray method could discriminate
benign cystic lesions (serous cystadenomas + pseudocysts) from mucin-producing cystic tumors
(MCN and IPMN) with sensitivity/specificity of 78%/80%. Interestingly, the combination with
cyst fluid CA 19-9 improved sensitivity/specificity to 87%/86% [171]. Further, improved
biomarker performance by measurement of glycans on specific proteins has been demonstrated
[172]. Interestingly, combined detection of the standard CA 19-9 along with CA 19-9 on
MUC5AC and MUC16 improved the sensitivity of PC detection over CA 19-9 alone in each
sample set [172]. Moreover, a serum ELISA has been developed using NPC-1C antibody that
detects specific epitopes expressed by tumor-associated MUC5AC in PC but not by normal
tissues. This serum test may be a new tool to aid in the improved diagnosis of PC [173].
3.3.G.b Pancreatic cancer therapy
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Development of resistance to different therapeutic modalities poses the biggest challenge in
targeting this devastating malignancy. In an attempt to therapeutically target PC, a chimeric
immunoglobulin (IgG1) called NPC-1C was developed. NPC-1C recognizes an immunogenic
MUC5AC-related tumor-associated antigen. Interestingly, during pre-clinical characterization of
NPC-1C antibody, it was demonstrated that none of the normal pancreas tissues reveal NPC-1C
reactivity while 48% of PC tissues demonstrate its staining. Further, the potential therapeutic
utility was highlighted as NPC-1C not only mediated PC cells killing but also impacted two to
threefold reduction in CFPAC-1 xenograft tumor growth compared to normal saline and IgG
controls [174]. Arlen et al. have established NPC1-C antibody targeting mutated MUC5AC. The
chimeric mAbs (NPC-1) targets a variant of MUC5AC. Xenograft studies with transplanted
human colon and pancreas tumors revealed the ability of mAb NPC-1 to diminish and in many
cases eliminate the growth of established tumor that was expanding in the animals. Also, NPC-1
monoclonal antibody exhibited greater than 40% killing of PC cells [175]. Yamazoe et al.
assessed the possibility of using MUC5AC as a target for immunotherapy of PC. Two peptide
epitopes [MUC5AC-A02-1398 (FLNDAGACV) and MUC5AC-A24-716 (TCQPTCRSL)]
elicited cytotoxic T-lymphocytes having specific cytotoxicity against the corresponding HLAA*0201- and A*2402-positive target cells [176]. Further, Gold et al. demonstrated high
specificity of PAM4 antibody (clivatuzumab) for PDAC in comparison to the normal pancreas,
benign lesions of the pancreas, and cancers originating from other tissues. Interestingly, this
PAM4 antibody specifically reacted with a reactive epitope present within the N-terminal
cysteine-rich subdomain2 (Cys2) of MUC5AC [177, 178]. These studies highlight the clinical
utility of PAM4 antibody for early stage diagnosis and therapy of PC.
3.3.H Colorectal cancer
Expression of MUC5AC has been extensively explored during colon adenoma-carcinoma
sequence. Different studies suggest an absence of MUC5AC expression in normal colon.
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However, MUC5AC is aberrantly expressed in adenomas that are considered to be the precursor
lesions of CRC. Intense overexpression of MUC5AC was a feature of rectosigmoid villous
adenomas (RVAs) with low-grade dysplasia than cases with high-grade dysplasia. It was
suggested that by acting as a specific marker for RVAs, MUC5AC may be useful for the early
detection of RVA recurrences [179]. In another study, MUC5AC was rarely detected in normal
colon, while its staining was of low intensity in hyperplastic polyps. MUC5AC immunoreactivity
was greatest in larger adenomas of moderate villous histology and dysplasia while it tended to
decrease in highly villous polyps and with severe dysplasia [180]. Interestingly, in a larger cohort
of colorectal carcinoma samples, expression of MUC5AC was strongly associated with
carcinogenic features via the serrated neoplasia pathway, including CIMP positivity, somatic
BRAF p.V600E mutation, mismatch repair deficiency, proximal location, poor differentiation,
lymphocytic response and increased T-stage (p<0.001) [181, 182]. Interestingly, on the basis of
significantly increased expression of secretory mucin MUC5AC and MUC2 in sporadic MSI-H
cancers it was suggested that serrated polyps of the colorectum may represent precursors of MSIH cancers [183]. It was further demonstrated that determination of MUC5AC hypomethylation
may be useful to identify serrated neoplasia pathway-related precursor lesions [184]. Besides
precursor lesions of CRC, increased expression of MUC5AC has been observed in 90% of highgrade dysplasia in UC, 89% of low grade dysplasia in UC, 73% of colitic cancer [185], 34.1% of
colon adenocarcinoma samples, 33% of signet-ring carcinoma of the colorectum [186], 60% of
mucinous carcinoma, and 19% of lymph node metastatic cases [187-189]. On the basis of
observed higher incidence of MUC5AC in UC-associated neoplasms than sporadic tumors, its
utility in the differential diagnosis of UC-associated neoplasms and sporadic ones was also
suggested [185].
Concerning expression of MUC5AC and its impact on prognosis of CRC patients, it has
been reported that absence of MUC5AC can be a prognostic factor for more aggressive colorectal
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carcinoma [187]. In an interesting study, naturally occurring MUC5AC antibodies were detected
in the sera of 27.3% healthy subjects, 45% patients with polyps, and 60% CRC patients.
Interestingly, MUC5AC antibody positive patients had shorter disease-free survival and overall
survival [190]. Significant correlation of MUC5AC presence with the lack of mismatch repair
protein MLH1 expression (p<0.005) in colorectal carcinomas has also been demonstrated [191].
Besides this, expression of MUC5AC in colorectal adenocarcinoma was significantly correlated
with tumor differentiation, invasion (P<0.01) along with positive correlation to E-Cadherin
expression [189]. Another study on T1-stage colorectal carcinoma patients revealed that
MUC5AC-positive patients had significantly higher incidences of right sided carcinoma
(p=0.005), polypoid growth carcinoma (p=0.009), and mucinous adenocarcinoma (p=0.035) than
in MUC5AC-negative patients [192]. Kesari et al. reported a significant positive correlation of
MUC5AC expression in CRC with tumor grade (p=0.006). The percentage of cases showing
MUC5AC expression increased as the stage of disease progressed from 1 to 4 [25]. Not only in
humans, but also in rat colon cancer model (MNNG treatment based), increased Muc5ac
expression was observed in typical aberrant crypt foci (ACF) in the colon mucosae underscoring
utility of Muc5ac as an early marker of colon carcinogenesis [193, 194].
Not much has been published about mechanisms associated with increased MUC5AC
expression during colon carcinogenesis. On the basis of concordant expression of SOX2 with
MUC5AC in serrated polyps, mucinous, signet ring cell carcinomas, it was suggested that SOX2
may play an important role in upregulation of MUC5AC in these pathologies [195]. However,
later another study demonstrated that SOX2 expression is not specifically linked to mucinous
CRCs, and MUC5AC is expressed independently of SOX2 in these CRCs [196].
3.3.I Ovarian cancer
Mucins play an important role in early diagnosis, prognosis, and treatment of ovarian cancer
[197]. However, about secretory mucin MUC5AC, the majority of the studies have focused on its
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expression and diagnostic utility in ovarian carcinoma cases. Among these, one study reported an
absence of MUC5AC in effusion specimens from ovarian serous carcinomas and suggested that
MUC5AC-/WT-1+ immunostain profile may differentiate ovarian serous carcinomas from
pancreatic carcinomas (MUC5AC+/WT-1-) [198]. In another study, a partial positivity of
MUC5AC was reported in a rare case of the mucinous borderline-like tumor arising from a
mature cystic teratoma (MCT) of the ovary [199]. Further, MUC5AC+/MUC1- immunostain
profile was recommended to differentiate ovarian mucinous tumors (OMTs) of the intestinal type
from the different metastatic tumors to the ovary (pancreatic, colorectal, cholangiocarcinoma,
gastric and esophageal carcinoma). Notably, 97.2% cases of OMTs were strongly and uniformly
positive for MUC5AC [200]. An interesting study investigated the factors associated with ovarian
cancer-peritoneal cell interaction [201]. For this, ovarian cancer and mesothelial cells were cocultured. Interestingly, an increased expression of secretory mucin MUC5AC was observed in the
co-culture secretome [201]. By this, authors suggested that MUC5AC may be a novel mediator of
ovarian cancer and peritoneal interaction, resulting in ovarian cancer cell invasion and adhesion
to distant sites [201].
3.3.J Cervical cancer
Cervical cancer is the second most common cause of cancer death in women worldwide. The
identification of novel targets for the development of new diagnosis, prognostic, and treatment
strategies merits special attention [202]. A strong expression of MUC5AC has been reported in
the normal endocervical epithelium (100%) and neoplastic lesions (73%), while it was diminished
in most neoplastic glandular lesions and absent in cases of tubal metaplasia and endometriosis
[203]. Looking at its differential expression, the utility of MUC5AC expression as a marker to
distinguish different cervical lesions was suggested. Further, a significant reduction of MUC5AC
expression in adenocarcinomas of the cervix compared to the normal endocervical epithelium has
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been reported. Interestingly, a significant association of its absence to poor survival of patients
was observed [204].
3.3.K Prostate cancer
Expression of MUC5AC in mucosecreting cells of the prostatic urethra has been assumed to be
probable cause for the histogenesis of benign villous tumors and primary mucinous
adenocarcinomas arising from the prostatic urethral epithelium [205]. Contrary to this, the study
by Legrier et al. revealed that very rare cells in the xenograft of a human hormone-dependent
prostate tumor expressed MUC5AC, with no expression in hormone-independent variants [206].
Additionally, different investigations have reported an absence of MUC5AC expression in normal
and prostate tumor tissues [119, 207, 208].
3.3.L Urothelial bladder cancer
Urothelial bladder cancer (UBC) is a malignancy of common genitourinary areas [209]. Secretory
mucin MUC5AC expression is usually absent in urothelial cells. However, expression of
MUC5AC has been reported in 11.1% of urothelial bladder carcinomas (UBCs) [209], 100% of
the flat urothelial carcinoma in situ of the bladder with glandular differentiation [210], 43.8% of
UBCs with divergent differentiation [211], 50% of the adenocarcinomas admixed to urothelial
carcinomas, 66.6% of primary pure signet-ring cell adenocarcinoma (SRCA) of the urinary
bladder [212], variable in microcystic urothelial bladder carcinoma [213], and absent in a case of
clear cell adenocarcinoma of the urinary bladder [214]. Interestingly, a significant relationship
between MUC1 and MUC5AC expression (p<0.001) was observed in 83% of UBCs expressing
MUC5AC. Notably, MUC5AC positivity did not correlate with survival of UBC patient [209].
3.3.M Extramammary Paget’s disease
Extramammary Paget's disease (EMPD) is a rare skin cancer of the genital region. In EMPD,
cancer cells (Paget cells) with enlarged nuclei and pale cytoplasm are scattered singly in the
affected epidermis. The Paget cells contain mucin which is never found in normal epidermis
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[215]. Expression of MUC5AC has been reported previously in the majority cases of EMPD in
the anogenital areas. It was concluded that EMPD in the anogenital areas may arise from ectopic
MUC5AC+ cells originating from Bartholin's or some other unidentified glands [216]. With no
expression of MUC5AC in normal skin cells, expression in all the intraepithelial lesions and loss
in invasive lesions, it was suggested that that loss of MUC5AC may play an important role in the
invasive growth of Paget cells [217]. In contrast, the significantly higher (p<0.01) expression of
MUC5AC in invasive lesions and metastatic lymph nodes compared to in situ lesions has also
been reported. It was concluded that MUC5AC may be a useful marker for identifying high-risk
EMPD cases [218]. Despite all the expressional information, further studies identifying the exact
roles of secretory mucin MUC5AC in EMPD are obscure.
3.3.N Pseudomyxoma peritonei
Pseudomyxoma peritonei (PMP) is the neoplasm of the peritoneum [219]. It originates from
appendicular tumors [219] and is characterized by progressive dissemination of mucinous tumors
and ascites with a distinctive pattern of peritoneal spread. During PMP, increased ectopic
secretion and deposition of MUC5AC along with MUC2 and MUC5B has been observed in the
peritoneal cavity, resulting in major part of the morbidity [220-222]. However, studies regarding
the specific role of MUC5AC in the peritoneal spread and the degree of malignant transformation
are still missing. Besides this, the mechanisms associated with increased MUC5AC secretion and
accumulations in PMP are missing. In a significant revelation, it was shown that activating GNAS
mutations result in the induction of MUC5AC in low-grade appendiceal mucinous neoplasms,
which can be a cause of PMP [223].
4. Functional and mechanistic implications of MUC5AC in cancer
In a study conducted to understand the functional significance of MUC5AC in PC, it was
demonstrated that MUC5AC expression might accelerate the progression of PC by activating the
VEGFR-1 signaling pathway in an autocrine manner. Suppression of MUC5AC resulted in
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significantly lower adhesion and invasion to extracellular matrix components compared to
controls along with downregulation of genes associated with adhesion and invasion (MMP-3,
integrins and VEGF). Furthermore, production of VEGF and phosphorylation of VEGFR-1 were
significantly reduced on MUC5AC inhibition. There was reduced activation of Erk1/2 and
reduced subcutaneous tumor formation on knockdown of MUC5AC in nude mice. However, the
mechanisms associated with MUC5AC mediated tumor formation in vivo remained obscure
[224]. Furthermore, in an interesting study, it was demonstrated that GLI mediated expression of
MUC5AC modulates E-cadherin/β-catenin regulated PC cell properties [22]. Interestingly, it was
suggested that expression of MUC5AC in the intercellular junctions of pancreatic ductal
adenocarcinoma cells might have inhibited homophilic ligation and stabilization of E-cadherin on
the cell membrane. By these observations, authors suggested that future studies could target
breakdown of the polymerized MUC5AC gel structure mediated restoration of E-cadherinmediated intercellular adhesion and may lead to the downregulation of β-catenin signaling,
preventing the migration and invasion of PDA cells [22]. Another study showed that expression
of MUC5AC does not impact in vitro PC cell growth, but it was intimately involved in tumor
growth in vivo. Mechanistically, infiltration of CD45R/B220+ and Gr-1+ cells was observed in
tumor tissues generated by implanting si-MUC5AC cells into mice suggesting that infiltrated
neutrophils might have antitumor effects mediated by antibody-dependent cell cytotoxicity
(ADCC) via phagocytosis, elastase, or superoxide generation. Another possible reason assumed
for the in vivo inhibition of tumorigenicity was a possible association of MUC5AC in immune
suppression and avoidance. However, future studies are needed to investigate the MUC5AC
mediated immunosuppressive mechanisms in human PC. Further, Hoshi et al. observed that
suppression of MUC5AC inhibits in vivo tumor growth due to increased infiltration of neutrophils
resulting in TRAIL-mediated increased apoptosis [225]. Overexpression of MUC5AC is a poor
prognostic marker in LC. In an attempt to functionally characterize MUC5AC in LC, it was
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demonstrated that MUC5AC was associated with epithelial to mesenchymal transition (EMT) in
LC cells. Besides this, an interaction of MUC5AC with integrin-β4 mediated phosphorylation of
FAK at Y397 residue leading to increased LC cell migration was also reported [20]. Further, to
elucidate the mechanisms associated with increased tumorigenicity and metastasis of GC,
silencing of MUC5AC was performed in GC cells (SNU216 and AGS). Knockdown of
MUC5AC increased the invasion and migration of SNU216 and AGS cells. Mechanistically
MUC5AC silencing increased Akt phosphorylation, expression of VEGF and matrix
metalloproteinase-7, which were blocked by inhibitors of the phosphatidylinositol 3-kinase/Akt
pathway [21].
5. Muc5ac mice models
Shekels et al. for the first time reported the MGM gene identified from murine gastric cDNA, to
be a murine homolog of human MUC5AC [226]. The mouse Muc5ac gene was mapped to 215 kb
secretory mucin gene cluster on distal chromosome 7 band F5, 69.0 cM from the centromere.
Similar to human homolog it was organized with other mucins as Muc6-Muc2-Muc5ac-Muc5b
indicating that they have been well conserved through evolution [227]. The genomic region
encoding for Muc5ac was found to be 29 kb, included 49 exons, and predicted to produce a 9 kb
RNA transcript [228]. The size of Muc5ac central exon was estimated to be approximately 6.5 kb
[227]. Regarding orientation, the mucins Muc2, Muc5ac, and Muc5b were arranged in the same
direction, while Muc6 in opposite direction. Further investigations indicated that the peptides
from different secretory mucins had striking sequence similarities in their N- and C-terminal
regions, and also to pre-pro-von Willebrand factor like domains (D, B, C and C-terminal cystine
knot (CK) domains). However, the Proline/Threonine/Serine-rich central region of different
secretory mucins was specific for mucin-type and species. The 48 nucleotides tandem repeats of
Muc5ac encode a serine and threonine rich consensus sequence of 16 amino acid
(QTSSPNTGKTSTISTT) residues [226]. Expression studies also showed that similar to human
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MUC5AC, murine Muc5ac was observed most prominently in airways, stomach, and conjunctiva
of mice [226, 229]. Overall, this information laid the foundation for the investigation of Muc5ac
gene regulation and function utilizing the animal models [227]. Multiple studies as mentioned
below have utilized the genetically modified mice models of Muc5ac, to understand the
mechanisms associated with its regulation and functionally characterize this secretory mucin in
pathologies related to different organs.
A study by Hasnain et al. highlighted the role of Muc5ac as a crucial effector molecule
during infections of the intestine, besides being a structural component of the mucus barrier. It
was demonstrated that IL-13 and IL-4 induced Muc5ac protects from Trichuris muris (T. muris)
infection. The deficiency of Muc5ac (Muc5ac-/-) renders mice more susceptible to chronic T.
muris infection along with a significant delay in the expulsion of other infectious agents such as
Trichinella spiralis and Nippostrongylus brasiliensis from the intestines of infected mice
compared to infected wild-type (WT) mice [230]. Interestingly, Muc5ac-deficient mice infected
with T. muris revealed significantly elevated IFN-γ, increased goblet cell numbers, Muc2 levels,
significantly higher levels of ATP in worms compared to the worms isolated from the infected
WT mice. There was also a slight increase in IFN-γ in uninfected Muc5ac-deficient mice [230].
This suggests that Muc5ac plays an important role in alleviation of inflammatory response thus
playing a protective role. Another study investigated relationship between inflammation, Muc5ac
hypersecretion, and airways obstruction and highlighted the protective role of Muc5ac during
airway pathologies. For this, the Muc5ac transgenic mouse was developed by cloning full-length
Muc5ac cDNA to be overexpressed in murine small and large airways. The resultant Muc5ac
transgenic mice revealed a 17.7 fold increased Muc5ac secretion in bronchoalveolar lavage fluid
and approximately 2-fold increase over the OVA-challenged model compared with WT mice
[228]. There was no compensatory impact on other mucins suggesting independent regulation of
these mucins in the absence of disease. Further, there was no evidence of small airways, large
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airways obstruction suggesting its efficient clearance from airway surfaces [228]. Interestingly,
the increased mucus was handled by increasing the height of the mucus layer, with no change in
its concentration. Moreover, the protective antiviral impact of Muc5ac was uncovered by the
resistance of Muc5ac-Tg mice to PR8/H1N1 influenza in vivo [228]. It was shown that α-2, 3linked sialic-acid residues on the Muc5ac act as a decoy to bind virus, limiting its access to the
airways epithelial surfaces, thus preventing infection [228]. Interestingly, reduced neutrophilic
response thus limiting the lung tissue damage was observed in Muc5ac-Tg mice exposed to
infection [228]. However, the exact mechanisms addressing the impact of Muc5ac on reduced
neutrophil infiltration remained elusive, needing further investigations. This study cautions for
careful titration of any future therapeutics designed to reduce Muc5ac production for the purpose
of ameliorating airway obstruction, as this may lead to compromised host defense [228].
Contrary to above mentioned protective roles of Muc5ac, another study provided the
evidence of the detrimental role of Muc5ac during Acute lung injury (ALI). For this, the Muc5ac/-

mice were subjected to ventilator-induced lung injury (VILI) [231]. WT mice exposed to VILI

revealed increased Muc5ac transcript and protein levels mediated by transcription factor NF-κB
[231]. Surprisingly, Muc5ac-/- mice exposed to VILI had significantly improved pulmonary gas
exchange, significantly reduced pulmonary edema, complete abolishment of Myeloperoxidase
(MPO) levels, attenuated regulation of cytokine, chemokine and chemokine receptor levels
(Cxcl1, Cxcl2 and IL-6 transcripts and proteins), and significantly increased survival than WT
littermate controls. The presence of Muc5ac also increased in trafficking of Ly6Ghigh/CD11bhigh
polymorphonuclear (PMN) cells in the pulmonary tissue of WT mice exposed to VILI [231].
Concerning possible mechanisms, it was assumed that by acting as a cytokine ‘‘sponge’’, Muc5ac
may prolong the half-life of these inflammatory cytokines and other inflammatory mediators,
thereby resulting in enhanced lung inflammation and increased neutrophil trafficking.
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Besides studies delineating the role of Muc5ac in airway pathophysiology its potential
role in the maintenance of ocular homeostasis has also been investigated. In Muc5ac-/- mice
model there was a compensatory increase of another secretory mucin-Muc5b at mRNA and
protein level along with significant enlargement of mucous cells on the ocular surface [232]. Lack
of Muc5ac markedly destabilized the tear film (TF) resulting in qualitative TF insufficiency with
the tear volume remaining intact [232]. Besides this, a few Muc5ac-/- developed opacification on
their ocular surface (mainly on the cornea) warranting further investigations on the molecular and
mechanistic basis of this observation. This study highlighted the therapeutic potential of artificial
tear fluid supplemented with Muc5ac to have a beneficial effect on dry eye patient [232].
However, contradicting above mentioned observations, it was reported that loss of Muc5ac does
not produce a dry eye phenotype in mice. They did not observe any obvious changes or defects in
the gross appearance of the cornea or eyelids and concluded that Muc5ac-/- mice are a poor animal
model of the human dry eye disease [36]. The authors suggested that the corneal opacification
noted in the previous study might be a secondary cause relating to infection due to debris or
pathogens and not actually due to the deletion of the Muc5ac gene. Besides this, they did not
observe any qualitative or quantitative changes in goblet cells of conjunctival epithelium in
Muc5ac deficient mice, thus disproving the observations from the previous study [36].
A study from our lab evaluated the stage-specific expression pattern of mucins during PC
progression in KrasG12D; Pdx1-Cre (KC) murine PC model and observed a progressive increase in
the expression of secretory mucin Muc5ac in the pancreas of KC mice both at mRNA and protein
level. Muc5ac expressed in the pancreas of KC mice as early as at 10 weeks (fold change 1.2)
compared to none in control LSL-KrasG12D mice [233]. Interestingly, MUC5AC expression
progressively increased from 10th week to the 50th week of progression compared to none in the
pancreas of age-matched unfloxed LSL-KrasG12D mice [233]. Interestingly, Muc5ac was strongly
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expressed in the metastatic lesions involving liver, small intestines and lungs at 50 weeks of age
[233].
6. Regulation of MUC5AC expression
Secretory mucin MUC5AC is aberrantly expressed under inflammatory conditions, and multiple
malignancies such as PC, LC, and CRC. A plethora of studies in last decade has investigated the
regulation of MUC5AC expression, in different physiological and pathological contexts. Briefly,
MUC5AC has been shown to be regulated by environmental pollutants (cigarette smoke extracts,
acrolein, ozone), viral mediators (respiratory syncytial virus, rhinovirus), bacterial products (LPS,
LTA, peptidoglycans, flagellin), cytokines (TNF-α, IL-1β, IL-4, IL-6, IL-9, IL-13, IL-17), growth
factors (EGF, TGF-α, RA, thyroid hormones), and proteases (neutrophil elastase) [73, 80]. Recent
studies demonstrated the miRNA-mediated regulation of MUC5AC and utility of their
therapeutic targeting for modulation of MUC5AC expression. It has been shown that mucus
overproduction during inflammatory airway diseases can be managed by manipulation of
miRNAs. MUC5AC production by airway epithelial cells stimulated by neutrophil elastase was
downregulated by miR-146a mediated inactivation of JNK and NF-κB signaling [234].
Interestingly, it has been displayed that overexpression of hemeoxygenase-1 (HMOX1),
decreased the expression of miR-378 (Oncomir/Angiomir), reversed miR-378 mediated increased
MUC5AC, vascular endothelial growth factor (VEGF), interleukin-8 (IL-8), and Ang-1 leading to
decreased proliferation, migration, and angiogenic potential of NCI-H292 LC cells both in vitro
and in vivo. Thus, this study underscores a prospective therapeutic strategy, to inhibit miR-378mediated impact on LC cell growth and metastasis [235]. Another study showed that in IL-13stimulated nasal epithelial cells (NECs), mRNA and protein expression levels of MUC5AC could
be significantly decreased by the forced expression of miR-143 [236].
Little is known about the mechanisms associated with atypical expression of MUC5AC
in pancreatic tumors. It has been shown that forskolin and vasoactive intestinal peptide (VIP)
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stimulate adenylyl cyclase and protein kinase A (PKA) pathway to increase MUC5AC antigen
expression and release from SW1990 PC cells [237]. Further, transcription factor SP-1 is
involved in basal transcription of the MUC5AC gene [238]. The AP-1 transcription factor is also
involved in both basal and PMA induced MUC5AC promoter activation via PKC/ERK and
PKC/JNK pathways [238]. Moreover, epigenetic mechanisms also regulate expression of
MUC5AC in PC cell lines. The distinct CpG methylation status in the distal region of the
MUC5AC promoter was responsible for expression of MUC5AC in different PC cell lines [127].
Also, MUC5AC is a direct transcriptional target of GLI1 in PC cells. GLI1 and GLI2 could
activate the promoter of MUC5AC through its conserved CACCC-box like cis-regulatory
elements [22]. Further, utilizing pancreatic ductal lineage cells (HPDE and PK-8), it was
concluded that mutation of GNAS induces MUC5AC expression in IPMNs through interaction
with MAPK and PI3K pathways [239].
7. Hypoxia and MUC5AC
Hypoxia is closely associated with the inflammatory process. Fundamental mechanisms
underlying overproduction of secretory mucin MUC5AC during lung inflammation remained
unknown. Different mucins (MUC1, MUC3, and MUC17) have been known to be induced under
hypoxic conditions associated with different pathologies [240-242]. Hence, multiple studies
investigated hypoxia-mediated MUC5AC expression under conditions of inflammation associated
hypoxia. A consensus-binding motif for transcription factor HIF1-α was observed in the core
promoters of all the mammalian MUC5AC orthologs, suggesting the role of hypoxia in the
regulation of MUC5AC. It was demonstrated that the -64 bp hypoxia response element (HRE) on
MUC5AC promoter is essential for the response to hypoxia, as mutations of this site virtually
abolished the activity of MUC5AC promoter [243]. Under inflammatory conditions, IL-13 and
EGF-mediated induction of HIF1-α binding to Muc5ac promoter resulted in increased
transcription of Muc5ac, while a mutation in the binding motif dramatically reduced the Muc5ac
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promoter activity [75, 244]. Interestingly, Yang et al. demonstrated that human neutrophil
elastase (HNE) induces the generation and activation of HIF-1α, to further activate protein kinase
C (PKC), and subsequently increase the levels of transient receptor potential vanilloid subtype 1
(TRPV1) phosphorylation, resulting in TRPV1 sensitization mediated increase in the production
of MUC5AC and pro-inflammatory cytokines [245]. It has also been shown that increased
secretory mucin MUC5AC expression and production during sinusitis can be reduced either by
increasing the oxygen tension or by modulating the HIF1-α activity [246]. In another study, the
multifunctional or multidirectional action of silver NPs to alleviate allergic asthma by attenuating
MUC5AC hypersecretion was assumed to be mediated via blocking of HIF-1α and Th-2
cytokines [247]. Further, Yu et al. drew attention to cigarette smoke-induced MUC5AC
expression by HIF-1α via EGFR mediated activation of PI3K and ERK signaling pathways in
human airway epithelial cells [248]. Overall, these studies underscore that increased MUC5AC
mediated pathological implications can be alleviated by therapeutically targeting hypoxia
mediator HIF1-α under inflammatory conditions.
8. Smoking and MUC5AC
Earliest report on the association of smoking and MUC5AC expression demonstrated that
cigarette smoke inhalation activates EGFR, resulting in up-regulation of MUC5AC production
[249]. Further investigation elucidated that smoking generated reactive oxygen species (ROS)
activate TNF-α converting enzyme (TACE). TACE caused increased TGF-α shedding, leading to
EGFR phosphorylation mediated MUC5AC induction in human airway epithelial (NCI-H292)
cells [250]. Baginski et al. reported a synergistic impact of cigarette smoke and proinflammatory
inducers like TNF-α, TGF-α, LPS and amphiregulin on MUC5AC hyper-production in airways
[251]. Further, tobacco smoke activates of AP-1 resulting in induction of MUC5AC, independent
of oxygen radical mediated EGFR and JNK activation [252]. Cigarette smoke-induced EGFR and
CLCA1 affects the production of MUC5AC as a part of a single complex signaling pathway
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[253]. Further, it was demonstrated that inflammatory cytokine IL-13, lung toxicants [cigarette
smoke total particulate matter (TPM), and cigarette smoke constituent-acrolein] increased the
percentage of MUC5AC positive cells and induced a profound effect on cellular differentiation
[254]. An association of MCP-1 expression with increased MUC5AC expression in the airway
epithelium of smokers has been demonstrated. MCP-1 induced expression of MUC5AC by
initiating interaction of its receptor CCR2B with G(q) subunits in caveolae and subsequent PLCβ,
PKC and ERK1/2 activation [255]. Overall, the therapeutic utility of targeting MCP-1 to
attenuate CS-induced mucus hypersecretion in COPD patients was underscored [255]. Yu et al.
reported that NRG1β/ErbB3 signaling via the MAPK and PI3K signal pathways mediates
induction of MUC5AC in CS-exposed airway epithelial cells (16HBE) [256]. Also, cigarette
smoke exposed lungs produce growth differentiation factor 15 (GDF15) that activates PI3K
pathway to promote MUC5AC production [257]. Cigarette smoke exposure results in increased
SP1 nuclear translocation and binding to MUC5AC promoter region to induce MUC5AC gene
transcription [258]. Interestingly, cigarette smoke causes increased inflammation in middle ear
epithelial cells resulting in increased expression of MUC5AC via EGFR signaling, implicating in
otitis media with effusion [72].
Multiple studies were done with an objective to find ways to alleviate manifestations
associated with increased expression of MUC5AC devised multiple strategies to modulate
cigarette smoke-mediated induction of MUC5AC. To mention a few, Lee et al. observed through
in-vitro and in vivo studies that rebamipide inhibits cigarette smoke-induced TNF-α release and
MUC5AC production [259]. The same group investigated the effect of PPAR-γ agonist
(Rosiglitazone) and observed that these agonists inhibit cigarette smoke-induced MUC5AC
production by upregulating PTEN signaling and downregulating AKT expression [260]. In an
interesting revelation utility of the powerful anti-inflammatory and antioxidant enzyme Heme
oxygenase-1 (HO-1) in attenuation of cigarette smoke-mediated airway mucus hypersecretion in
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animals and humans was emphasized [261]. Cortijo et al. underscored the clinical efficacy of
aclidinium (long-acting muscarinic antagonist) for suppressing cigarette smoke-induced
MUC5AC overexpression in human airway epithelial cells [262]. Interestingly, cigarette smoke
significantly modulates expression of GAD67 gene (rate limiting enzyme in GABA synthesis) in
small and large airway epithelium of smokers. A significant positive correlation was revealed
between GAD67 gene expression and MUC5AC expression. Hence, GAD67 was considered to
be a novel therapeutic target to curb manifestations of mucus overproduction due to smoking
[263]. Fu et al. reported that Ly-6 protein (Lynx1) agonists or mimetic could be utilized to
attenuate MUC5AC production in CS-induced pathologies, due to its ability to negatively
regulate α7nAChR downstream signaling mediated by inhibition of Src activation [264].
9. Conclusions and perspectives
Extensive research efforts in last decade established mucins as one of the clinically relevant
molecules. Under physiological conditions, mucin glycoproteins primarily function to provide
protection against various ambient stimuli, lubrication and for the establishment of homeostasis at
the epithelial surfaces lining the internal organs of the body. Mucins also participate in different
diseases including inflammatory, benign and malignant conditions. One such mucin that has been
extensively studied in last decade is secretory mucin MUC5AC. MUC5AC has been associated
with protection and lubrication to multiple organs such as conjunctiva, lungs, stomach, and
endocervix by its property of forming polymeric gels over epithelial surfaces of these organs. It
has been assumed that MUC5AC plays a critical role in the innate mucosal defense in these
organs along with mucociliary defense in the airways. Lack of appropriate models mimicking the
pathological contexts hindered understanding of the exact contextual roles played by MUC5AC.
However, with the advent of genetically engineered mouse models, our understanding of the
mechanisms associated with MUC5AC mediated processes are getting refined, but they are far
from being clearly elucidated. For an example, despite information about MUC5AC expression in
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endocervix, nothing is indicated about its role in the reproductive process. Besides, the
differences in anatomy and physiology of rodents and humans are also a disadvantage in fully
understanding the exact functions and exploiting them to therapeutic benefit.
Much progress has been made to elucidate the major domains, structure and assembly of
MUC5AC. However, not much has been done to understand exact roles of these domains in
different contexts. Moreover, information about molecular interacting partners of MUC5AC
needs extensive research. It has been assumed that by its cysteine-rich D-domains and vWF-like
domains, MUC5AC may interact with other proteins having similar domains. As a component of
mucus, through ionic or hydrophobic interactions, it might even interact with other mucins and
play an important role in maintaining the stability of mucus. However, this warrants further
investigations. Most of the previous studies for identifying mucin-interacting proteins were
conducted under conditions that disrupted mucin interactions within mucus. Since MUC5AC is a
secretory mucin, therefore it is important to identify its associated molecules without disrupting
the mucus gel, thus providing clarity on nature of the MUC5AC barrier, and the interactions
holding it together. The knowledge gained will help to devise strategies for better facilitation of
pharmaceuticals and gene therapy agents across MUC5AC polymeric gel barrier.
Looking at the aberrant alterations of MUC5AC in multiple pathological states
significant efforts were invested to comprehend mechanisms of its regulation, utility as early
stage diagnostic marker, prognostic marker, and its functions in different contexts. Substantial
strides were made to characterize promoter of MUC5AC and understand the transcriptional,
epigenetic mechanisms associated with MUC5AC expression, in cell and tissue-specific manner,
and explain how its aberrant expression occurs in inflammatory, benign conditions and
carcinogenesis. The biggest challenge that remained was the procurement; processing and
absolute quantification of MUC5AC levels in samples from healthy versus diseased states.
Therefore, the lack of current understanding regarding the levels to which altered MUC5AC
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levels should be titrated has impacted appropriate therapeutic targeting of this mucin, rendering
mixed outcomes. Further, some studies recently highlighted post-transcriptional regulation of
MUC5AC mediated by miRNAs in different pathologies providing an underexplored field with a
huge promise to explore further.
Another area that demands extensive attention be the characterization of posttranslational modifications such as differential glycosylations associated with MUC5AC,
specifically during different disease states in comparison to the healthy individuals. The
knowledge gained from here can be employed to devise better diagnostic markers and diseasespecific therapeutic modalities. Interestingly, extensive efforts are currently being made to utilize
MUC5AC in conjunction with other markers as an early stage diagnostic marker of
cholangiocarcinoma and pancreatic ductal adenocarcinoma. Interestingly, recent studies have
linked genetic variants of MUC5AC to be involved in predisposition to cystic fibrosis and gastric
cancers. Functional variations in MUC5AC owing to variations in domain structure and
regulatory regions resulting in different pathologies are also emerging. Interestingly, not much
has been investigated concerning aberrant assembly of MUC5AC due to genetic polymorphisms,
stress conditions such as hypoxia and smoking, which may predispose individuals to various
disease conditions and malignancies.
Contradictory roles of MUC5AC have been demonstrated in different malignancies like
gastric cancer and pancreatic cancer. It would be interesting to comprehend how the pathological
context and associated microenvironment impacts the various roles played by MUC5AC. Future
studies can focus on extensively understanding the mechanisms related to roles played by
MUC5AC in various malignancies. Further, it will be important to take cues from the
mechanisms associated with clearance of overexpressed and hypersecreted MUC5AC in airway
diseases. These cues could be of help in developing therapeutic strategies for clearance of
MUC5AC in malignancies having overexpression of MUC5AC. Finally, the promise and the
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driving objective of research on MUC5AC is the opportunity to discover novel diagnostic
markers for different cancers and new therapies that can normalize its levels under different
pathological conditions.
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Figure 1.1: Schematic representation of genomic and structural organization of MUC5AC:
MUC5AC gene is located within a single 400-kb genomic DNA segment on chromosome 11 in
the subtelomeric locus 11p15.5. On this locus MUC5AC is clustered with four other mucin genes
in a sequence MUC6-MUC2-MUC5AC-MUC5B from telomere to centromere. The array
indicates direction of transcription (not to scale). MUC6 transcribes in opposite direction to
MUC2, MUC5AC and MUC5B. The genomic DNA of MUC5AC transcribes to ~17.5 kb of
mRNA that is made up of 49 exons. The large central exon is predicted to be exon 31. MUC5AC
mRNA translates to a multidomain protein of ~5654 amino acids. Protein structure of MUC5AC
is broadly divided into N-terminus, Tandem repeat region and C-terminus. The N-terminus is
made up of a 19 amino acid leader peptide and four von Willebrand factor type D domains-D1,
D2, D’ and D3. The D1 domain also contains a leucine zipper pattern. The tandem repeat region
consists of nine CysD domains and four proline, threonine and serine rich tandem repeats (TR1TR4). The C-terminus of MUC5AC is made up of D4, B, C (von Willebrand factor type C
domain) and CK (cysteine knot domain) domains. D4 domain contains a GDPH putative cleavage
site.
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Table 1.1: Normal expression of MUC5AC in the human body
S. No.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16

Organ epithelium
Conjunctiva/ocular surface
Eustachian tube
Middle ear
Salivary glands
Nasopharyngeal mucosa
Esophagus
Breast
Lung
Stomach
Gall bladder/ intrahepatic bile ducts
Pancreas
Ileum
Colon
Endocervix
Sebum cells in epidermis
Normal Skin
Prostate
Urothelial cells

Physiological presence
+
+
+
Poorly detected
+
+
+
+
+
+
-

Reference
[36, 39]
[37]
[38]
[104]
[265]
[82]
[119]
[12]
[42]
[46, 138]
[94]
[99]
[49]
[45]
[50]
[217]
[119]
[209]
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Table 1.2: Expression of MUC5AC in inflammatory and benign conditions
S. No.
1
2
3
4

6

Benign conditions
Allergic rhinitis
Chronic rhinosinusitis
Otitis media with effusion
Asthma
Chronic obstructive
pulmonary disease
Cystic fibrosis

7
8
9
10
11

Barrett's esophagus
Helicobacter pylori infection
Pancreatitis
Ulcerative colitis
Crohn's disease

5

Altered expression
Increased
Increased
Increased
Increased

Reference
[52]
[62]
[40]
[29]

Increased

[29]

Increased
Decreased
Increased
Decreased
Increased
Increased
Increased

[77]
[78]
[82]
[88]
[96]
[101]
[99]
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Table 1.3: Expression and associated role of MUC5AC in different malignancies
S. No.
1

Cancer
Salivary gland carcinoma

Altered expression
Increased

2

Lung cancer

Increased

3

Breast cancer

Increased

4

Gastric cancer

Decreased

5

Gall bladder cancer

Decreased

6

Cholangiocarcinoma

Increased

7

Pancreatic cancer

Increased

8

Colorectal cancer

Increased

9
10
11
12
13
14

Ovarian cancer
Cervical cancer
Prostate cancer
Urothelial bladder cancer
Extramammary Paget's disease
Pseudomyxoma peritonei

Increased
Decreased
Absent
Increased
Increased
Increased

Association to cancer
higher grade tumor
Post-operative relapse
Post-operative distant metastasis, Shorter
survival
Shorter disease free survival
Shorter survival
Higher tumor stage, Increased invasion
Decreased overall survival
More advanced tumors
Neural invasion
Poor prognosis
Better survival
Shorter survival
Lymph node metastasis
Less aggressive
Increased tumor grade
Increased invasion
Increased invasion
Poor survival
NA
No correlation with survival
Invasive lesions and metastatic lymph nodes
NA

Reference
[106]
[113]
[117]
[125]
[133]
[134-136]
[139, 140]
[146]
[148]
[23, 147]
[155, 163, 166]
[164]
[165]
[187]
[25]
[189]
[201]
[204]
[207, 208]
[209]
[218]
[221, 222]
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General Hypothesis and Objectives
A multitude of studies has now recognized that mucins that constitute the mucous barrier are
intimately involved in the process of carcinogenesis. Cancer cells express aberrant forms and
amounts of mucins that contribute to the tumor properties in several ways. Mucins act as tumor
promoters or tumor suppressors and are identified as diagnostic, prognostic markers along with
attractive therapeutic targets in cancer. Among tumor associated mucins, exhaustive research
efforts from our group and others have elucidated the role of mucins MUC1, MUC4, MUC16 in
pancreatic cancer and MUC2, MUC4, MUC17 in colorectal cancer. In addition to these, secretory
mucin MUC5AC has also been implicated to play a significant role in different cancers including
pancreatic and colorectal cancer. It seems that MUC5AC might also have redundant functions
similar to other mucins that are simultaneously expressed by a cancer cell. However, the absence
of MUC5AC in normal pancreas and colon, its overexpression in inflammatory conditions of
pancreas and colon, expression in early stage precursor lesions of both pancreas and colon,
overexpression in pancreatic adenocarcinoma, colorectal cancer, and its secretory nature supports
that MUC5AC has unique functions different from other mucins implicated in pancreatic and
colon cancer.
As discussed in the introductory chapter, unlike transmembrane mucins like MUC1,
MUC4, MUC16 that contain hydrophobic transmembrane domain in their structure, secretory
mucin MUC5AC lacks a transmembrane domain and forms large polymeric gels over cell surface
by forming disulfide bonds between cysteine residues of N- and C-terminal domains. This
structural variation between mucin molecules results in varied functions due to interactions with
diverse protein molecules. Therefore, considering the unique attributes of secretory mucin
MUC5AC, I decided to explore its role in pancreatic cancer by using various pancreatic cancer
cell lines and mouse models. Further, I have investigated the diagnostic utility of MUC5AC in
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conjunction with other mucins and associated glyco-epitopes to differentiate precursor lesions of
colorectal cancer and for early stage prediction of colorectal malignancy.
Genetically engineered mouse model of pancreatic cancer (KrasG12D; Pdx1-Cre) that
closely mimics the histopathology of human pancreatic cancer, have been extensively useful in
last decade to comprehend and elucidate the mechanisms involved in the initiation and
progression of this malignancy. Hence in my dissertation, I have utilized the KrasG12D; Pdx1-Cre
mouse model along with Muc5ac knockout mice model to understand the role of MUC5AC in
pancreatic cancer.
Overall, the following objectives were proposed:
1. Elucidate the MUC5AC mediated functions and associated mechanisms in pancreatic cancer
2. Explore the role of MUC5AC using KrasG12D; Pdx1-Cre and KrasG12D; Pdx1-Cre; Muc5ac-/pancreatic cancer mouse models
3. Expression analysis of MUC5AC in conjunction with other mucins and associated glycans in
colon adenoma-carcinoma sequence for their utility to predict colorectal cancer
4. Explore the utility of MUC5AC in combination with other mucins and associated glycoepitopes for discriminating the premalignant lesions of serrated neoplasia pathway and
conventional pathway from benign hyperplastic polyps
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Chapter II: Materials and Methods

1. Molecular basis of MUC5AC mediated cell cycle regulation, metastatic properties,
angiogenesis and chemoresistance of pancreatic cancer
2: Loss of Muc5ac mediated impact on pancreatic cancer progression in KRasG12D; Pdx1-Cre
mouse model
3: Mucins and associated glycans signatures in colon adenoma-carcinoma sequence: Prospective
pathological implication(s) for early diagnosis of colon cancer
4: Combinatorial assessment of CA 19-9/MUC17/MUC5AC expression discriminates sessile
serrated adenoma/polyp and tubular adenoma from hyperplastic polyps
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1. Molecular basis of MUC5AC mediated cell cycle regulation, metastatic properties,
angiogenesis and chemoresistance of pancreatic cancer
1.A Immunohistochemistry
Formalin-fixed paraffin embedded (FFPE) PDAC samples having adjacent normal pancreatic
tissues obtained during Whipple procedure were utilized to investigate the expression of secretory
mucin MUC5AC during pancreatic cancer. For this, tissues were baked overnight at 56°C,
deparaffinized with xylene, and rehydrated with graded alcohols (5 min each). Endogenous
peroxidase activity in tissues was quenched by incubation with a Methanolic solution of 3%
H 2 O 2 for one hour. For antigen retrieval, slides were boiled in 0.05M citrate buffer (pH 6.0,
95°C) for 15 min and then blocked with 2.5% horse serum (ImmPRESS Universal antibody kit;
Vector Laboratories, Burlingame, CA) for 3 hours. Next, tissues were incubated with the antiMUC5AC antibody (Abcam ab3649, 45M1, 1µg/ml) overnight at 4°C. The sections were then
washed with PBST, and incubated with anti-rabbit/anti-mouse secondary antibody (ImmPRESS
Universal antibody kit; Vector Laboratories) for 30 min and color was developed using substrate
chromogen-3, 3’-diaminobenzidine solution (DAB substrate kit; Vector Laboratories). The
positive expression was indicated by a reddish brown precipitate. The slides were counterstained
with Harris hematoxylin, dehydrated in graded ethanol, xylene, and mounted with Permount
(Vector Laboratories). All the stained slides were reviewed, confirmed for diagnosis, evaluated,
scored by a pathologist (Dr. Yuri Sheinin at UNMC), and the representative photographs were
taken. The intensity of MUC5AC staining was scored on a scale of 0–3 (0-negative, 1-weak, 2moderate, 3-intense staining) to give intensity scores (IS). For a given intensity, the percentage of
cells positive for MUC5AC expression within a given lesion was also scored on a scale of 0-1 (0:
0% cells staining, 1: 100% cells staining). The IS and corresponding score for the percentage of
immunoreactive cells were then multiplied to obtain a histology score (HS), representing overall
expression ranging from 0-3. A section was considered “positive” for MUC5AC expression if HS
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was greater than >0.01. Accordingly, tissues were also classified as being “Positive” or
“Negative” for MUC5AC expression.
1.B Cell culture and transfections
The metastatic fast growing (FG) variant of COLO357 pancreatic cancer cells (FG/COLO357)
[1] and SW1990 cells were previously purchased in our lab from the American type culture
collection (ATCC) for the study. These cells were cultured in DMEM supplemented with 10%
fetal bovine serum and antibiotics (100 μg/mL penicillin and 100 μg/mL streptomycin). The
cultures were incubated at 37°C in a mixture of 5% carbon dioxide, 95% oxygen in a humidified
atmosphere, and maintained for no longer than 12 weeks after recovery from frozen stocks. The
endogenous expression of MUC5AC was stably knocked down using three different MUC5AC
shRNA constructs (pSUPER.retro.puro-shMUC5AC) Table 2.1. For this, MUC5AC shRNA and
scramble vectors were transfected into Phoenix cells [2] using Lipofectamine 2000TM (Invitrogen,
Carlsbad, CA, USA). Transfected Phoenix cells culture generate high yields of virion-containing
supernatant that was collected and filtered 48-hours post-transfection. Simultaneously,
FG/COLO357 and SW1990 parental cells were plated in a 24-well cell culture Petri dish at a
seeding density of 2.5x104 cells per well and grown to 70% confluency. Before retroviral
infection FG/COLO357 and SW1990 cells were maintained in serum-free growth medium for 6
hours. The filtered viral supernatant was then used to infect the FG/COLO357 and SW1990 cells
with the addition of 4 µg/mL polybrene. Clones transduced with MUC5AC shRNA constructs
were selected and maintained using the antibiotic puromycin (4μg/ml) in 10% DMEM medium to
obtain stably transfected cells.
1.C Immunoblotting
For protein analysis, 2×106 of FG-Scr/Sh5AC and SW-Scr/Sh5AC cells were plated on a 100 mm
cell culture Petri dishes in complete growth medium. After 48 hours of incubation, cells were
processed for protein extraction using radioimmunoprecipitation assay buffer containing protease
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and phosphatase inhibitors followed by western blotting using standard procedures. Similar
procedure was employed for protein extraction after treatment of cells mentioned above with
1µM Gemcitabine for 48 hours, and HMEC-1 cells treated with conditioned media from
MUC5AC expressing and knockdown cells for 48 hours. Protein concentrations were determined
using a Bio-Rad D/C protein estimation kit. For MUC5AC, the proteins (40µg) were resolved by
electrophoresis on a 2% SDS-agarose gel under reducing conditions. For β-actin, XIAP, GAPDH,
β-Catenin, SP1, CD133, CD24, ESA, SOX2, and OCT3/4 10% SDS-PAGE and for Cyt-c, BCL2,
BAD, Cleaved-Caspase-3, Cleaved-Caspase-9, and SHH 15% SDS-PAGE were performed under
similar conditions. Resolved proteins were transferred onto the polyvinylidene difluoride (PVDF)
membrane and blocked in 5% non-fat milk in phosphate-buffered saline (PBS) for 2 hours. The
blots were then incubated with respective antibodies overnight at 4°C (Table 2.2), followed by
4X10 min washes in TBST (50 mM Tris –HCl, pH 7.4, 150 mM NaCl and 0.05% Tween-20).
Further, the membranes were incubated in Horseradish peroxidase-conjugated secondary
antibodies (Amersham Biosciences, Buckinghamshire, UK) (diluted at 1:2000 in PBS with 3%
non-fat milk) for 1 hour at room temperature, followed by four washes in TBST. The blots were
then processed with ECL chemiluminescence kit (Amersham Biosciences), and the signal was
detected by exposing the processed blots to X-ray films (Biomax Films, Kodak, NY, USA).
1.D Immunofluorescence/Confocal microscopy
Expression and localization of MUC5AC protein were observed using confocal laser scan
microscopy. For this, 10×103 cells were plated on coverslips and grown for 48 hours. After
washing with Hank’s buffered salt solution (HBSS) (pH=7.4), the cells were fixed in ice-cold
methanol at −20°C for 2 min and blocked with 10% goat serum containing 0.05% Tween-20 for 1
hour followed by incubation with specific antibodies overnight at 4°C. Cells were then washed
and incubated with FITC-conjugated goat antimouse/rabbit secondary antibodies for 60 min.
After that, the coverslips were mounted on glass slides with antifade Vectashield mounting
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medium (Vector Laboratories, Burlingame, CA, USA). Immunostaining was observed under a
Zeiss (Carl Zeiss Microimaging, Thornwood, NY) confocal laser scanning microscope, and
representative photographs were captured digitally using the 510 LSM software.
1.E RNA extraction, RT-PCR, Q-PCR
Total RNA was isolated from cell lines using the QIAGEN RNeasy Mini kit (QIAGEN, Valencia,
CA, USA) respectively, according to the manufacturer’s protocol. The mRNA isolated was
converted to cDNA using oligo-dT primers and was used (1:5 diluted) to determine the
expression of MUC5AC mRNA by PCR using specific primers (Table 2.1). Quantitative realtime PCR was performed on Roche Light Cycler 480 system (Roche Diagnostics, Mannheim,
Germany). For PCR, 10 μl reactions [5 μl 2x SBYR green Master Mix, 3.2 μl of autoclaved
nuclease free water, 1 μl diluted RT product (1:5) and 0.4 μl each of forward and reverse primer
(5 pmol) (Table 2.1)] were performed in triplicate along with non-template controls (NTCs) for
each assay under the same conditions. The cycling conditions were comprised of 95°C for 10min,
followed by 40 cycles of 95°C for 15 s and 58°C for 1min. Gene expression levels were
normalized to the level of β-actin expression used as a control.
1.F MTT Assay
Cell viability was determined using 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium
bromide assay as described previously. In brief, FG-Scr/Sh5AC and SW-Scr/Sh5AC cells were
seeded into 96-well microplate at a density of 5x103 cells per well, in complete growth medium
containing 10% FBS. After 24 hours, the culture media was aspirated and replaced with growth
medium containing 1% FBS. Every 24 hours, cells were incubated with 10 μl of 3-(4, 5dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (5 mg/ml in PBS) solution added to each
well for 3 hours, and then the absorbance was read at 560 nm with a reference wavelength of 670
nm using microplate reader. Readings were taken for 6 days.
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For analyzing impact of Gemcitabine on FG-Scr/Sh5AC and SW-Scr/Sh5AC cells were
seeded into 96-well microplate at a density of 10x103 cells per well, in complete growth medium
containing 10% FBS. The pharmacy at the Lied Transplant Center at UNMC, kindly provided the
injectable solution of Gemcitabine, GEMZARH (Eli Lilly Company, Indianapolis, IN). After 48
hours, cells were treated with different concentrations of Gemcitabine and incubated at 37°C for
48 hours. Untreated cells were considered as controls. After 48 hours, cells were incubated with
10 μl of 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (5 mg/ml in PBS)
solution added to each well for 3 hours, and then the absorbance was read at 560 nm with a
reference wavelength of 670 nm using microplate reader. The half maximal inhibitory
concentration (IC-50) of Gemcitabine was determined in each cell line from interpolating values
in the graph (% Cytotoxicity vs. Gemcitabine Concentration).
For analyzing the impact of MUC5AC on endothelial cell viability, HMEC-1 cells were
seeded into 96-well microplate at a density of 5x103 cells per well, in complete growth medium
containing 10% FBS. After 48 hours, cells were treated with conditioned media from MUC5AC
expressing and knockdown cells and incubated at 37°C for 48 hours. After 48 hours, cells were
incubated with 10 μl of 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (5 mg/ml
in PBS) solution added to each well for 3 hours, and then the absorbance was read at 560 nm with
a reference wavelength of 670 nm using microplate reader.
1.G Anchorage independent proliferation assay
For anchorage-independent proliferation assay, 2.5x103 FG-Scr/Sh5AC cells suspended in 0.35%
noble agar were plated as top layer, over a layer of 0.5% noble agar, in a six well multidish. Cells
were incubated at 37°C for 3 weeks and provided with complete growth medium two times a
week. After 21 days, colonies formed were visualized under microscope, photographed and
counted.
1.H Apoptosis assay
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Apoptosis was measured by using the Annexin-V Fluos staining kit (Roche Diagnostics,
Indianapolis, IN, USA).For this, FG-Scr/Sh5AC and SW-Scr/Sh5AC cells were plated at a
density of 1X106 cells in 60 mm cell culture Petri dishes for 48 hours at 37°C. After 48 hours, the
cells were washed with PBS (3x) and then made serum-free for next 48 hours.
In another experiment, the cells were treated with 1µM Gemcitabine for 48 hours and the
induction of apoptosis and necrosis was measured by staining the cells with Annexin-V and
propidium iodide solution, followed by fluorescence-activated cell sorting analysis (FACS).
1.I Cell cycle analysis
FG-Scr/Sh5AC and SW-Scr/Sh5AC cells were plated at density of 1x106 cells in 60 mm cell
culture Petri dishes. Next day, for in vitro synchronization in G0 phase, the cells were properly
washed with PBS, and maintained in serum-deprived medium for 48 hours [3]. The cells were
then released from the block by replacing with complete culture medium. Post 48 hours of
release, the cells were collected and fixed in 1 ml of 70% ethanol for 45 minutes at 4°C and
centrifuged to decant ethanol. The cell pellets were washed once with PBS and then resuspended
in 1 ml of Telford’s reagent [4]. After incubating at 4°C for 1 hour, the total DNA content was
analyzed using the fluorescence-activated cell sorting method.
1.J Motility assay
For motility assays, 1×106 cells suspended in 2 ml serum-free medium were plated in the top
chamber of polyethylene terephthalate membrane inserts (six-well inserts; pore size 8 µm; Becton
Dickinson, Franklin Lakes, NJ, USA). To provide chemotactic drive, two ml of 10% serumcontaining medium was added to the lower chamber of the well and the cells were allowed to
migrate for 24 hours. After removing the non-migrated cells from the upper side of the
membrane, the migrated cells on the lower side of the membrane were stained with a Diff-Quick
cell stain kit (Dade-Behring Inc, Newark, DE 19714, USA). They were then photographed in 10
random fields of view at 10X magnification. Cell numbers were counted and expressed as the
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average number of cells/field of view. The experiments were repeated three times and data were
represented as the average of the three independent experiments with the standard error of the
mean.
1.K Cell adhesion assay
For cell adhesion assays, Matrigel-coated 96 well plates (BD BiocoatTM, Bedford, MA, USA)
were utilized. A single-cell suspension of FG-Scr/Sh5AC cells and SW-Scr/Sh5AC (1×104 cells)
in 100 μl of full growth medium was added to each well. Cells were allowed to adhere for 120
min at 37˚C. The cells were subsequently washed with PBS to remove nonadherent cells. The
adhered cells were stained with 50μl of 0.5% crystal violet (Sigma-Aldrich Corp., St Louis, MO,
USA) in 20% methanol for 30 min. The cells were then washed with deionized water and were
lysed in 50 μl of 30% acetic acid. Cell adhesion was calculated by measuring the absorbance of
the eluted dye at 570 nm using a microplate reader.
1.L Angiogenesis tube formation assay
For angiogenesis assay, FG-Scr/Sh5AC and SW-Scr/Sh5AC (1X106 cells) were plated in 6 well
multi plates. Next day the complete growth media was replaced by SF media and cells were
incubated for 48 hours at 37°C and the cell culture supernatant was collected. Before assay,
endothelial cells (HMEC-1) were incubated in SF media for three hours, trypsinized, resuspended
in conditioned medium mentioned above and 20X103 cells/ well were plated in triplicate on 96well Matrigel-coated plates. The assay plate was incubated at 37°C overnight and endothelial
tubes thus formed were examined, and pictures were taken using a light microscope. The
quantitative analysis of a total number of endothelial tube junctions formed and percentage
vessels area was done by Angiotool software (national cancer institute, USA).
1.M Co-immunoprecipitation
For Co-immunoprecipitation study, FG/COLO357 and SW1990 cells were grown to confluency,
and then lysed in non-denaturing lysis buffer [20mM Tris-HCl pH 8.0, 137mM NaCl, 2mM
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ethylenediaminetetraacetic acid (EDTA), 1% Nonidet P-40 (NP-40), 1mM NaF, 1mM sodium
orthovanadate (Na 3 VO 4 ), 1mM PMSF, aprotinin 5mg/ml, leupeptin 5mg/ml and containing 1%
Triton X-100] for 25–35 min at 4°C. For pre-cleaning, the processed lysates were incubated with
protein A+G Sepharose beads (Sigma-Aldrich Corp., St Louis, MO, USA) for 4 hours at 4°C on a
rotator. Total protein concentration in pre-cleared lysates were quantified and equal amounts of
total protein (500 µg) in 500µl volumes of non-denaturing lysis buffer were then incubated
overnight with anti-MUC5AC/β-Catenin/E-Cadherin/Src antibodies or with respective IgG at 4°C
on a rotator. The protein-antibody complexes were incubated with protein A+G Sepharose beads
on a rotator for 4 hours at 4°C. The pulled-down Immunocomplexes were washed with the lysis
buffer (3X) followed by two wash with PBS. The immunoprecipitates and input were
electrophoretically resolved and immunoblotted with anti-MUC5AC/β-Catenin/E-Cadherin/Src
antibodies.
1.N Orthotopic implantation
To examine the effect of MUC5AC knockdown in vivo, subconfluent cultures of FG-Scr/Sh5AC
cells (>95% viable) were resuspended in PBS at a concentration of 5x105 cells/50 µl, and
orthotopically implanted in the pancreas of immunodeficient mice as per the established protocol
[5] (8 per group; purchased from the Animal Production Area of the National Cancer InstituteFrederick Cancer Research and Development Center, Frederick, MD, USA). The mice were
maintained in accordance with the Institutional Animal Care and Use Committee guidelines. All
mice were sacrificed after 50 days of implantation, and the presence of metastatic lesions to
distant organs (liver, spleen, lung, mesenteric lymph nodes, and on the peritoneal wall) was
determined by thorough gross inspection and histological analysis. Pancreatic tumors were
excised, weighed, measured, formalin fixed, paraffin embedded and were later sectioned into
0.5µm thick sections. A part of the tumor tissue was also frozen for RNA and protein analysis.
The experiment was repeated twice.
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1.O Subcellular fractionation
For the cytoplasmic and nuclear extracts, the cells were rinsed with ice-cold PBS, collected and
incubated on ice for 1 hour in cytoplasmic-extraction buffer [10 mM HEPES (pH 7.4), 10 mM
KCl, 0.2% NP-40, 0.1 mM EDTA, 10% glycerol, 1.5 mM MgCl 2 , supplemented with protease
inhibitor cocktail, 1 mM DTT, 1 mM PMSF, 5 mM Na 3 VO 4 , and 5mM NaF]. Cells were lysed
using a 25 Gauge needle every 20 min. Cells were then centrifuged at 16000Xg and the
supernatant was collected as the cytoplasmic extract. The remaining pellet was thoroughly
washed with PBS 3 times followed by incubation with the nuclear extraction buffer [20 mM
HEPES (pH 7.6), 420 mM NaCl, 1 mM EDTA, 20% glycerol, 1.5 mM MgCl 2 , 1 mM DTT, 1
mM PMSF, 5 mM Na 3 VO 4 , 5 mM NaF] for 1 hour, sonicated at 60% amplitude for 10s,
subjected to centrifugation and supernatant was collected as a nuclear extract.
1.P Statistical analyses
Statistical significance for in vitro functional assays mentioned above was evaluated with the
student t-test. All the experiments were performed in triplicates. For in vivo experiments mean
tumor weights were compared between groups using a two-tailed independent sample student’s ttest. A p-value of <0.05 was considered statistically significant.

83

2. Loss of Muc5ac mediated impact on pancreatic cancer progression in KRasG12D; Pdx1Cre mouse model
2.A Generation of KrasG12D; Pdx1-Cre; Muc5ac-/- mouse model
The C57BL/6 Muc5ac-/- mice were obtained from Dr. Christopher Evans at the University of
Colorado. The Pdx1-Cre and Muc5ac-/- mice and the LSL-KrasG12D and Muc5ac-/- mice previously
available in our lab were crossed to generate F1 progeny. The F1 progeny was genotyped for
Kras, Pdx1-Cre and Muc5ac-/- using specific primers for all three genes by Polymerase chain
reaction (PCR) to obtain the final genotype Pdx1-Cre; Muc5ac-/- and LSL-KrasG12D; Muc5ac-/-.
The F1 progeny were then further crossed to remove the LSL cassette in order to activate
KrasG12D and obtain the F2 progeny having the genotype KrasG12D; Pdx1-Cre; Muc5ac-/- in the
pancreas of the mouse. Hence, animals positive for KrasG12D; Pdx1-Cre; Muc5ac-/- expressed the
mutated KrasG12D in the pancreas where Muc5ac is knocked out. The KrasG12D; Pdx1-Cre;
Muc5ac-/- animals (positive for both Kras and Pdx1-Cre in the absence of Muc5ac) and KrasG12D;
Pdx1-Cre animals (carrying wild type Muc5ac) were euthanized at 10, 20, 30, 40 and 50 weeks of
age (three animals/group/time point). Throughout the experiment, animals were provided with
food and water ad libitum and subjected to a 12-hour dark/light cycle. Animal studies were
performed in accordance with the U.S. Public Health Service "Guidelines for the Care and Use of
Laboratory Animals" under an approved protocol by the University of Nebraska Medical Center
Institutional Animal Care and Use Committee (IACUC).
2.B Immunohistochemistry (Mouse tissues)

The KrasG12D; Pdx1-Cre; Muc5ac-/- (n=3) animals were sacrificed at 10, 20, 30, 40, and 50
weeks of age. A portion of the pancreas from these mice was fixed in 10% formalin (Fisher
Scientific, Fair Lawn, NJ, USA). The fixed tissues were then embedded in paraffin and serial
tissue sections (5 μm thick) were cut from the UNMC tissue core facility. The sections were
deparaffinized using Xylene (Fisher Scientific, Fair Lawn, NJ, USA) and dehydrated using
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diluted alcohol gradually. Subsequently, the sections were stained with hematoxylin and
eosin (H&E) stains and examined under a light microscope. In addition to H&E, the slides
were processed for immunostaining as described previously. All stained slides were
evaluated by a pathologist under a Nikon E400 Light Microscope and representative
photographs were taken.
2.C c-DNA isolation and genotyping
Genotyping was performed on the DNA isolated from the clipped tails from mice. The tails were
clipped at 10-14 days of mice age and DNA isolation was performed using the standard protocol
(Maxwell 16 mouse tail DNA purification kit, Promega, Madison, WI, USA). The genotyping of
Kras, Pdx-1-Cre, Muc5ac-/-, was performed by PCR using the primer sequences mentioned in
Table 2.1.
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3. Mucins and associated glycan signatures in colon adenoma-carcinoma sequence:
prospective pathological implication(s) for early diagnosis of colon cancer
3.A Tissue specimens
Colon tissue arrays (Cat# CO809a) having normal (9), inflamed (10), hyperplastic polyp (10),
adenomas including villous, tubulovillous, tubular and serrated subtypes (30), and
adenocarcinoma (16) samples were obtained from US Biomax, Rockville, MD.
3.B Immunohistochemistry (IHC)
Immunohistochemistry (IHC) was performed on the colon tissue arrays listed above. The colon
disease arrays were baked overnight at 56°C, followed by deparaffinization with xylene and
rehydration with graded alcohols (5 min each). Tissues were incubated with a methanolic solution
of 3% H2O2 for quenching endogenous peroxidase activity, followed by heat induced antigen
retrieval with 0.05M citrate buffer (pH 6.0, 95°C) for 15 min. Sections were then blocked with
2.5% horse serum (ImmPRESS Universal antibody kit; Vector Laboratories, Burlingame, CA) for
3 hr. The tissue samples were incubated overnight at 4°C with well characterized and specific
anti-mucin and anti-mucin associated glycans antibodies listed in (Table 2.3). Next, the tissue
arrays were washed and incubated with anti-rabbit/anti-mouse secondary antibody (ImmPRESS
Universal antibody kit; Vector Laboratories) for 30 min. The color was developed by adding
substrate chromogen, 3, 3’-diaminobenzidine solution (DAB substrate kit; Vector Laboratories).
A reddish brown precipitate indicated positive expression. The slides were counterstained with
Harris hematoxylin, dehydrated in graded ethanol followed by xylene and mounted with
Permount (Vector Laboratories). Each tissue core in the array was reviewed, confirmed for
diagnosis, and evaluated by a pathologist (Dr. Sonny L. Johansson at UNMC) to determine the
staining score. The intensity of staining for each of the markers was scored on a scale of 0–3 (0negative, 1-weak, 2-moderate, 3-intense staining) to give intensity scores (IS). The percentage of
cells positive for mucin or glycan within a given lesion was scored on a scale of 1–4 as follows:
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1: 0–25%; 2: 26–50%; 3: 51–75%; and 4: 76–100% cells positive. The staining intensity scores
and scores corresponding to the percentage of immunoreactive cells were then multiplied to
obtain a composite score (CS) representing overall expression ranging from 0-12. CS was further
categorized as 0: negative, 1-3: weak, 4-6: mild, 7-9: moderate, and 10-12: strong expression. A
section was considered ‘‘positive’’ for a particular marker if the CS was ≥1.
3.C Statistical Analysis
For statistical analysis, each spot on the array was considered as an individual sample. CS and IS
values were compared with the Kruskal-Wallis test and Wilcoxon test for pairwise comparisons.
No adjustments were made for multiple comparisons. Further, multivariate logistic regression
method was used to evaluate marker combinations as predictors of hyperplastic polyps vs.
adenoma/adenocarcinoma combined as well as two additional models comparing polyps vs.
adenoma and polyps vs. adenocarcinoma separately. For each of the multivariate models, full
models were fit, including marker (MUC17, MUC2, MUC4, MUC5AC, and Tn/STn-MUC1)
composite scores as continuous variables. This model allows us to evaluate the effect of a single
marker on outcome while adjusting for all the other markers. Reduced models were also
considered utilizing backward variable selection with α set at 0.10 for variable inclusion in the
model. Firth’s penalized maximum likelihood estimation was used to reduce bias in the parameter
estimates because separability occurred in some of the multivariate models. P-values <0.05 were
considered to be statistically significant. All statistical analyses were performed using SAS
software Version 9.3 (SAS Institute Inc., Cary, NC).
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4. Combinatorial assessment of CA 19-9/MUC17/MUC5AC expression discriminates sessile
serrated adenoma/polyps and tubular adenoma from hyperplastic polyps
4.A Tissue specimens and patient demographics
After institutional review board approval (IRB#167-15-EP), formalin fixed paraffin-embedded
tissue specimens of hyperplastic polyps (n=33), sessile serrated polyps/adenomas (n=39) and
tubular adenomas (TA) (n=36) were obtained from the Department of Pathology at University of
Nebraska Medical center (UNMC). Available H&E slides were examined initially by a
pathologist (Dr. Yuri Sheinin at UNMC) to recheck the original histological diagnosis. All the
selected polyps fulfilled current diagnostic criteria, and had sufficient available tissue for
immunohistochemical (IHC) analyses.
Demographic data were retrieved from available hospital records. The clinical and
endoscopic findings of the patients and their polyps are summarized in (Table 2.4). There were
no significant differences with regard to age, sex ratio, ethnicity, site of polyp, family history of
colon cancer, tobacco consumption, polyp size, and prior or subsequent colonoscopies. TA were
the most common polyp type diagnosed followed by SSA/P’s and HP’s (Table 2.4).
4.B Immunohistochemistry (IHC)
IHC was performed on the polyps following a standardized protocol [6]. After overnight baking
at 56°C, tissue sections were deparaffinized with xylene (10 min, 4X), rehydrated with graded
alcohols (5 min each wash). Endogenous peroxidase activity was quenched by incubation in a
methanolic solution of 3% H 2 O 2 (30 min). Antigens were retrieved by boiling tissue sections in
0.05M citrate buffer (pH 6.0, 95°C, 15 min), and blocked with 2.5% horse serum (ImmPRESS
Universal antibody kit; Vector Laboratories, Burlingame, CA) for one hour. Tissues sections
were then incubated with well characterized anti-mucin and anti-mucin associated glycan
epitopes specific antibodies overnight at 4°C (Table 2.3). Next, the sections were washed with
PBS-T (10 min, 4X), incubated with Horseradish peroxidase-conjugated anti-rabbit/anti-mouse
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secondary antibody (ImmPRESS Universal antibody kit; Vector Laboratories) (30 min), washed
with PBS-T (10 min, 4X), developed for colorimetric detection by 3.3’ diaminobenzidine kit
(Vector Laboratories, Burlingame, CA, USA) and counterstained with hematoxylin. Tissues were
dehydrated (graded alcohol and xylene), dried, mounted with Permount, and evaluated by the
pathologist (Dr. Yuri Sheinin at UNMC) to investigate the staining scores corresponding to the
pathologic lesions as well as adjacent normal areas.
The intensity of staining for each of the markers was scored on a scale of 0–3 (0negative, 1-weak, 2-moderate, 3-intense staining) to give intensity scores (IS). For a given
intensity, the percentage of cells positive for mucin or associated glycan epitopes within a given
lesion was also scored on a scale of 0-1 (0: no cells staining, 1: 100% cells positively stained).
The staining intensity Scores and corresponding score for the percentage of immunoreactive cells
were then multiplied to obtain a histology Score (H-Score), representing overall expression
ranging from 0-3. The respective tissue specimens were further classified by H-score as havingno reactivity H-score=0, focal reactivity (H-score >0 but ≤0.1), mild reactivity (H-score >0.1 but
≤1), moderate reactivity (H-score >1.0 but ≤2.0) and strong reactivity (H-score >2.0). Further,
differential immunohistochemical localization pattern of mucin and associated glycan epitopes
expression within colon crypts was also considered for analysis.
4.C Statistical analysis
Patient characteristics for each polyp subtype were compared using chi-square or Fisher’s exact
test for categorical variables and ANOVA or Kruskal-Wallis test for continuous variables. Hscore for each polyp subgroup were compared using Kruskal-Wallis test and Wilcoxon signed
rank test for pairwise comparisons. Wilcoxon signed rank test was used to compare H-Score of
polyp subtypes and the respective adjacent normal controls. Adjustments for multiple
comparisons were made using Bonferroni’s method. H-score was also categorized into reactivity
groups and these were compared by polyp subtype using Chi-square test. Localization pattern of
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secretory mucin MUC5AC in HP and SSA/Ps crypts was compared using Chi-square test.
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Table 2.1 List of the primers used in the study
Gene

Primer
K006F-5’-CCT TTA CAA GCG CAC GCA GAC TGTAGA-3’

Kras (mouse) genotyping
K005R-5’-AGCTAG CCA CCATGGCTTGAG TAA GTC TGC A-3’
F-5’-CTGGACTACATCTTGAGTTGC -3’
Pdx1;Cre (mouse) genotyping
R-5’-GGTGTACGGTCAGTAAATTTG -3’
F- 5’-GTTTCCACAAAGCACAACCAAAC-3’
Muc5ac (mouse) genotyping

R- 5’-TAGGGCCAGGCTAAGAGAAACC-3’

F: 5’-CTCAGGAATGACGCTTGGACATGG-3’
MUC5AC human (qPCR)

R: 5’-GGCTGAGGTAGGAGTGAGGTTCTT-3’
F: 5’-TGATTCTGCCCTCCTCCTTCTG-3’

VEGF-A human (qPCR)

R: 5’-TGATTCTGCCCTCCTCCTTCTG-3’
F: 5’-PO 4 GATCCCCGGACGGTGCTTGACGACATTTCAAGAGAATGTCGTCAA
GCACCGTCCTTTTTA-3’

MUC5AC shRNA-1

R: 5’-PO 4 AGCTTAAAAAGGACGGTGCTTGACGACATTCTCTTGAAATGTCGT
CAAGCACCGTCCGGG-3’
F: 5’-PO 4 GATCCCCCGTTTGACGGGAAGCAATATTCAAGAGATATTGCTTCC
CGTCAAACGTTTTTA-3’

MUC5AC shRNA-2

R: 5’-PO 4 AGCTTAAAAACGTTTGACGGGAAGCAATATCTCTTGAATATTGCT
TCCCGTCAAACGGGG-3’
F: 5’-PO 4 GATCCCCGGACAAAGTGGTTCGACGTTTCAAGAGAACGTCGAACC
ACTTTGTCCTTTTTA-3’

MUC5AC shRNA-3

R: 5’-PO 4 AGCTTAAAAAGGACAAAGTGGTTCGACGTTCTCTTGAAACGTCGA
ACCACTTTGTCCGGG-3’
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Table 2.2: List of antibodies and respective dilutions used in chapter III and IV

S.no.

Parameter

Source

Catalogue #

Dilutions
1:400

1.

MUC5AC (CLH2)

Dr. Hollingsworth

Enriched
Hybridoma
supernatant

2.

MUC5AC (45M1)

Abcam

ab3649

1:400

3.

β-Actin

Sigma

A5316

1:10000

4.

p27

Cell signaling

#3686

1:1000

5.

p21

Santa Cruz

Sc-6246

1:200

6.

Cyclin-D1

Cell signaling

#2922

1:1000

7.

Cyclin-E

Abcam

ab7959

1:200

8.

Cytochrome-c

Cell signaling

#4280

1:1000

9.

BCl2

Santa Cruz

Sc-492

1:200

10.

XIAP

Cell signaling

#2045

1:1000

11.

BAD

Cell signaling

#9292

1:1000

12.

Cleaved-Caspase3

Cell signaling

#9664

1:1000

13.

Cleaved-Caspase9

Cell signaling

#9509

1:1000

14.

GAPDH

Cell signaling

#5174

1:1000

15.

CD133

Abcam

Ab19898

1:1000

16.

CD24

Santa Cruz

Sc-11406

1:1000

17.

ESA

Cell signaling

#2626S

1:1000

18.

SHH

Santa Cruz

Sc-9024

1:1000

19.

SOX2

Santa Cruz

Sc-20088

1:1000
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20.

OCT3/4

Santa Cruz

Sc-5279

1:500

21.

E-Cadherin

Dr. Keith Johnson

Enriched hybridoma
supernatant

1:50

22.

Integrins

Cell signaling

#4749

1:1000

23.

SRC

Santa Cruz

Sc-19

1:200

24.

p-SRC

Cell signaling

#2101

1:1000

25.

β-Catenin

Sigma

C2206

1:100

26.

pAKT(Ser473)

Cell Signaling

#4060

1:1000

27.

pERK1/2

Santa Cruz

Sc-81492

1:200

28.

pFAK(Y397)

Cell signaling

3283

1:1000

29.

Ki67

Abcam 15580

15580

1:300
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Table 2.3 List of antibodies and respective dilutions used in Chapter V and Chapter VI

S.no.

Parameter

Antibody

Dilutions

1.

MUC1

HMFG2

1:5

2.

MUC4

8G7

1:2000

3.

MUC17

SN-1132

1:150

4.

MUC2

5.

MUC5B

19.4E (Abcam)

1:300

6.

MUC5AC

45M1
(Abcam)

1:300

7.

MUC6

CLH5

1:100

8.

CA 19-9

NS19.9

1:100

9.

TAG72

CC49

1:1000

10.

Tn/STn on MUC1

5E5

1:300

EPR6145
(Abcam)

1:500
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Table 2.4: Demographic and clinicopathological characteristics of patients included
in the study

HP
(n=33)
17 (61%)
11 (39%)
5

SSA/P
(n=39)
22 (59%)
15 (41%)
2

TA
(n=36)
18 (56%)
14 (44%)
4

59 (50-91)

60 (28-77)

61 (47-84)

6 (23%)

2 (6%)

3 (11%)

20 (77%)
0
0
7

30 (91%)
0
1 (3%)
6

24 (86%)
1 (4%)
0
8

Cecum
Ascending
Transverse
Descending
Sigmoid
Rectum
N/A

0
2 (8%)
1 (4%)
4 (15%)
10 (38%)
9 (35%)
7

4 (11%)
10 (27%)
6 (16%)
5 (14%)
7 (19%)
5 (14%)
2

4 (13%)
10 (31%)
6 (19%)
3 (9%)
4 (13%)
5 (15%)
4

No
Yes
N/A
No
Yes
N/A

18 (72%)
7 (28%)
8
6 (23%)
20 (77%)
7

Polyp size (cm3)

Mean (SD)

0.048 (0.084)

Number of polyps
Number of precancerous
polyps
Prior or subsequent
colonoscopies
with polyps

Median (range)

2 (1-7)

29 (83%)
6 (17%)
4
13 (37%)
22 (63%)
4
0.101
(0.168)
2 (1-7)

27 (87%)
4 (13%)
5
10 (32%)
21 (68%)
5
0.088
(0.174)
3 (1-7)

0.018

Median (range)

1 (0-6)

2.5 (1-4)

3 (1-7)

<0.0001

Median (range)

1 (1-3)

3 (0-5)

1 (0-3)

0.28

Gender
Age

Ethnicity

Polyp site

Family History of colon
cancer

Tobacco

Female
Male
N/A
Median
(Range)
African
American
Caucasian
Hispanic
Asian
N/A

p-value

0.93
0.9

0.19

0.2

0.34

0.5

0.41

Abbreviations: HP, Hyperplastic polyps; SSA/Ps, Sessile serrated adenoma/Polyps; TA, Tubular
adenoma; SD, Standard deviation
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Chapter III

Molecular basis of MUC5AC mediated cell cycle regulation,
metastatic properties, angiogenesis and chemoresistance of
pancreatic cancer
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1. Synopsis
Pancreatic ductal adenocarcinoma is one of the deadliest solid malignancies. Despite extensive
research efforts, the prognosis of this malignancy remains grim mainly due to diagnosis at
advanced stages when cancer have metastasized to distant organs. Pancreatic cancers very often
develop resistance to chemotherapy. Surgical resection offers the only chance of cure if detected
early. Hence, identification of newer molecules that can be targeted is essential for improving
overall prognosis of this lethal malignancy. Mucins are heavy weight glycoproteins that are
known to play a critical role in initiation and progression of the pancreatic cancer. In this context,
secretory mucin MUC5AC is overexpressed in pancreatic cancer while it is not detected in the
normal pancreas. Association of MUC5AC with poor prognosis of pancreatic cancer has also
been demonstrated. Few in vitro studies have highlighted the role of MUC5AC in increased
migration and adhesion of pancreatic cancer cells. However, the elucidation of underlying
mechanisms remained elusive. Therefore, in this study, we developed MUC5AC knockdown
pancreatic cancer cell lines and observed that loss of MUC5AC results in decreased cell viability,
increased apoptosis, reduced migration, negatively impacts angiogenesis and increased the
sensitivity of pancreatic cancer cells to Gemcitabine. Further, in vivo tumor formation and
metastasis to distant organs was also decreased in an orthotopic mouse model on knockdown of
MUC5AC. Interestingly, we observed that decrease in MUC5AC results in decreased expression
of cell cycle regulatory proteins, loss of integrin expression, increased E-Cadherin expression
thus impacting pancreatic cancer cell growth and metastasis. Moreover, we observed greater
enrichment of stem cell population on the treatment of MUC5AC expressing pancreatic cancer
cells with Gemcitabine. Further, we observed that MUC5AC by physically interacting with ECadherin and β-Catenin may impact pancreatic cancer cell growth and metastasis. Altogether, our
findings demonstrate that MUC5AC significantly contributes towards pancreatic cancer
progression.
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2. Background and Rationale
Pancreatic cancer (PC) is one of the most lethal cancers known to affect the mankind [1]. As per
the estimates of American cancer society, approximately 53,070 new cases of PC and 41,780
deaths are expected in 2016 [3]. PC is projected to become the second leading cause of cancerrelated deaths by 2030 [2]. Continuous research efforts over the past few decades have
culminated into a slight upturn of 5 year survival rate for PC from <6% to ~8% [3]. However, the
overall prognosis of this malignancy still remains grim [1]. This dismal prognosis is primarily
attributed to the asymptomatic nature of this malignancy and diagnosis at locally advanced or
metastatic stage of disease [4]. In addition, PC remains a therapeutic challenge. Surgery is the
only curative option with some success for local disease [5]. Chemo-radiation and Gemcitabine
are the available treatment options for metastatic pancreatic cancer. However, the intrinsic and
acquired chemoresistance limits the benefits [6]. Since the progress made in improving the life
expectancy of PC patients have not made significant strides, further investigation is required to
develop a much more comprehensive understanding of this complex disease.
Mucins are high molecular weight glycoproteins, primarily associated with protection,
repair and survival of the epithelial cell surface during conditions of physicochemical and
biological insults [7, 8]. Expression of aberrant forms and amounts of mucins has been implicated
in initiation, progression and poor prognosis of PC [7-10]. By virtue of deregulated expression of
mucin core proteins, differential glycosylation and unique domains, mucins are implicated in
enhanced tumorigenicity, invasiveness, metastasis, drug resistance and control of the tumor
microenvironment [10]. Hence, mucins have been identified as useful diagnostic, prognostic
markers and therapeutic targets in PC [9].
Secretory mucin MUC5AC has been associated with multiple inflammatory benign
conditions [11]. Aberrantly increased expression of MUC5AC and its association with poor
prognosis has been reported in different cancers including lung cancer [12], cholangiocarcinoma
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[13] and colorectal cancer [14]. During global gene expression analysis MUC5AC appeared
among the top differentially expressed genes in PC when compared with normal pancreas [15].
We and others have recently shown that MUC5AC is not detected in normal pancreas, while it is
overexpressed in PC and the expression increases as the cancer progresses from the precursor
lesions [Pancreatic Intraepithelial Neoplasia (PanIN)] to metastatic PC [16, 17]. Interestingly, few
in vitro and in vivo studies revealed oncogenic role of MUC5AC. MUC5AC was associated with
increased adhesion and invasion to extracellular matrix proteins and in vivo tumor growth [18,
19]. However, conclusive mechanistic basis of these observations remained elusive. Realizing the
significance of MUC5AC in various malignancies, its overexpression in PC and functional
studies highlighting its oncogenic role, we were intrigued to extensively investigate the
MUC5AC mediated functional roles and mechanistic basis in PC.
3. Results
3.A MUC5AC is overexpressed in PC tissues and PC cell lines
In our immunohistochemical analysis on pancreatic adenocarcinoma tissues procured during
Whipple procedure on pancreatic cancer patients, we observed a significantly increased
expression (p<0.001) of MUC5AC in pancreatic adenocarcinoma cases (HS Mean±SE,
0.93±0.14) compared to no expression of this mucin in adjacent normal pancreas (HS Mean±SE,
0±0) (Figure 3.1A.a,b and Figure 3.1B). Increased expression of MUC5AC was observed in
79.4% pancreatic adenocarcinoma cases compared to none of the normal pancreas. Overall, these
results suggest that MUC5AC is overexpressed in PC cases.
Looking at the differential expression of MUC5AC in pancreatic adenocarcinoma tissues,
we further investigated expression of MUC5AC in different PC cell lines. Very high expression
of MUC5AC mRNA was observed by q-PCR in different PC cell lines (T3M4, ASPC-1, BXPC3,
FG/COLO357, COLO357, SW1990, SU86.86 and HUPT3) relative to the normal pancreas cells
(HPNE) (Figure 3.1C). Similar to the transcript levels, at protein level, MUC5AC expression
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was not observed in normal pancreatic cells (HPNE), while its increased expression was observed
in different PC cells (ASPC1, BXPC3, COLO357, SW1990, and T3M4) (Figure 3.1D). All other
PC cells tested were observed to be negative for MUC5AC protein expression (CD18/HPAF,
CAPAN1, MiaPaCA, Panc-1) (Figure 3.1D). Additionally, to delineate the exact subcellular
localization of MUC5AC, we also performed immunofluorescence studies on BXPC3,
FG/COLO357, and SW1990 cells. A granular staining pattern of MUC5AC expression was
observed in the cytoplasmic compartments as well as it was also observed to be at intercellular
junctions (Figure 3.1E).
Further, to functionally characterize the MUC5AC mediated implications in PC and
further explore the associated mechanistic basis, we performed stable knockdown of MUC5AC
expression in two PC cell lines (FG/COLO357, and SW1990), which endogenously
overexpressed MUC5AC. Knockdown of MUC5AC in PC cells was validated by western blot
analysis. We observed a reduction in MUC5AC expression, at protein level in knockdown cells
(FG-Sh5AC and SW-Sh5AC) compared to the respective scramble control cells (FG-Scr, SWScr) (Figure 3.1F).
3.B MUC5AC silencing decreased cell viability, anchorage-independent growth and induces
apoptosis
To analyze the effect of MUC5AC knockdown on PC cell viability, we performed MTT assay
under reduced serum (1%) conditions. In this assay, we observed moderately reduced viability of
the PC cells on knockdown of MUC5AC (FG/COLO357, p<0.05; SW1990, p<0.01) compared to
the scramble controls (Figure 3.2A). To further analyze the impact of MUC5AC knockdown on
anchorage-independent growth we performed soft agar assay and observed significant reduction
(p<0.001) in number of colonies formed on knockdown of MUC5AC in FG/COLO357 PC cells
(Figure 3.2B), suggesting that secretory mucin MUC5AC assists in anchorage-independent
growth of PC cells. Next, to investigate that whether reduced viability and anchorage independent
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growth of PC cells in absence of MUC5AC is mediated by increased apoptosis, we performed
apoptosis assay (Annexin-V, PI staining) under conditions of serum starvation. We observed that
there was a significant increase (p<0.05) in FG/COLO357 PC cell apoptosis on inhibition of
MUC5AC expression (Figure 3.2C). Overall, the results from these experiments suggest that
MUC5AC plays a role in increased viability of PC cells.
3.C MUC5AC silencing induces G1/S phase cell cycle arrest
To further investigate the mechanism underlying the reduced viability of PC cells following
MUC5AC knockdown, we performed cell cycle assessment of the MUC5AC knockdown cells by
fluorescence activated cell sorting analysis. Interestingly, on inhibition of MUC5AC expression
there was a significant increase in the percentage of cells in G1-phase and a significant decrease
in the percentage of cells in S-phase (13%, p<0.05; 19%, p<0.001) in FG/COLO357 and SW1990
PC cells respectively compared to the scramble control cells. (Figure 3.3A and B). The effect of
MUC5AC knockdown on delayed G1/S progression prompted us to examine the expression of
key regulators of the G1/S phase cell cycle transition. We observed a significant upregulation of
cell cycle inhibitor protein p27, and downregulation of Cyclin-D1 and Cyclin-E cell cycle
regulatory proteins on knockdown of MUC5AC compared to the scramble control cells (Figure
3.3 C). These observations suggest that by impacting cell cycle regulatory proteins MUC5AC
may impact the PC cell growth and anti-apoptosis effects.
3.D MUC5AC confers resistance to Gemcitabine in pancreatic cancer cells
Looking at MUC5AC mediated anti-apoptotic and cell cycle effects, we next investigated the
anti-proliferative impact of current standard chemotherapeutic drug Gemcitabine after inhibition
of MUC5AC expression in FG/COLO357 PC cells. For this we used a range of effective
concentrations of Gemcitabine in MTT assay that can inhibit the proliferation of PC cells. The
results from MTT assay indicated that the control FG-Scr cells were less sensitive to the antiproliferative effects of Gemcitabine as compared to MUC5AC knockdown cells. The values of
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the half maximal inhibitory concentration (IC-50) obtained for FG-Scr cells were higher than the
values for MUC5AC knockdown cells (Figure 3.4A). This observation suggested that the
downregulation of MUC5AC in FG/COLO357 cells was accompanied by an enhanced sensitivity
of PC cells to Gemcitabine compared to MUC5AC expressing control cells. Further, we observed
a dose dependent, significant reduction (p<0.001) in viability of the PC cells by MTT assay on
MUC5AC Knockdown after 48 hours of Gemcitabine treatment (Figure 3.4B). As previously
described, we observed anti-apoptotic function of MUC5AC in PC cells in response to serum
starvation. Therefore, to further determine the function of MUC5AC in the development of
resistance to Gemcitabine in PC cells, we assessed the effect of MUC5AC down-regulation on
Gemcitabine-induced apoptosis in PC cells. To analyze the apoptotic index, the scramble control
and MUC5AC knockdown cells were treated with Gemcitabine for 48 hours. The Gemcitabine
treatment was directly associated with significant increase in percentage of cells undergoing
apoptosis (p<0.05) and necrosis (p<0.05) on MUC5AC knockdown compared to the scramble
control cells (Figure 3.4C).
To further elucidate the mechanistic basis of MUC5AC mediated anti-apoptotic effects
on Gemcitabine treatment, we investigated the levels of different apoptotic mediators in the
intrinsic pathway. For this we prepared cytosolic extracts from scramble control and MUC5AC
knockdown PC cells after 48 hours of treatment with Gemcitabine. By immunoblotting, we
observed high levels of Cyt-c, higher expression of apoptotic mediator BAD, Cleaved-Caspase-9,
Cleaved-Caspase-3 along with reduced levels of anti-apoptotic protein XIAP and BCl2 in the
cytosolic extracts from MUC5AC knockdown cells treated with Gemcitabine for 48 hours
compare with the scramble control cells treated with Gemcitabine for 48 hours (Figure 3.4D).
This suggested Gemcitabine mediated significant induction of apoptosis in the absence of
MUC5AC.
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Looking at the previous reports suggesting the reactivation of WNT/β-Catenin pathways
in Gemcitabine-resistant cancer cells. WNT/β-Catenin signaling has been demonstrated to
coordinate the stemness and cancer stem cell states. Also, GLI1 mediated increased expression of
MUC5AC results in nuclear accumulation of β-Catenin. Therefore, we hypothesized that on
Gemcitabine treatment MUC5AC mediates nuclear translocation of β-Catenin resulting in
resistance of PC cells by enrichment of stem cell markers. Interestingly, we observed that in
MUC5AC knockdown cells treated with Gemcitabine there was a significant reduction in nuclear
translocation of β-Catenin (Figure 3.4E). Further analysis of stem cell markers revealed
significant reduction in expression of stem cell markers ESA, SHH, SOX2 and OCT3/4 in
MUC5AC knockdown cells on treatment with Gemcitabine (Figure 3.4F). Overall, on basis of
our results, we conclude that MUC5AC mediated Gemcitabine resistance in PC cells might be
mediated by β-Catenin mediated enrichment of stemness.
3.E MUC5AC knockdown reduces cell motility and adhesion to extracellular matrix
proteins
MUC5AC has been shown to be associated with increased metastasis of lung cancer cells.
Therefore, we investigated whether inhibition of MUC5AC expression in PC cells would impact
their motility and metastasis. For this, we examined the motility of MUC5AC knockdown cells in
comparison to control cells (FG-Scr) utilizing Boyden chamber assay. MUC5AC knockdown
cells demonstrated a significant reduction in the migration capability (p<0.0001) compared with
the scramble control cells (Figure 3.5A).
By virtue of being a secretory mucin, on its secretion from PC cells MUC5AC may
modulate cell-ECM interactions. Therefore, we investigated whether overexpression of
MUC5AC in PC cells may impact PC cell-ECM interactions. For this binding affinity of FGScr/Sh5AC and SW-Scr/Sh5AC PC cells to Matrigel was examined. MUC5AC expressing
control cells (FG-Scr, SW-Scr) demonstrated significantly higher (p<0.05, p<0.001 respectively)
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adherence to Matrigel in comparison to MUC5AC knockdown cells (Figure 3.5B). This suggests
that overexpression of MUC5AC in PC cells plays an important role in tumor progression by
modulating tumor cell-matrix interactions.
Next, we investigated the probable mechanistic basis of MUC5AC mediated increased
motility and adherence to matrigel in PC cells. For this, we investigated the expression of cell
adhesion markers on inhibition of MUC5AC expression. Interestingly, we observed a significant
increase in expression of E-Cadherin levels on knockdown of MUC5AC (Figure 3.5C). Further,
integrins are the cell adhesion receptors that have been demonstrated to regulate initiation,
progression and metastasis of tumors. Study conducted on lung cancer cells has also highlighted
MUC5AC mediated impact on integrins protein expression. Therefore, we investigated MUC5AC
mediated impact on integrin expression in PC cells. We observed a significant reduction in the
expression of αV- and β5-integrins on knockdown of MUC5AC in comparison to the scramble
control cells (Figure 3.5C). As downstream mediators of integrin signaling, we investigated
phosphorylation of Src and observed that phosphorylation of Src at Y-416 is reduced on
knockdown of MUC5AC in comparison to the scramble control cells (Figure 3.5C). Overall, our
study suggests that MUC5AC may impact motility of PC cells by impacting expression of ECadherin and integrin signaling cascades.
3.F MUC5AC exists in a complex with E-Cadherin and β-Catenin
Colocalization of MUC5AC with E-Cadherin results in loss of E-Cadherin function. Besides this,
it has been reported that MUC5AC alters PC cell-cell adhesion and migration by modulating ECadherin and β-Catenin localization. Based on these reports we hypothesized that MUC5AC may
interact with E-Cadherin/β-Catenin complex to modulate their function. To explore interactions
between MUC5AC and E-Cadherin, we pulled down MUC5AC and probed with anti-E-Cadherin
and β-Catenin antibodies. MUC5AC was found to be immunoprecipitated with E-Cadherin and βCatenin as indicated by immunoprecipitation assays (Figure 3.5D). We further confirmed the co-
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localization of MUC5AC and E-Cadherin by confocal analysis. We could observe the
colocalization of MUC5AC and E-Cadherin at intercellular junctions (Figure 3.5E). Looking at
MUC5AC interactions with E-Cadherin, we suggest that by interfering with assembly of ECadherin adherens junction, MUC5AC might facilitate β-Catenin nuclear translocation and thus
impact the PC cell growth and metastasis.
3.G Impact of MUC5AC on endothelial cell viability and tube formation capacity
Previous studies have shown that in presence of MUC5AC, increased VEGF-A secretion may
interact with VEGFR-1 in autocrine manner to impact PC cell growth. In this study, we also
observed a reduction in relative VEGF-A mRNA levels by q-PCR on knockdown of MUC5AC in
PC cells (Figure 3.6A). Therefore, we hypothesized that angiogenic factors released in the
presence of MUC5AC may impact endothelial cell viability and contribute to the endothelial cell
tube formation. To test this hypothesis, the HMEC-1 endothelial cells were cultured in
conditioned media from MUC5AC expressing and knockdown PC cells. In MTT assay, a
significant decrease (p<0.05) in the viability of HMEC-1 cells cultured with conditioned media
from MUC5AC knockdown cells was observed compared to the HMEC-1 cells cultured with
conditioned media from scramble control cells (Figure 3.6B). Further, the HMEC-1 cells grown
on Matrigel in the presence of conditioned media from MUC5AC knockdown PC cells had a
significant reduction in a total number of endothelial tube junctions (p<0.005) (Figure 3.6C, D)
and vessels percentage area (p<0.005) compared to the endothelial cells grown in conditioned
media from the scramble control PC cells (Figure 3.6C, E). We further analyzed the signaling
mechanisms associated with these observations. HMEC-1 cells treated with conditioned media
from MUC5AC knockdown PC cells revealed a reduced phosphorylation of cell survival
associated protein AKT (Ser-473) and phosphorylation of the protein associated with increased
motility-FAK (Y-397) (Figure 3.6F). Further, there was no impact on phosphorylation of Erk1/2.
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Overall, these results suggest that MUC5AC mediated increased release of VEGF-A may impact
tumor angiogenesis.
3.H Inhibition of MUC5AC in pancreatic cancer cells results in decreased tumorigenicity
and metastasis in vivo
To examine the effect of MUC5AC knockdown on pancreatic tumor growth and metastasis in
vivo, we orthotopically implanted FG-Scr/Sh5AC PC cells into the pancreas of the nude mice.
The animals were sacrificed 50 days post-implantation. The primary pancreatic tumors were
observed in all the mice implanted with FG-Scr/Sh5AC PC cells. Interestingly, there was a
significant reduction (p=0.03) in pancreatic tumor weight of FG-Sh5AC mice group (Mean±SE,
303±74.3 mg) compared to FG-Scr group (Mean±SE, 801±195.5 mg) (Figure 3.7A). In support
of increased tumor weight we could observe a significantly high number of Ki67 expressing
nuclei in tumors from MUC5AC expressing PC cells in comparison to the tumors from
MUC5AC knockdown cells (Figure 3.7B). Further, in our examination of the peritoneum,
intestine, diaphragm, liver, lung, ovary, and mesenteric lymph nodes for the presence of
metastatic lesions, we observed metastatic lesions in greater number of the FG-Scr mice group
compared to the FG-Sh5AC mice group (Figure 3.7C). These results suggest that MUC5AC
profoundly impacts in vivo tumor growth and metastasis of the PC cells to the distant organs.
4. Discussion
PC remains the most lethal malignancy with five year survival <8% [1]. Therefore, multiple
research studies have continuously focused on identifying and validating different molecules for
the early diagnosis and treatment of PC. Despite all these efforts, PC remains to be a devastating
disease. This highlights the lacunae in our understanding of the biological and molecular
processes involved in the initiation and progression of this deadly malignancy. This necessitates
functional characterization of pancreatic tumor associated proteins to develop a more in-depth
understanding of the various signaling pathways deregulated in PC. The knowledge gained can be
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employed to devise efficient early stage diagnostic markers, prognostic markers and targeted
therapies for PC.
Mucins are universally recognized to be deregulated in cancer and have been identified as
biomarkers or molecular targets for the treatment of PC [9]. Interestingly, secretory mucin
MUC5AC was observed to be the top most differentially expressed genes in PC when compared
to the normal pancreas [15]. MUC5AC is not expressed in normal pancreas while its de novo
expression is observed as early as PanIN-1 lesions to further increase during the progression of
pancreatic ductal adenocarcinoma [16]. Overexpression of MUC5AC has been associated with
poor prognosis of PC patients [20]. Few in vitro, in vivo studies also highlighted the role of
MUC5AC in pancreatic tumor growth and metastasis [18, 19]. However, the conclusive
mechanistic basis remained obscure. In light of these observations, we proposed that MUC5AC
might have a significant role during the progression of PC. We sought to functionally characterize
this mucin in PC and explore the underlying mechanisms with an objective to contribute towards
better understanding of the disease and developing therapeutic modalities.
Concordant to previous studies [16], our immunohistochemical analysis done on pancreatic
cancer samples from whipple procedure revealed that MUC5AC is absent in the normal pancreas,
while its expression is significantly increased in PC. Perineural invasion (PNI) is one of most
characteristic feature of PC. PNI indicates aggressive behavior of pancreatic tumor and correlates
with poor prognosis of PC patients [21]. Interestingly, one of the most interesting observations
that we could make was an increased expression of secretory mucin MUC5AC in the areas of
PNI. These observations suggest that overexpressed MUC5AC may play an important role in the
progression of PC.
Mucins have been associated with PC cell growth, motility, invasion, angiogenesis and
chemoresistance [7]. MUC5AC has been shown to modulate lung cancer cell growth, motility
and chemoresistance properties [22]. Hence, for functional characterization of MUC5AC, we
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identified endogenously MUC5AC expressing PC cell lines (FG/COLO357 and SW1990) and
performed knockdown of MUC5AC. Assays conducted using these cell line models demonstrated
that MUC5AC is a critical player in facilitating PC cell proliferation, migration, angiogenesis,
and chemoresistance. Decreased expression of MUC5AC resulted in the impaired viability of PC
cells, significantly decreased anchorage-independent growth, and increased apoptosis. Regulation
of cell cycle is extensively deregulated in cancer impacting cancer cell proliferation and tumor
growth [23]. Hence, the impact of MUC5AC on cell proliferation was further validated by cell
cycle analysis assay. Interestingly, we observed that MUC5AC is associated with significantly
faster progression of the PC cells through G1/S phase of the cell cycle. Aberrant expression of
G1/S phase cyclins and especially cyclin D and cyclin E is involved in different types of cancer
and results in tumor formation [24]. Mechanistically, we observed increased expression of cell
cycle inhibitor p27 and decreased expression of G1/S phase regulatory proteins Cyclin-D1 and
Cyclin-E on knockdown of MUC5AC.
One of the biggest problems associated with PC is early stage metastasis to distant
locations. As MUC5AC is expressed at early stages of PC, we wanted to explore whether
overexpressed MUC5AC can impact migration and adhesive properties to extracellular matrix
proteins. In this study, we observed a significant reduction in the migratory potential of PC cells
on knockdown of MUC5AC. Cancer cell and extracellular matrix interactions play a vital role in
progression and metastasis of cancer [25]. Interestingly, MUC5AC positive cells revealed a
significantly higher tendency to adhere to Matrigel, advocating the role of MUC5AC in the
metastatic process. Increasing evidences suggest that epithelial-mesenchymal transition (EMT) is
associated with pancreatic cancer metastasis and drug resistance [26]. Interestingly, there was an
increased expression of epithelial marker E-Cadherin on knockdown of MUC5AC. As a recent
study highlighted the role of MUC5AC in regulating expression of integrins in lung cancer [22] ,
hence we investigated the impact of MUC5AC on the expression of integrins. We observed a
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downregulation of αV-, β5-integrins on knockdown of MUC5AC. As β5-integrin is known to
mediate its effects through Src-FAK signaling [27], we further investigated the impact of
MUC5AC knockdown on phosphorylation of Src kinase. Interestingly, knockdown of MUC5AC
decreases phosphorylation of Src-(Y416). It has been speculated that that MUC5AC may impact
localization of E-Cadherin to cell membrane [28] and by colocalizing with E-Cadherin,
MUC5AC and MUC1 modulate E-Cadherin function [29]. In light of these observations, we
tested the hypothesis that MUC5AC may physically interact with E-Cadherin. Interestingly, in
our immunoprecipitation experiment, we observed that in PC, MUC5AC interacts and co-localize
with E-Cadherin. Interestingly, we could also observe an interaction of MUC5AC with β-Catenin
and Src. WNT/β-Catenin signaling is associated with initiation and progression of the PC [30].
Overall, Looking at these observations, we assume that by its interactions with E-Cadherin
MUC5AC may interfere with its assembly resulting in increased nuclear translocation of βCatenin to the nucleas thereby impacting PC cell growth and metastasis.
Furthermore, angiogenesis is one of the most important factor associated with growth and
metastasis of pancreatic cancer [31]. Previous studies showed MUC5AC mediates PC cell growth
by its impact on phosphorylation of VEGFR-1 [18]. Therefore, we further explored whether
MUC5AC impacts expression of angiogenic factors and impact angiogenesis process in paracrine
manner. We observed that knockdown of MUC5AC decreases mRNA levels of VEGF-A, and
significantly decreased the endothelial cell viability and tube formation capacity quantified as
percentage vessels area and a total number of junctions formed. From these observations, we
assumed that MUC5AC assist metastasis of PC cells through increased angiogenesis. This led us
to further investigate the impact of MUC5AC on metastasis in vivo. Hence, we utilized an
orthotopic model of PC [32]. As expected, we observed a significantly high pancreatic tumor
size/weight and number of metastases to distant organs in mice orthotopically injected with
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MUC5AC expressing cells. In conclusion, using various biochemical assays we report for the
first time a novel cell cycle regulatory and metastasis-related role of MUC5AC in PC.
It has been speculated that polymeric gel forming secretory mucins MUC5AC may form
a gel like layer over cell surface and hinder the effective targeting of therapeutics. In a recent
study from our lab, it was shown that MUC5AC plays a critical role in cisplatin resistance of lung
cancer cells [22]. Looking at our observations of MUC5AC mediated anti-apoptotic impact,
impact on expression of integrins, we hypothesized that MUC5AC may play an important role in
resisting the anti-proliferative impact of chemotherapeutic drug-Gemcitabine. Interestingly, we
observed that decreased expression of MUC5AC sensitizes PC cells to Gemcitabine. There was a
significant increase in apoptosis and necrosis in Gemcitabine-treated MUC5AC knockdown PC
cells. Mechanistically, we observed increased expression of apoptotic mediators Cyt-c, BAD,
cleaved caspase-3 and cleaved caspase-9 in cytoplasmic extracts form MUC5AC knockdown PC
cells. Reactivation of Wnt/β-Catenin signaling in Gemcitabine-resistant cancer-cells has
previously been demonstrated [33]. WNT/β-Catenin signaling coordinates cancer stem cell state
[34]. Increased MUC5AC expression mediates nuclear accumulation of β-Catenin in the nucleus
[28]. Therefore, we tested the hypothesis that MUC5AC mediated increased nuclear translocation
of β-Catenin may enrich the stem cell population in Gemcitabine-resistant PC cells. Interestingly,
we observed a drastic decrease in nuclear translocation of β-Catenin in Gemcitabine treated
MUC5AC knockdown cells. Further evaluation of stem cell markers revealed a significant
reduction in expression of ESA, SHH, SOX2 and OCT3/4 in Gemcitabine-treated MUC5AC
knockdown PC cells. Overall, from our study we conclude that MUC5AC may mediate
chemoresistance by impacting expression of integrins and enrichment of stem cell population in
β-Catenin dependent manner.
In totality, secretory mucin MUC5AC plays a critical role in the progression of PC and
can be an important therapeutic target for PC.
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Figure 3.1: Overexpression of secretory mucin MUC5AC in PC tissues and PC cell lines. (A)
Immunohistochemical (IHC) analysis of MUC5AC expression in paraffin embedded sections of
the pancreatic cancer tissues (n=34) from whipple procedure using anti-MUC5AC Mab 45M1.
Representative images for MUC5AC expression in tumor adjacent normal pancreas (a) pancreatic
ductal adenocarcinoma (b) at magnification 10X. Yellow arrow denotes normal duct in normal
pancreas with no expression of MUC5AC while in adenocarcinoma it highlights the increased
expression of MUC5AC in tumor tissue. (B) Box plots showing distribution of H-Score for
MUC5AC expression in pancreatic cancer cases compared to the adjacent normal pancreas.
Significantly increased expression of MUC5AC (p<0.002) was observed in pancreatic cancer
tissues with a mean H-score of 0.93 (range 0-3) as compared with the histologically normal
pancreatic tissues with a mean H-Score of 0. (C) Expression of MUC5AC relative to its
expression in normal pancreatic cell line HPNE was determined in a panel of PC cell lines at
mRNA level by q-PCR. β-actin was used for normalization in q-PCR analysis. (D) Expression of
MUC5AC was determined at protein level by western blotting utilizing 2% SDS-Agarose gel.
Expression of MUC5AC was not detected in normal pancreatic cell lines human pancreatic nestin
expressing (HPNE) and human pancreatic ductal epithelial (HPDE). Differential expression of
MUC5AC was observed in PC cells. Expression of MUC5AC in A549 cells was utilized as a
positive control. β-actin was used as loading control for western blot analysis. (E) Localization of
MUC5AC expression in BXPC-3, SW1990 and FG/COLO357 PC cells was determined by
confocal microscopy. The cells were grown at low density on sterilized coverslips, washed, and
fixed with methanol, and permeabilized before incubation with antibodies against MUC5AC
(45M1). Fluorescence signals from each cell type were acquired by confocal microscopy.
MUC5AC (green) was detected by using a fluorescein-conjugated secondary antibody. The
yellow arrow indicates cytoplasmic, granular and intercellular localization of MUC5AC
expression in these cells. (F) Silencing of MUC5AC expression in FG/COLO357 and SW1990
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PC cells. Cells were infected with retroviruses carrying short hairpin RNAs (ShRNAs) against
MUC5AC in pSUPER.retro.puro vector or with scrambled sequence containing vector used as
control. Transfected cells were selected using Puromycin antibiotic and positive clones were
tested for MUC5AC expression using 2% SDS-Agarose gel. Significant decrease in expression of
MUC5AC protein was observed in cells stably transfected with different MUC5AC ShRNAs
targeting at different sites of MUC5AC mRNA. β-actin was used as the loading control.
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Figure 3.2: MUC5AC knockdown decreases cell viability, anchorage independent growth
and induces apoptosis in PC cells. (A) Results from MTT assay (Day 1-6) showing that
knockdown of MUC5AC in FG/COLO357 and SW1990 cells reduced viability of PC cells in
comparison with scramble control cells. (B) Impact of MUC5AC on anchorage-independent
growth was analyzed by soft agar assay. Statistical analysis revealed a significant reduction of
anchorage-independent colony formation (*p<0.001) on knockdown of MUC5AC in
FG/COLO357 cells. (C) Annexin-V and propidium iodide staining analysis by flow cytometry to
identify apoptosis in FG-Scr/Sh5AC cells. For this, FG-Scr/Sh5AC cells were plated at a density
of 1X106 cells in 60 mm cell culture Petri dishes for 48 hours at 37°C. After 48 hours, the cells
were washed with PBS (3x) and then made serum-free for next 48 hours. The induction of
apoptosis was measured by staining the cells with Annexin-V and propidium iodide solution,
followed by fluorescence-activated cell sorting analysis (FACS). The statistical analysis showed
significantly increased percentage of PC cells undergoing apoptosis on knockdown of MUC5AC
expression (*p<0.05).
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Figure 3.3 MUC5AC knockdown induces cell cycle arrest in PC cells. (A, B) FG/COLO357,
SW1990 knockdown and scramble control cells were synchronized by serum starvation for cell
cycle analysis. After synchronization, cells were stained with propidium iodide (PI) and analyzed
by flow cytometry to evaluate the number of cells in different phases of the cell cycle. PC cells
are significantly accumulated in G1 phase of cell cycle and progress slowly through S phase on
knockdown of MUC5AC when compared to the scramble control cells. (C) A total of 40 µg
protein from FG-Scr/Sh5AC, SW-Scr/Sh5AC cells was resolved by SDS-Agarose (for
MUC5AC) and SDS–PAGE, followed by immunoblotting for the expression of MUC5AC, p21,
p27, Cyclin-D1, and Cyclin-E. Increased expression of cell cycle inhibitor p27 and decreased
expression of cell cycle regulatory proteins Cyclin-D1 and Cyclin-E is observed on knockdown
of MUC5AC in comparison to the scramble control cells. β-actin was used as a loading control.

118

Figure 3.3

A
FG-Sh5AC

FG/COLO357-Cell Cycle Analysis

% Cells

FG-Scr

80
70
60
50
40
30
20
10
0

*P<0.05
* *
*

G1

G2/M
S
Cell cycle phase

SW1990-Cell Cycle Analysis
SW-Scr

SW-Sh5AC

70
60

*p<0.001

*

50

% Cells

B

Scr
Sh5AC-1
Sh5AC-2

*

40
30

SCR
Sh5AC-2

20
10
0
G1

S
G2/M
cell cycle phase

119

Figure 3.3 Contd…

C
Sh5AC-2

Scr

Sh5AC-1

SW1990

Sh5AC-3

Sh5AC-2

Sh5AC-1

Scr

FG/COLO357

MUC5AC
MUC5AC

p21

p27

p27
Cyclin- D1
Cyclin-D1
Cyclin-E
Actin

Cyclin- E
β-Actin

120

Figure 3.4 MUC5AC mediated impact on Gemcitabine resistance. (A) Table showing the
reduced IC-50 of Gemcitabine on MUC5AC knockdown in PC cells compared to the scramble
control cells. (B) Anti-proliferative effects induced by Gemcitabine treatment on FG-Scr/Sh5AC
PC cells in full growth medium. The PC cells were untreated (assay control) or treated with
indicated Gemcitabine concentrations (0, 50, 100, 200, 400, 800, 1600 nM) for 48 hours. The cell
proliferation was evaluated by MTT assay. A significant dose dependent reduction in viability of
PC cells (p<0.001) was observed on Gemcitabine treatment to MUC5AC knockdown cells in
comparison to scramble control cells. (C) FG-Scr/Sh5AC cells were plated in 10 cm petridishes
and treated with 1 µM Gemcitabine for 48 hours. The cells were then stained with PI and
Annexin-V and percentage of cells undergoing apoptosis and necrosis was analysed by FACS.
The results are expressed as the percentage (Mean±SE) of the apoptotic and necrotic cells for FG
-sh5AC cells compared with FG-Scr cells after treating with 1 µM Gemcitabine for 48 hours.
Gemcitabine treatment resulted in significantly higher percentage of apoptosis (p<0.05) and
necrosis (p<0.001) in PC cells with MUC5AC knockdown. (D) Intrinsic apoptotic pathway was
assessed in FG-Scr/Sh5AC cells in response to Gemcitabine treatment. For this cells were treated
with 1 µM Gemcitabine for 48 hours, followed by cytosolic extract preparation as described in
materials and methods section. A total of 50 µg protein from each cytosolic extract was resolved
by SDS–PAGE (15%), followed by immunoblotting with anti-Cyt-c, BCl2, XIAP, BAD, Cleaved
Caspase-3, Cleaved Caspase-9 and GAPDH (loading control) antibodies. (E) FG-Scr/Sh5AC
cells were treated with 1 µM Gemcitabine for 48 hours and were lysed to prepare whole cell
extract (WCE), nuclear extract (NE) and cytosolic extract (CE) and immunoblotted with anti-βCatenin antibody. Expression of SP1 and GAPDH was done to investigate the purity of nuclear
fraction and cytosolic fraction respectively. Nuclear translocation of β-Catenin is reduced in
MUC5AC knockdown PC cells compared to the scramble control cells on treatment with
Gemcitabine. (F) Impact of Gemcitabine treatment on enrichment of stem-cell markers in
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MUC5AC expressing and knockdown cells. Untreated control cells and cells treated with 1µM
Gemcitabine for 48 hours were lysed to prepare lysates that were further immunoblotted with the
indicated antibodies. Significant reduction in expression of ESA, SHH, SOX2 and OCT3/4 was
observed in MUC5AC knockdown cells in comparison to the scramble control cells on treatment
with Gemcitabine.
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Figure 3.5: MUC5AC mediated impacts on motile properties of pancreatic cancer cells. (A)
Boyden chamber assay to assess the migration of PC cells. The FG-Scr/Sh5AC cells (1X106)
were plated on boyden chamber in serum free conditions and were allowed to migrate under
chemotactic drive. The migration of MUC5AC knockdown cells was observed to be significantly
reduced (*p<0.0001) in comparison to the scramble control cells. (B) Cell-adhesion assay to
evaluate MUC5AC mediated impacts on PC cell and extracellular matrix interaction. For this a
single-cell suspension of FG-Scr/Sh5AC cells and SW-Scr/Sh5AC (1×104 cells) in 100 μl of full
growth medium was added to each well. After 2 incubation at 37˚C, the nonadherent cells were
washed with PBS and the adhered cells were stained with 50μl of 0.5% crystal violet in 20%
methanol for 30 min. The cells were then washed with deionized water and were lysed in 50 μl of
30% acetic acid. Cell adhesion was calculated by measuring the absorbance of the eluted dye at
570 nm using a microplate reader. In the absence of MUC5AC there was a significant reduction
(FG/COLO357, p<0.05; SW1990, p<0.001) in adhesion of PC cells to the Matrigel in comparison
to the control cells. (C) Cell lysates were prepared from FG/COLO357 scramble and MUC5AC
knockdown cells to perform immunoblot analysis of various proteins associated with migration
and adhesion of PC cells. Upon knockdown of MUC5AC the expression of integrins αV, β3, β5
and phosphorylation of Src (Y416) were decreased while expression of cell-cell adhesion marker
E-Cadherin was increased as compared with scramble control cells. β-actin was immunoblotted
as loading control. (D) Immunoprecipitation assay to investigate the proteins interacting with
MUC5AC demonstrated that MUC5AC strongly interacts with E-Cadherin along with β-Catenin
and Src. (E) Colocalization of MUC5AC and E-Cadherin in PC cells as detected by
immunofluorescence. Fluorescence signals from each scan were acquired sequentially. MUC5AC
(green) was detected by using a Alexa-fluor 488 secondary antibody; E-Cadherin was identified
with Alexa-fluor 648 secondary antibody (red). Dual-merge of MUC5AC/E-Cadherin (green and
red) showed colocalization.
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Figure 3.6 MUC5AC mediated impact on angiogenesis. (A) Q-PCR assessment of VEGF-A
mRNA in MUC5AC overexpressing and knock down cells. Levels of VEGF-A mRNA
determined by q-PCR were downregulated on knockdown of MUC5AC in SW1990 pancreatic
cancer cells. (B) HMEC-1 endothelial cell viability as determined by MTT assay, was
significantly high (p<0.05) on treatment with conditioned media from PC cells expressing
MUC5AC in comparison to the HMEC-1 cells treated with conditioned media from the PC cells
having knockdown of MUC5AC expression. (C) Higher number of endothelial tubes were
observed by tube formation assay done by plating HMEC-1 endothelial cells suspended in
conditioned media from FG-Scr/Sh5AC (a, b) and SW-Scr/Sh5AC (c, d) cells on Matrigel coated
plates. (D) A significantly higher number of endothelial tube junctions (p<0.005) were formed in
HMEC-1 endothelial cells on treatment with conditioned media FG-Scr/Sh5AC and SW1990Scr/Sh5AC. (E) HMEC-1 endothelial cells have significantly higher percentage of vessels area
(p<0.005) on treatment with conditioned media from FG-Scr/Sh5AC and SW1990-Scr/Sh5AC
cells. (F) On treatment with conditioned media from MUC5AC knockdown pancreatic cancer
cells, there was decreased phosphorylation of AKT (S473) and FAK (Y397) in HMEC-1
endothelial cells compared to controls.

128

Figure 3.6

A

B
SW-SH2

1
0.8
0.6
0.4
0.2
0

HMEC1-SH5AC-CM

MUC5AC VEGF-A

0.7
0.6

*

0.5
0.4
0.3

200
150
100
50
0

c

d

0.1
0
48 HR

**p<0.005

**
Vessels % Area

Total no. of Juctions

250

**

b

0.2

E

300

a

*

24 HR

Total no. of Junctions

Sh5AC-CM

Scr-CM

*P<0.05

0.8

D
350

C

0.9

HMEC-1

1.2

SW-SCR

Cell Viability [Optical density
(565nm/670nm)]

Relative mRNA levels

1.4

HMEC1-SCR5AC-CM

20
18
16
14
12
10
8
6
4
2
0

F

Vessels % Area

**

**

HMEC1

**p<0.005

pAKT(Ser473)

pFAK (Y397)

pERK1/2

β-ACTIN

129

Figure 3.7: MUC5AC knock down inhibits in vivo tumorigenicity and reduces metastasis.
(A) Box plot showing the distribution of the tumor weight (mg) from mice injected with FGScr/Sh5AC PC cells. Error bars represent SE for n=7 mice in each group. There was a significant
reduction in pancreatic tumor weight (p<0.05) on knockdown of MUC5AC compared to the
tumors formed by scramble control cells. (B) Immunohistochemistry of MUC5AC expressing
cells and Ki67 in pancreatic tumor sections obtained from the mice orthotopically injected with
FG-Scr/Sh5AC PC cells. Reduced nuclear expression of Ki67 was observed in mice tumor
sections from MUC5AC knockdown cell compared to the control. (C) Immunohistochemistry
utilizing anti-MUC5AC antibody (45M1) revealed presence of MUC5AC expressing cells at
metastatic sites (Liver, Diaphragm and Peritoneum).
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Chapter IV
Loss of Muc5ac Expression in the; KrasG12D; Pdx1-Cre;
Muc5ac-/- mouse model delays onset and progression of
pancreatic cancer
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1. Synopsis
MUC5AC is a gel forming secretory mucin that has been shown to be overexpressed in different
types of cancers such as cholangiocarcinoma, colorectal cancer, and lung cancer including
pancreatic cancer (PC). Previously published reports and studies on rapid autopsy samples from
our group have shown that MUC5AC is aberrantly overexpressed in pancreatic intraepithelial
lesions (PanINs), in primary pancreatic tumor tissues, and in the metastatic tissues from different
sites. Further, its association with poor prognosis of PC patients has also been shown. Owing to
the suitability of genetically engineered mouse models (GEMMs) of PC to study initiation and
progression of this malignancy and to obtain further insight and elucidate the oncogenic role of
MUC5AC in PC, we utilized a very well characterized KrasG12D; Pdx1-Cre (KC) PC mouse
model for our studies. This model revealed expression of Muc5ac along with other mucins (Muc1
and Muc4) during the progression of PC. We acquired the Muc5ac-/- mice and crossed them with
the KC mice to finally obtain the KrasG12D; Pdx1-Cre; Muc5ac-/- (KCMuc5ac-/-) mice along with
KrasG12D; Pdx1-Cre; Muc5ac+/+ (KCMuc5ac+/+) as control mice. We observed that there was no
significant difference in the total number of PanIN lesions formed during the progression of PC.
However, delayed onset and progression of PC was evident from the fact that the KCMuc5ac-/mice had less incidence of PanIN-I (p<0.01) and PanIN-2 lesions at 10 weeks of age in
comparison to KCMuc5ac+/+ control mice at 10 weeks of age. Moreover, progression from 20
weeks to 30 weeks of age revealed a very low incidence and significantly low number of highgrade PanINs (PanIN-3 lesions) in KCMuc5ac-/- mice compared to the KCMuc5ac+/+ mice.
Interestingly, KCMuc5ac-/- mice had significantly less number of Ki-67 stained nuclei in
pancreatic ductal cells compared to KCMuc5ac+/+ mice, suggesting an impact of Muc5ac on
pancreatic duct epithelial cell proliferation. We also observed less number of secondary
metastatic lesions at 50 weeks of age in KCMuc5ac-/- mice in comparison to the KCMuc5ac+/+
mice. These observations suggest that in the absence of Muc5ac expression, onset and
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progression of PC is delayed. Hence, our results indicate that Muc5ac plays a critical role in the
progression of PC.
2. Background and rationale
Pancreatic ductal adenocarcinoma (PDAC) is the most lethal cancer, and the fourth leading cause
of cancer-related deaths in the US [1]. Successive accumulation of mutations in key oncogenes
and tumor suppressor genes during disease progression makes PDAC a complex, heterogeneous
and genetically unstable disease [2]. Due to its asymptomatic nature, early metastatic spread, lack
of sensitive and specific biomarkers to detect early, therapeutic resistance, and frequent
recurrence the survival rate and prognosis of this malignancy remains dismal [3].
Emerging studies have highlighted the role of mucins in PDAC pathogenesis [4, 5]. In a
physiological setting, mucins primarily protect the epithelial cell surfaces from environmental
insults by forming a physical barrier. However, under adverse conditions, by virtue of their
altered expression, glycosylation patterns, and unique domains mucins are conferred oncogenic
roles [6]. Hence, mucins have been identified as novel targets for diagnostic, prognostic and
therapeutic purposes [5, 7].
Secretory mucin MUC5AC is aberrantly expressed in different benign disease conditions
such as inflammatory bowel diseases [8], pancreatitis [9] and gastrointestinal malignancies such
as gastric cancer [10], colorectal cancer [11], gall bladder cancer [12] and cholangiocarcinoma
[13] including PC [14]. Different studies have highlighted the utility of MUC5AC in early stage
diagnosis of malignancies [15-17]. Secretory mucin MUC5AC is not expressed in normal
pancreas while we have shown that it is significantly overexpressed during the progression of
PDAC. Further, an association of increased MUC5AC levels with poor prognosis of PC patients
has also been suggested [18]. Further, our in vitro studies suggest a critical role of MUC5AC in
PC cell growth, metastasis, angiogenesis and chemoresistance making it a clinically relevant
molecule.
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Hence, to further my studies for understanding the oncogenic role of MUC5AC, I utilized
the genetically engineered mouse model (GEMM) that closely mimics the pathology of human
PC [19]. These models have proved their utility for (a) identifying key players that contribute
towards the complexity of the disease, (b) procuring early stage pancreatic tissue and serum
samples that are very challenging to obtain from human PC patients and (c) as preclinical models
to identify potential therapeutic drugs or regimens. Concordant with human PC, The KrasG12D;
Pdx1-Cre (KC) mice model of PC, reveals a progressive increase in the expression of mucins
both at mRNA and protein levels (Muc1, Muc4 and Muc5ac) during the progression of PDAC
[20]. However, it is still unknown whether increased expression of Muc5ac has a role to play
during initiation and progression of PC. Therefore, looking at the critical role of MUC5AC in PC,
I utilized the Muc5ac knockout mice and the KC mice as control for delineating in vivo role of
Muc5ac in PC.
3. Results
3.A Breeding strategy and establishment of PDAC mice model with knockout of Muc5ac
To explore the role of MUC5AC in PC the Muc5ac-/-; KrasG12D; Pdx1-Cre (KCMuc5ac-/-) mouse
model was developed by breeding Muc5ac-/- mice with LSL-KrasG12D and Pdx1-Cre mice (Figure
4.1). The KCMuc5ac-/- animals (mice that were positive for both KrasG12D and Pdx1-Cre and
negative for Muc5ac) and age matched littermate control KCMuc5ac+/+ animals (mice that were
positive for KrasG12D, Pdx1-Cre and Muc5ac) were euthanized at 10, 20, 30, 40 and 50 weeks of
age (N=3 for each time point) and the individual pancreas were resected and weighed.
3.B Progression of PC in the KrasG12D; Pdx1-Cre; Muc5ac -/- mouse model
The average weight of the pancreas isolated from the KCMuc5ac+/+ animals was found to be
higher than the pancreas of age-matched KCMuc5ac-/- mice (Figure 4.2A). The difference
between weights of the pancreas was not statistically significant between two groups up to 40
weeks of progression. However, at 50 weeks of age the weight of pancreas of KCMuc5ac+/+ was
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significantly high (p<0.01) in comparison to the pancreas of KCMuc5ac-/- mice (Figure 4.2A).
These observations suggest significant histological alterations associated with loss of Muc5ac
expression during late stages of the mouse PC progression. Further, to analyze the impact of
Muc5ac knockout on overall histopathology of mice pancreas the pancreatic tissue sections
isolated from the KCMuc5ac+/+ and KCMuc5ac-/- mice were stained with hematoxylin and eosin
(H&E) and observed by a pathologist (Figure 4.2C). As per the observations made by
pathologist, there was a sequential decrease in overall percentage of normal pancreas in
KCMuc5ac+/+ mice from 10 to 50 week of progression, compared to the KCMuc5ac-/- mice
(Figure 4.2B, C). Interestingly, percentage of the normal pancreas were significantly high
(p<0.05) in pancreas of KCMuc5ac-/- mice compared to KCMuc5ac+/+ mice at 50 weeks of PC
progression (Figure 4.2B, C). This suggests that the loss of Muc5ac during PC progression may
slow down the onset and advancement of pancreatic malignancy. However, this observation
needs further validation in larger number of mice per group.
To further evaluate the degree of delay between the initiation and progression of PC in
the KCMuc5ac-/- mice and KCMuc5ac+/+ mice, we evaluated the number of PanINs/frame/time
point/mouse model. We observed an approximately 50% increase in average number of PanIN-1
lesions, no change in average number of PanIN-2 lesions and approximately 50% reduction in
incidence of PanIN-3 lesions in KCMuc5ac-/- mice in comparison to KCMuc5ac+/+ mice (Figure
4.3A). Further analysis of respective PanIN lesions types during PC progression from 10 to 50th
week revealed that during initial stages (10th week), loss of Muc5ac delays onset of PC, as evident
by less formation of PanIN-1 (p<0.01) and PanIN-2 lesions (Figure 4.3B, C). During further
advancement from 20th to 50th week, we observed slowed PC progression in KCMuc5ac-/- mice
evident by increased number of PanIN-1, PanIN-2 lesions and significantly lower number of
PanIN-3 lesions (at 40th week) compared to control KCMuc5ac+/+ mice (Figure 4.3B, C, D).
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Hence these observations, substantiate the delay in the onset and further progression of PC as
observed in KCMuc5ac-/- mice in comparison to the KCMuc5ac+/+ mice.
Further to evaluate whether reduced onset and progression of PC in KCMuc5ac-/- mice is
due to reduced proliferation, we estimated Ki-67 positive nuclei in pancreatic tissues from
KCMuc5ac+/+ and KCMuc5ac-/- (10th and 50th week) by immunohistochemical staining. Ki-67
protein is a marker of cellular proliferation. In our observation and quantitative analysis, we
observed that pancreas of KCMuc5ac-/- mice had significantly reduced number of Ki-67 positive
nuclei both at 10th (p<0.01) and 50th week (p<0.005) (Figure 4.4A, C). Interestingly Muc5ac
expressing ducts revealed higher proliferative index indicated by simultaneous expression of
Muc5ac and nuclear Ki-67 in ductal epithelial cells (Figure 4.3B). This suggests that Muc5ac is
critical for increased proliferation of PC cells during sequential progression of this malignancy.
4. Discussion
PC is currently the fourth leading cause of cancer-related deaths in the US, and is expected to be
the second most common cause of death by 2030 [1, 21]. As per American Cancer society,
53,070 new cases of pancreatic ductal adenocarcinoma are estimated in 2016, with a shocking
41,780 deaths [22]. Despite all the efforts in last decade, the five-year survival rate after diagnosis
of PC lingered around six months. The main reasons being the diagnosis at advanced stages,
when the patient already have metastasis to distant organs and available treatments remain
palliative, along with development of resistance to existing therapeutic strategies [3]. Hence, it
becomes clearer that further in-depth investigations are warranted to identify effective early
diagnostic markers and therapeutic targets.
In this context, we and others have previously shown overexpression of secretory mucin
MUC5AC during the progression of PC. MUC5AC has been associated with increased metastasis
and poor prognosis in PC [14, 18]. The utility of secretory mucin MUC5AC as an early stage
biomarker for detection of PC has also been underscored recently [17]. Functionally, increased
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MUC5AC levels in lung cancer have been associated with increased proliferation and migration
[23]. Further, few in vitro studies demonstrated MUC5AC mediated impact on migration of PC
cells [14]. However, none of these studies could systematically elaborate on role of MUC5AC
and related mechanisms in PC progression. Therefore, further studies are required to elucidate the
exact roles of MUC5AC and associated mechanisms in PC.
Some of the recent advances in PC have been possible by employing genetically
engineered mouse models of exocrine pancreatic neoplasia. These preclinical models mimic the
genetic alterations, pathologic changes ranging from PanINs to fully invasive and metastatic
disease as implicated in the progression of PC [24] making them the best tool to investigate early
stage diagnostic markers, chemoprevention strategies, different anti-cancer therapeutic
approaches, and to understand the molecular mechanisms underlying PC progression with an
objective to improve PC prognosis [25]. Therefore, to identify the potential role of MUC5AC in
PC, we utilized a well characterized KC mouse model of PC progression that mimics human PC
[19]. In humans expression of MUC5AC is absent in normal pancreas while its de novo
expression has been observed as early as PanIN-1 lesions. Similarly, in KC mice model
expression of Muc5ac was observed as early as 10 weeks of age in PanIN-1 lesions suggesting
that Muc5ac expression is an early event in PC progression. Further, expression of Muc5ac in
complete spectrum of PanINs, primary tumor and invasive lesions underscored suitability of this
model for investigating role of Muc5ac during PC progression [20].
Previous studies have shown that murine Muc5ac has 76.3% and 62.5% sequence homology in its
N-terminus and C-terminus respectively with human homolog of secretory mucin MUC5AC [26].
The expression pattern in murine Muc5ac matches to that of human homolog with the most
prominent expression observed in airways and gastric mucosa [26]. Therefore, to better
understand the role of MUC5AC in physiological and pathological conditions, homozygous
Muc5ac-deficient mice were produced by targeted deletion of exon-1 [27]. Muc5ac deficient
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mice developed normally except for inconsistent dry eye phenotype [28] and slightly increased
levels of IFN-γ levels [29]. Further, utility of Muc1-null PDA mouse to fully elucidate the
oncogenic role of MUC1 has previously been demonstrated [30]. Hence, to further dissect the
role of Muc5ac in PC, we generated KCMuc5ac-/- mice, by breeding Muc5ac-/- mice [27] with
KrasG12D; Pdx-1 Cre mouse model of PC [19]. As my first observation we found a consistent
decrease in pancreas weight at all-time points in KCMuc5ac-/- mice compared to KCMuc5ac+/+
mice. On further investigation high percentage of the normal pancreas were observed during the
progression of PC in KCMuc5ac-/- mice compared to KCMuc5ac+/+ mice. This suggested of less
tumor burden and more stable disease on the loss of Muc5ac. In my observation, I did not observe
any significant difference in total number of PanIN-lesions from KCMuc5ac+/+ and KCMuc5ac-/mice. However, on individual analysis of PanIN lesions, I observed significantly reduced number
of PanIN-1 and PanIN-2 lesions at the 10th week of age, that were increased in number at 20th,
30th, 40th, and 50th week of age. Further, significantly decreased number of high-grade PanIN-3
lesions at 20th, 30th, 40th and 50th weeks of age in KCMuc5ac-/- mice was also observed.
Interestingly, we observed a significant reduction in the number of nuclei staining positive for Ki67 in KCMuc5ac-/- mice pancreas highlighting its role in proliferation. Therefore, from this study,
I provide the first evidence that Kras mutation mediated upregulation of Muc5ac during PC, plays
a critical role in the onset and progression of PC, and loss of Muc5ac may provide survival
benefit. Further studies are warranted to investigate the Muc5ac mediated in vivo roles and
associated mechanisms in PC.
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Fig. 4.1 Schematic outline of the breeding strategy utilized for developing the KRasG12D;
Pdx1-Cre; Muc5ac-/- mouse model to investigate the role of Muc5ac during pancreatic
cancer progression. Unfloxed LSL-KRasG12D and Pdx1-Cre mice were crossed with Muc5ac-/mice respectively to obtain the F1 progeny having LSL-KrasG12D; Muc5ac-/- and Pdx1-Cre;
Muc5ac-/- genotype. The F1 progeny were further crossed with each other to obtain the KrasG12D;
Pdx1-Cre; Muc5ac-/- pancreatic cancer mouse model along with the KrasG12D; Pdx1Cre;
Muc5ac+/+ control mice. The F2 progeny were then euthanized at the 10th, 20th, 30th, 40th and 50th
weeks of age to analyze pancreatic cancer progression in the absence of Muc5ac expression
compared to controls.
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Figure 4.1
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Figure 4.2 Alterations in the weight and gross histology of pancreas during PC progression
in KrasG12D; Pdx1-Cre; Muc5ac-/- mice model: (A) Comparison of average weight of the
pancreas obtained from KrasG12D; Pdx1-Cre; Muc5ac+/+, and KrasG12D; Pdx1-Cre; Muc5ac-/- PC
mice model (n=3 in each group) at different time points (*p-value<0.01). (B) Comparison of the
percentage of normal pancreas as per the pathologist evaluation between KrasG12D; Pdx1-Cre;
Muc5ac+/+ and KrasG12D; Pdx1-Cre; Muc5ac-/- PC mice model at different time points (*pvalue<0.04). (C) Histopathology of H&E stained pancreatic tissues from KrasG12D; Pdx1-Cre;
Muc5ac-/- mice and KrasG12D; Pdx1-Cre; Muc5ac+/+ mice demonstrating normal pancreas, PanIN
lesions and adenocarcinoma in pancreas at 10th, 20th, 30th, 40th, and 50th weeks (C6-C10) of
progression. The KrasG12D; Pdx1-Cre; Muc5ac-/- mice showed higher percentage of normal
pancreas, delayed onset of PanIN lesions and overall delayed progression of PC (C6-C10)
compared to KrasG12D; Pdx1-Cre; Muc5ac+/+ mice (C1-C5).
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Figure 4.2
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Figure 4.3 Reduced progression of PC in KrasG12D; Pdx1-Cre; Muc5ac-/- mice model: (A)
Number of PanIN-1, PanIN-2 and PanIN-3 lesions observed per field, during progression of PC
from 10th to 50th weeks of age in KrasG12D; Pdx1-Cre; Muc5ac-/- mice compared to KrasG12D;
Pdx1-Cre; Muc5ac+/+ mice. No significant difference was observed in total count of PanIN-1,
PanIN-2 and PanIN-3 during progression from 10th week to 50th week. (B) Number of PanIN-1
lesions observed per field, during progression of PC from 10th to 50th weeks of age in KrasG12D;
Pdx1-Cre; Muc5ac-/- mice compared to KrasG12D; Pdx1-Cre; Muc5ac+/+ mice. Number of PanIN-1
lesions observed at 10th week of progression were significantly less (p<0.01) in KrasG12D; Pdx1Cre; Muc5ac-/- mice compared to KrasG12D; Pdx1-Cre; Muc5ac+/+ mice. No significant difference
was observed in PanIN-1 counts during later stages of progression. (C) Number of PanIN-2
lesions observed per field, during progression of PC from 10th to 50th weeks of age in KrasG12D;
Pdx1-Cre; Muc5ac-/- mice compared to KrasG12D; Pdx1-Cre; Muc5ac+/+ mice. Less number of
PanIN-2 were observed during 10th week while the difference remained negligible at later stages
of progression. (D) Number of PanIN-3 lesions observed per field, during progression of PC from
10th to 50th weeks of age in KrasG12D; Pdx1-Cre; Muc5ac-/- mice compared to KrasG12D;Pdx1Cre;Muc5ac+/+mice. Less Number of advanced PanIN-3 lesions were observed in KrasG12D; Pdx1Cre; Muc5ac-/- mice compared to the KrasG12D; Pdx1-Cre; Muc5ac+/+ mice from 20th to 50th week
of pancreatic cancer progression.

147

KCMuc5ac+/+

8
7
6
5
4
3
2
1
0

B

KCMuc5ac+/+
KCMuc5ac-/-

7

KCMuc5ac-/-

# of PanIN-1/field

A

# per field during pancreatic
cancer progression

Figure 4.3

*p<0.01

6
5
4
3
2

*

1
0

PanIN1

PanIN2

PanIN3

10

20

30

40

50

Weeks

KCMuc5ac+/+
KCMuc5ac-/-

10
9
8
7
6
5
4
3
2
1
0

D
# of PanIN-3/Field

# of PanIN-2/Field

C

10

20

30
Weeks

40

50

KCMuc5ac+/+

4.5
4
3.5
3
2.5
2
1.5
1
0.5
0

KCMuc5ac-/*p<0.01

*

10

20

30
Weeks

40

50

148

Figure 4.4 Muc5ac mediated cellular proliferation enhances PC progression: (A) Representative
micrographs (40X) showing Ki-67 staining performed on pancreatic tissue sections, from KrasG12D; Pdx1Cre; Muc5ac+/+ and KrasG12D; Pdx1-Cre; Muc5ac-/- mice at 10th week and 50th week. (B) Representative
micrograph (40X) demonstrating simultaneous expression of Muc5ac and Ki-67 in a pancreatic duct. (C)
Quantification of number of Ki-67 positive nuclei observed per field, during progression of PC in 10th and
50th weeks of age in KrasG12D; Pdx1-Cre; Muc5ac-/- mice in comparison to KrasG12D; Pdx1-Cre; Muc5ac+/+
mice.
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Figure 4.4

A
KCMuc5ac-/-

10 Week

KCMuc5ac+/+

C

KCMuc5ac+/+
KCMuc5ac-/-

50 Week

# of Ki-67 positive nuclei

140

B
50th Week

MUC5AC

Ki-67

**p<0.005

120
100
80

*p<0.01

60
40
20
0
50

10
Weeks

150

Reference List
[1] M. Hidalgo, New insights into pancreatic cancer biology. Ann. Oncol. 23 Suppl 10 (2012)
x135-x138.
[2] C.A. Iacobuzio-Donahue, V.E. Velculescu, C.L. Wolfgang, and R.H. Hruban, Genetic basis
of pancreas cancer development and progression: insights from whole-exome and wholegenome sequencing. Clin. Cancer Res. 18 (2012) 4257-4265.
[3] D.P. Ryan, T.S. Hong, and N. Bardeesy, Pancreatic adenocarcinoma. N. Engl. J. Med. 371
(2014) 1039-1049.
[4] S. Kaur, S. Kumar, N. Momi, A.R. Sasson, and S.K. Batra, Mucins in pancreatic cancer and
its microenvironment. Nat. Rev. Gastroenterol. Hepatol. 10 (2013) 607-620.
[5] M.P. Torres, S. Chakraborty, J. Souchek, and S.K. Batra, Mucin-based targeted pancreatic
cancer therapy. Curr. Pharm. Des 18 (2012) 2472-2481.
[6] M.A. Hollingsworth and B.J. Swanson, Mucins in cancer: protection and control of the cell
surface. Nat. Rev. Cancer 4 (2004) 45-60.
[7] D.W. Kufe, Mucins in cancer: function, prognosis and therapy. Nat. Rev. Cancer 9 (2009)
874-885.
[8] M.E. Forgue-Lafitte, B. Fabiani, P.P. Levy, N. Maurin, J.F. Flejou, and J. Bara, Abnormal
expression of M1/MUC5AC mucin in distal colon of patients with diverticulitis, ulcerative
colitis and cancer. Int. J. Cancer 121 (2007) 1543-1549.
[9] A. Bobrowski, M. Spitzner, S. Bethge, F. Mueller-Graf, B. Vollmar, and D. Zechner, Risk
factors for pancreatic ductal adenocarcinoma specifically stimulate pancreatic duct glands
in mice. Am. J. Pathol. 182 (2013) 965-974.
[10] C.T. Zhang, K.C. He, F. Pan, Y. Li, and J. Wu, Prognostic value of Muc5AC in gastric
cancer: A meta-analysis. World J. Gastroenterol. 21 (2015) 10453-10460.
[11] M.V. Kesari, V.L. Gaopande, A.R. Joshi, S.V. Babanagare, B.P. Gogate, and A.V.
Khadilkar, Immunohistochemical study of MUC1, MUC2 and MUC5AC in colorectal
carcinoma and review of literature. Indian J. Gastroenterol. 34 (2015) 63-67.
[12] L. Xiong, Z. Yang, L. Yang, J. Liu, and X. Miao, Expressive levels of MUC1 and
MUC5AC and their clinicopathologic significances in the benign and malignant lesions of
gallbladder. J. Surg. Oncol. 105 (2012) 97-103.
[13] T. Abe, H. Amano, F. Shimamoto, M. Hattori, S. Kuroda, T. Kobayashi, H. Tashiro, and H.
Ohdan, Prognostic evaluation of mucin-5AC expression in intrahepatic
cholangiocarcinoma, mass-forming type, following hepatectomy. Eur. J. Surg. Oncol. 41
(2015) 1515-1521.

151

[14] S. Inaguma, K. Kasai, and H. Ikeda, GLI1 facilitates the migration and invasion of
pancreatic cancer cells through MUC5AC-mediated attenuation of E-cadherin. Oncogene
30 (2011) 714-723.
[15] A. Ruzzenente, C. Iacono, S. Conci, F. Bertuzzo, G. Salvagno, O. Ruzzenente, T.
Campagnaro, A. Valdegamberi, S. Pachera, F. Bagante, and A. Guglielmi, A novel serum
marker for biliary tract cancer: diagnostic and prognostic values of quantitative evaluation
of serum mucin 5AC (MUC5AC). Surgery 155 (2014) 633-639.
[16] A. Silsirivanit, N. Araki, C. Wongkham, C. Pairojkul, Y. Narimatsu, K. Kuwahara, H.
Narimatsu, S. Wongkham, and N. Sakaguchi, A novel serum carbohydrate marker on
mucin 5AC: values for diagnostic and prognostic indicators for cholangiocarcinoma.
Cancer 117 (2011) 3393-3403.
[17] D. Liu, C.H. Chang, D.V. Gold, and D.M. Goldenberg, Identification of PAM4
(clivatuzumab)-reactive epitope on MUC5AC: a promising biomarker and therapeutic
target for pancreatic cancer. Oncotarget. 6 (2015) 4274-4285.
[18] M. Takikita, S. Altekruse, C.F. Lynch, M.T. Goodman, B.Y. Hernandez, M. Green, W.
Cozen, M. Cockburn, S.M. Sibug, M. Topor, C. Zeruto, B. Abedi-Ardekani, M.E.
Reichman, and S.M. Hewitt, Associations between selected biomarkers and prognosis in a
population-based pancreatic cancer tissue microarray. Cancer Res. 69 (2009) 2950-2955.
[19] S.R. Hingorani, E.F. Petricoin, A. Maitra, V. Rajapakse, C. King, M.A. Jacobetz, S. Ross,
T.P. Conrads, T.D. Veenstra, B.A. Hitt, Y. Kawaguchi, D. Johann, L.A. Liotta, H.C.
Crawford, M.E. Putt, T. Jacks, C.V. Wright, R.H. Hruban, A.M. Lowy, and D.A. Tuveson,
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse.
Cancer Cell 4 (2003) 437-450.
[20] S. Rachagani, M.P. Torres, S. Kumar, D. Haridas, M. Baine, M.A. Macha, S. Kaur, M.P.
Ponnusamy, P. Dey, P. Seshacharyulu, S.L. Johansson, M. Jain, K.U. Wagner, and S.K.
Batra, Mucin (Muc) expression during pancreatic cancer progression in spontaneous mouse
model: potential implications for diagnosis and therapy. J. Hematol. Oncol. 5 (2012) 68.
[21] L. Rahib, B.D. Smith, R. Aizenberg, A.B. Rosenzweig, J.M. Fleshman, and L.M.
Matrisian, Projecting cancer incidence and deaths to 2030: the unexpected burden of
thyroid, liver, and pancreas cancers in the United States. Cancer Res. 74 (2014) 2913-2921.
[22] R.L. Siegel, K.D. Miller, and A. Jemal, Cancer statistics, 2016. CA Cancer J. Clin. 66
(2016) 7-30.
[23] I. Lakshmanan, S. Rachagani, R. Hauke, S.R. Krishn, S. Paknikar, P. Seshacharyulu, S.
Karmakar, R.K. Nimmakayala, G. Kaushik, S.L. Johansson, G.B. Carey, M.P. Ponnusamy,
S. Kaur, S.K. Batra, and A.K. Ganti, MUC5AC interactions with integrin beta4 enhances
the migration of lung cancer cells through FAK signaling. Oncogene(2016).
[24] M. Herreros-Villanueva, E. Hijona, A. Cosme, and L. Bujanda, Mouse models of
pancreatic cancer. World J. Gastroenterol. 18 (2012) 1286-1294.

152

[25] C.B. Westphalen and K.P. Olive, Genetically engineered mouse models of pancreatic
cancer. Cancer J. 18 (2012) 502-510.
[26] F. Escande, N. Porchet, A. Bernigaud, D. Petitprez, J.P. Aubert, and M.P. Buisine, The
mouse secreted gel-forming mucin gene cluster. Biochim. Biophys. Acta 1676 (2004) 240250.
[27] S.Z. Hasnain, C.M. Evans, M. Roy, A.L. Gallagher, K.N. Kindrachuk, L. Barron, B.F.
Dickey, M.S. Wilson, T.A. Wynn, R.K. Grencis, and D.J. Thornton, Muc5ac: a critical
component mediating the rejection of enteric nematodes. J. Exp. Med. 208 (2011) 893-900.
[28] C.K. Marko, A.S. Tisdale, S. Spurr-Michaud, C. Evans, and I.K. Gipson, The ocular
surface phenotype of Muc5ac and Muc5b null mice. Invest Ophthalmol. Vis. Sci. 55 (2014)
291-300.
[29] S.Z. Hasnain, C.M. Evans, M. Roy, A.L. Gallagher, K.N. Kindrachuk, L. Barron, B.F.
Dickey, M.S. Wilson, T.A. Wynn, R.K. Grencis, and D.J. Thornton, Muc5ac: a critical
component mediating the rejection of enteric nematodes. J. Exp. Med. 208 (2011) 893-900.
[30] D.M. Besmer, J.M. Curry, L.D. Roy, T.L. Tinder, M. Sahraei, J. Schettini, S.I. Hwang, Y.Y.
Lee, S.J. Gendler, and P. Mukherjee, Pancreatic ductal adenocarcinoma mice lacking mucin
1 have a profound defect in tumor growth and metastasis. Cancer Res. 71 (2011) 44324442.

153

Chapter V
Mucins and associated glycan signatures in colon adenomacarcinoma sequence: Prospective pathological implication(s)
for early diagnosis of colon cancer.
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1. Synopsis
Development of biomarkers that detect early stage resectable premalignant lesions of colon can
provide critical aid in the prevention of colorectal cancer. Recent lines of evidence suggest the
utility of mucin expression to predict malignant transformation of colon pre-neoplastic lesions. In
this study, we investigated the combined expression of multiple mucins and mucin-associated
glycans during the adenoma-carcinoma sequence of colon cancer progression. Further, we
evaluated their applicability as markers for differentiating adenomas/adenocarcinomas from
hyperplastic polyps. Immunohistochemical analyses performed on colon disease tissue
microarrays revealed downregulation of MUC2 and MUC4 expression (p<0.0001) while MUC1
and MUC5AC expressions were upregulated (p=0.01) during adenoma-adenocarcinoma
progression. Expression of MUC17 was downregulated in inflamed tissues compared to normal
tissues, but its increased expression differentiated adenomas (p=0.0028) and adenocarcinomas
(p=0.025) from inflammation. Glycan epitope-Tn/STn-MUC1 showed higher expression in
hyperplastic polyps (p=0.023), adenomas (p=0.042) and adenocarcinomas (p=0.0096) compared
to normal tissues. Multivariate regression analyses indicated that a combination of MUC2,
MUC5AC, and MUC17 could effectively discriminate adenoma-adenocarcinoma from
hyperplastic polyps. Altogether, a combined analysis of altered mucins and mucin-associated
glycans is a useful approach to distinguish premalignant/malignant lesions of colon from benign
polyps.
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2. Background & Rationale
For colorectal cancer (CRC), incidence and mortality rates are high worldwide [1]. CRC is the
third most common cancer in both men and women, and the second leading cause of cancer
deaths in the US [1]. In 2016, about 134,490 people will be diagnosed with CRC, and about
49,190 people will die of the disease [2]. Survival from CRC is associated with the stage of
cancer when diagnosed, with the advanced disease having the worst outcome; the 5-year survival
being 13% [3]. Only 40% of CRCs are diagnosed at early stages, due in part to the underuse of
screening modalities. Thus, there is a need for specific and sensitive modalities for early
diagnoses.
CRC is a heterogeneous disease. Its etiology involves modifiable, medical and hereditary
risk factors, and the precise events vary from one individual to another [4]. Various pathways of
neoplastic progression contribute to the molecular and biological heterogeneity exhibited by
CRCs [5]. About 85% of CRCs are sporadic and progress slowly by accumulating multiple
genetic mutations (APC, KRAS, p53, and DCC) in precancerous lesions (polyps/adenomas). The
process is referred to as adenoma-carcinoma sequence [6]. Recent studies highlight the diagnostic
potential of the mucin expression profiles in pre-neoplastic colon polyps [7, 8]. Intestinal mucosal
and goblet cells produce, store, and secrete heavily glycosylated proteins termed mucins (MUCs)
which are the building blocks of the gastrointestinal (GI) mucus system. Mucins provide a
selective molecular barrier for luminal protection of the GI tract against factors such as food,
acid, enzymes and bacteria [9, 10]. To date, 21 mucin genes have been identified and categorized
into two subgroups: membrane-bound and secretory mucins [11]. The apical cell surfaces of
intestinal enterocytes and colonic columnar cells anchor membrane-bound mucins (MUC1,
MUC4, and MUC17) [10]. These mucins sense the intestinal environment to mediate intracellular
signaling and provide a diffusion barrier [10]. In contrast, secretory mucins (MUC2, MUC5B,
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MUC5AC, and MUC6) form polymeric gels that facilitate lubrication and protection of GI
system [10]. Various inflammatory, benign (hyperplastic polyps), premalignant (adenomas), and
malignant conditions of colon are associated with alterations in mucin expression, organization,
glycosylation which in turn impact their functioning. Mucin aberrations affect a variety of cellular
activities, including growth, differentiation, transformation, adhesion, invasion, and immune
surveillance [12]. Several studies have investigated the expression of mucins, including MUC1,
MUC2, MUC4, MUC5AC, MUC6, and MUC17 and their associated glycans during the colon
adenoma-carcinoma progression [13-17]. However, there has been no analysis of these mucins as
a panel of markers for differentiating malignancies from normal/benign controls. The present
study, for the first time, compared concurrent expression of mucins (MUC1, MUC2, MUC4,
MUC5B, MUC5AC, MUC6, and MUC17) and mucin-associated glycans (Tn/STn-MUC1,
TAG72 and CA 19-9) in normal, inflamed colon tissues as well as in tissues obtained from
hyperplastic polyps, adenomas, and adenocarcinomas of the colon, and investigated the utility of
a panel of markers to differentiate premalignant and malignant lesions from benign conditions.
3. Results
The comprehensive immunophenotypic expression profiling of mucins and mucin-associated
glycans was performed utilizing a commercial colon disease spectrum array. The primary
objective was to delineate differentially expressed mucins for discriminating normal and benign
tissues

(hyperplastic

polyps)

from

premalignant

(adenomas)

and

malignant

(colon

adenocarcinoma) lesions. A further goal was to identify a panel of markers that could
differentiate benign colon tissues from neoplastic precursor lesions and malignant lesions.
3.A Expression of transmembrane mucins
Looking at previous reports of expression and association of transmembrane mucins (MUC1,
MUC4 and MUC17) with CRC, in this study, we investigated their comprehensive expression
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profile during adenoma-carcinoma sequence.
MUC1: In normal colon tissues, a weak to mild MUC1 expression (mean±SE CS, 3.5±0.5;
mean±SE IS, 1.7±0.2) was observed (Figure 5.1A, Table 5.1). In comparison to normal tissues,
no appreciable difference in expression of MUC1 was observed in inflamed tissues (mean CS,
5.2±1.2; mean IS, 1.9±0.3), hyperplastic polyps (mean CS, 3.8±1.1; mean IS, 2.1±0.3), or
adenomas (mean CS, 4.0±0.6; mean IS, 1.9± 0.2) (Figure 5.1B-D, Table 5.1). MUC1 expression
was higher in adenocarcinomas (mean CS, 5.8±0.9; mean IS, 2.4±0.2) in comparison to normal
tissues (Figure 5.1E, Table 5.1). Notably, a significant increase in the intensity and extent of
MUC1 expression was observed in adenocarcinomas (56% of tissues having 3+ intensity scores)
as compared to normal tissues (none having 3+ intensity scores).
MUC4: There was strong expression of MUC4 in 89% of the normal colon samples (mean CS,
11.6±0.3; mean IS, 3±0) (Figure 5.1F, Table 5.1); its expression was reduced to moderate levels
in inflamed tissues (mean CS, 7.9±1; mean IS, 2.5±0.3) (Figure 5.1G, Table 5.1). Relative to
normal tissues, expression of MUC4 was significantly low in hyperplastic polyps (mean CS,
4.4±1.5; mean IS, 1.5±0.4) (Fig 1H, Table 5.1). Further reduction in MUC4 expression in
adenomas (mean CS, 4.2±0.7; mean IS, 1.6±0.2) significantly differentiated them from normal
and inflammatory tissues (Figure 5.1I, Table 5.1). However, 13% of adenoma tissues exhibited
strong expression of MUC4. Adenocarcinomas had drastic reduction in MUC4 expression with
undetectable expression in 63% of samples (means CS, 0.6±0.3, mean IS, 0.5±0.2) (Figure 5.1J,
Table 5.1). Overall, expression of MUC4 was significantly downregulated (p<0.0001) in the
adenoma-carcinoma sequence.
MUC17: All normal tissues showed MUC17 positivity (mean CS, 8.5±1; mean IS, 2.4±0.2)
(Figure 5.1K, Table 5.1), with mild, moderate, and strong expression distributed uniformly.
Relative to normal tissues, expression of MUC17 was downregulated in inflamed tissues (mean
CS, 5.6±0.9; mean IS, 2±0.3), with none of the tissues having strong expression (Figure 5.1L,
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Table 5.1). There was no significant differences in MUC17 expression in hyperplastic polyps
compared to normal and inflamed tissues (mean CS, 7.7±1.5; mean IS, 2.3±0.3) (Figure 5.1M,
Table 5.1). In adenomas, however, there was significantly higher MUC17 expression in
comparison to inflamed tissues (mean CS, 9.5±0.6; mean IS, 2.5±0.1) (Figure 5.1N, Table 5.1),
with 60% of adenomas showing strong expression. Further, MUC17 expression significantly
differentiated adenocarcinomas from inflamed tissues (mean CS, 9±0.8; mean IS, 2.4±0.1)
(Figure 5.1O, Table 5.1). Overall, higher MUC17 expression was a significant marker (p=0.047)
to differentiate premalignant and malignant lesions from inflammation.
3.B Expression of secretory mucins
Alterations in the expression of secretory mucins (MUC2, MUC5AC, MUC5B and MUC6) have
been associated with CRC. Next, we examined their comprehensive expression signature during
adenoma-carcinoma sequence.
MUC2: Strong expression of MUC2 was observed in all normal colon samples (mean CS, 12±0;
mean IS, 3±0) (Figure 5.2A, Table 5.2). In tissues with inflammation, there was a slight decrease
in MUC2 expression (mean CS, 11.4±0.4; Mean IS, 3±0) (Figure 5.2B, Table 5.2). Expression
of MUC2 was significantly lower in hyperplastic polyps relative to normal tissues (mean CS,
9.7±1.1; mean IS, 2.9±0.1) (Figure 5.2C, Table 5.2), and in adenomas relative to normal,
inflamed tissues and hyperplastic polyps (mean CS, 7.4±0.6; mean IS, 2.8±0.1) (Figure 5.2D,
Table 5.2). Interestingly, 13% of adenomas exhibited relatively strong MUC2 expression. In
adenocarcinomas, significantly lower MUC2 expression (mean CS, 3.8±0.9; mean IS, 2±0.3) was
observed relative to normal, inflammation, hyperplastic polyps and adenoma tissues (Figure
5.2E, Table 5.2). Further, strong expression of MUC2 was reduced to only 6% of
adenocarcinomas. Overall, MUC2 expression was significantly decreased (p<0.0001) in the
adenoma-carcinoma sequence.
MUC5AC: The expression of MUC5AC was undetectable in the normal colon tissues (mean CS,

160

0±0; mean IS, 0±0) (Figure 5.2F, Table 5.2), however 30% of inflamed tissues expressed
MUC5AC at low levels (mean CS, 0.5±0.3; mean IS, 0.5± 0.3) (Figure 5.2G, Table 5.2). There
was a further significant increase in expression of MUC5AC in 50% of hyperplastic polyps (mean
CS, 1.8±1; mean IS, 0.9±0.4) (Figure 5.2H, Table 5.2) and in 63% of adenomas (mean CS,
3.1±0.6; mean IS, 1.5±0.2) (Figure 5.2I, Table 5.2) relative to normal tissues. For
adenocarcinomas, a statistically significant upregulation of MUC5AC was found in 38% of
tissues relative to normal colon (mean CS, 1.7±0.7; mean IS, 1.1±0.4) (Figure 5.2J, Table 5.2).
Overall, high MUC5AC expression was a significant marker (p=0.01) that differentiated
neoplastic precursors and malignant lesions from normals.
MUC5B and MUC6: None of the normal colon tissues expressed MUC5B and/or MUC6
(Figure 5.2K & Figure 5.2P, Table 5.2). However, expression of MUC5B was evident in a
fraction of inflamed tissues (20%) (Figure 5.2L), hyperplastic polyps (20%) (Figure 5.2M),
adenomas (27%) (Figure 5.2N), and adenocarcinomas (12.5%) (Figure 5.2O). In adenomas,
there was intense staining of MUC5B relative to normal tissues (mean IS, 0.8±0.2) (Table 5.2).
In contrast to MUC5B, MUC6 expression was noted in only 10% of adenomas (Figure 5.2S) and
in 19% of adenocarcinomas (Figure 5.2T). Overall, the expression of MUC5B and MUC6 were
not appreciably different between normal, inflammation, benign, and premalignant and malignant
colonic tissues.
3.C Expression of mucin-associated glycans
Altered glycosylation is one of the hallmarks of cancers. Looking at previously reported
diagnostic potential of alterations in mucin-associated glycans CA 19-9, TAG72 during CRC, we
examined their expression signature during adenoma carcinoma sequence.
CA 19-9 (Sialyl-LewisA): Weak expression of CA 19-9 (mean CS, 2.8±0.9; IS, 1.9±0.5) was
observed in 77.8% normal tissues (Figure 5.3F, Table 5.3) and a lack of expression in 22.2%
cases. There was a similar pattern in inflamed tissues (mean CS, 3±1; mean IS, 1.6±0.5) (Figure
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5.3G, Table 5.3). Relative to normal tissues, there was a mild increase in expression of CA 19-9
in hyperplastic polyps (mean CS, 3.3±0.9; mean IS, 2.1±0.3) (Figure 5.3H, Table 5.3) and
adenomas (mean CS, 3.2±0.6; mean IS, 1.8±0.2) (Figure 5.3I, Table 5.3). Further, there were
higher levels of CA 19-9 in adenocarcinomas relative to normal and inflamed tissues (mean CS,
6.1±1.2; mean IS, 2.2±0.3) (Figure 5.3J, Table 5.3). Interestingly, similar to normal colon, 25%
of the adenocarcinomas were negative for CA 19-9 expression. In summary, CA 19-9 expression
was higher in adenocarcinomas relative to normal tissues; however, this expression did not allow
significant differentiation between hyperplastic polyps, adenomas, inflammatory and normal
colon.
TAG72 (Sialyl-Tn): Normal colon tissues exhibited weak expression of TAG72 (mean CS,
1.7±0.3; mean IS, 1.1±0.2) (Figure 5.3K, Table 5.3). However, there was elevated expression in
inflamed tissues (mean CS, 3.5±0.3; mean IS, 1.7±0.3) (Figure 5.3L, Table 5.3) and hyperplastic
polyps (mean CS, 4.5±0.5; mean IS, 2.1±0.3) (Figure 5.3M, Table 5.3) relative to normal
tissues. Further, TAG72 expression was significantly elevated in adenomas (mean CS, 4.5±0.1;
mean IS, 2.0±0.1) (Figure 5.3N, Table 5.3) and adenocarcinomas (mean CS, 5.2±0.2; mean IS,
2.0±0.2) (Figure 5.3O, Table 5.3), differentiating these tissues from normal tissues. Relative to
normal tissues, 38% of cancers had intense staining (3+) for TAG72. Overall, there was a
progressive increase in TAG-72 expression during adenoma-carcinoma sequence.
Tn/STn-MUC1: Considering the overexpression of MUC1 during CRC, we also investigated the
antigenic expression of MUC1-associated Tn/STn glycans during adenoma-carcinoma sequence.
Although MUC1 was expressed in normal tissues, the presence of Tn/STn-MUC1 was not
detectable in 89% samples (mean CS, 0.1±0.1; mean IS, 0.1±0.1); while positive samples
exhibited weak expression (Figure 5.3A, Table 5.3). The expression of Tn/STn-MUC1 was
higher in 40% of inflamed tissues (mean CS, 1.3±0.7; mean IS, 0.5±0.3) (Figure 5.3B, Table
5.3). Further, significantly high expression of Tn/STn-MUC1 was observed in 60% of
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hyperplastic polyps (mean CS, 2.4±1; mean IS, 1.2±0.4), 47% adenomas (mean CS, 1.8±0.5;
mean IS, 0.9±0.2), and 63% adenocarcinomas (mean CS, 3.5±1.0; mean IS, 1.5±0.32) (Figure
5.3C-E, Table 5.3) relative to normal tissues. Overall, Tn/STn-MUC1 is progressively increased
during adenoma-carcinoma sequence and significantly differentiates normal tissues from
adenomas and adenocarcinomas.
Differences in CS for each colon tissue type were converted into a heat map for better
visualization (Supplementary Fig. 1).
3.D Multivariate analyses to evaluate biomarker combinations as predictors of malignancy:
To determine the ability of mucins and mucin-associated glycans as biomarkers for
discriminating adenoma/adenocarcinoma from hyperplastic polyp, we first performed univariate
analysis. We observed that loss of MUC2 was a significant predictor (p=0.016) of
adenoma/adenocarcinoma vs. hyperplastic polyps. We next investigated whether combinations of
significantly altered mucins (MUC2, MUC4, MUC5AC, and MUC17) and mucin-associated
glycans (Tn/STn-MUC1) can improve prediction of benign lesions (hyperplastic polyps) from
neoplastic precursors (adenomas) and malignant lesions (adenocarcinoma). For this multivariate
logistic regression method was utilized. In a full multivariate model, after adjusting for other
variables, for each one-unit increase in CS of MUC2 it was 33% less likely to have
adenoma/adenocarcinoma than hyperplastic polyp (p=0.014) (Table 5.4). Further, after adjusting
for other variables, for each one-unit increase in CS for MUC17 and MUC5AC, the likelihood of
adenoma/adenocarcinoma than hyperplastic polyp was 25% and 34% respectively (Table 5.4). In
a backward selected model including only MUC4 and MUC2, after adjusting for MUC4, for each
one-unit increase in CS for MUC2, it was 37% less likely to have adenocarcinoma than
hyperplastic polyp (p=0.011) (data not shown). In a reduced model which includes MUC17,
MUC5AC, and Tn/STn-MUC1, for each one-unit increase in CS for MUC17 after adjusting for
MUC5AC and Tn/STn-MUC1, it was 31% more likely to have adenoma than hyperplastic polyp
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(p=0.040) (data not shown). In summary, a combination of MUC2, MUC5AC, and MUC17
expression profiles could be useful for predicting the odds of having premalignant and/or
malignant lesions of the colon.
4. Discussion
Alterations in the expression of mucin proteins and in their O-glycosylation are postulated to be
involved in colon carcinogenesis and are considered as molecular markers for clinical use [19]. In
this context, the present study is the first to comprehensively evaluate the differential expression
of mucins and mucin-associated glycans during sequential progression to colon carcinogenesis
and to provide their utility in combinations for predicting the development of colon cancer.
MUC1 is a transmembrane mucin that is expressed in normal colon and overexpressed in
inflammatory bowel disease (IBD) [20]. It is expressed in 19-76% of adenomas and is associated
with increasing dysplasia along the adenoma-carcinoma sequence [14, 21]. Further, there is
overexpression of MUC1 in most colorectal tumors, with expression in the range of 30-100% [22,
23]. Higher expression of MUC1 positively correlates with stage, metastasis, poor tumor
differentiation, and worse long-term survival [22-25]. Although our results regarding MUC1 are
in accordance with aforementioned findings, its expression did not serve as a statistically
significant marker of tumor progression, a deficiency that could be attributed to the limited
sample size. However, MUC1 can be considered as a prognostic marker for colon cancer [22].
The present study represents a comprehensive analysis of MUC4 expression in the
adenoma-carcinoma sequence. MUC4 is a high-molecular-weight transmembrane mucin that is
overexpressed in many carcinomas and is associated with a poor prognosis [26], especially for
early stage CRCs [27]. An inverse relationship of MUC4 expression with the severity of Crohn’s
disease (CD) and ulcerative colitis (UC) has been established [28], and MUC4 expression is also
reduced in hyperplastic polyps. Similarly, loss of MUC4 expression in serrated adenomas has
been suggested to be a useful marker to identify patients with an elevated risk of developing
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colon cancer [13]. However, utilizing the Muc4-/- mice, it was demonstrated that during
conditions of increased inflammation, loss of Muc4 renders resistance to chemical induced colitis
and CRC. In addition, loss of Muc4 was shown to be compensated by elevation of Muc2 and
Muc3 in this colitis induced tumor model [29]. In current study, we observed low MUC4
expression in inflammatory colon samples, suggesting that different inflammatory pathways may
be involved in its regulation. In this regard, association of MUC4 with prognosis of IBD patients
who develop CRC needs further validation in a large cohort of samples. Further, association
between MUC4 expression and colon cancer has been variable among several studies.
Shanmugam et al. reported the complete loss/decreased MUC4 expression in 75% of CRCs [27].
Biemer-Huttmann et al. demonstrated MUC4 expression in 34% of adenocarcinomas and 47% of
mucinous colon cancers and suggested an inverse association between MUC4 expression and
tumor stage in MUC4-positive tissues [30]. Similarly, Zhang et al. observed intense MUC4
expression in 50% of colon cancers [31]. The findings of the present study align with
Shanmugam et al [27] which demonstrated strong MUC4 expression in normal colon with
progressive decrease during progression to carcinoma. Identification of the molecular
mechanisms underlying the downregulation of MUC4 expression during the adenoma-carcinoma
process could further establish its association with colon cancer carcinogenesis.
MUC17 is another membrane-bound mucin found by our laboratory, to be highly
expressed on normal colon apical epithelium and crypt columnar epithelial cells and is
downregulated in ulcerative colitis, Crohn’s disease, hyperplastic polyps, tubular, tubulovillous
adenomas, and adenocarcinomas [17]. Consistent with our previous report, there was mild to
strong expression of MUC17 in normal colon tissues, and it was reduced in inflamed colon.
However, contrary to our previous report, there was higher MUC17 expression in adenomas and
adenocarcinomas relative to inflamed tissues. Similar to present observation, a recent study
reported that there was an 82-fold increase in MUC17 expression that differentiated sessile
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serrated adenomas/polyps (SSA/P) from hyperplastic polyps, adenomatous polyps, and normal
tissues [32]. Further, our unpublished findings from another CRC cohort study suggested that loss
of the punctate immunostaining pattern and the diffused cytoplasmic staining pattern of MUC17
were associated with aggressive behavior of CRCs and shortened patient survival (data not
shown). The observation conflicts could be due to limited sample number, different site from
where the tissues were obtained or different ethnicity of patient population. Therefore, these
observations warrant further investigation in a larger set of subtypes of colorectal polyps and
adenocarcinomas for defining MUC17 as a marker to differentiate pre-malignant lesions and to
establish its conclusive association with colorectal carcinogenesis.
The gel-forming mucin, MUC2, is secreted by goblet and columnar cells of the colonic
epithelium and is organized into two layers of protective mucus [33]. In CRCs, there is lower
MUC2 expression at both the mRNA and protein levels and low expression correlates with
reduced patient survival and a high incidence of liver and nodal metastases [34-36]. In contrast to
colon adenocarcinomas, colonic mucinous carcinomas are characterized by overexpression of
MUC2 [15, 37]. Consistent with these studies, we found a sequential and significant reduction of
MUC2 in the adenoma-carcinoma sequence. Loss of MUC2 differentiates adenomas and
adenocarcinomas from normal and benign controls. Overall, the findings suggest that a reduction
of MUC2 in adenomas can be utilized as an early-stage marker to identify precursor lesions with
malignant potential.
MUC5AC is not expressed in normal colon mucosa [15], but there is aberrant
overexpression of MUC5AC in IBD [38], ulcerative colitis-associated dysplasia/neoplasms [39],
hyperplastic polyps (HP), tubular adenomas, and SSA/Ps [8, 15, 16, 40]. It is also found in poorly
differentiated adenocarcinomas located in the proximal colon independent of microsatellite
instability status [41] and in mucinous CRCs. Consistent with previous studies, we found no
expression of MUC5AC in normal colon tissues, but its expression was significantly higher in
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adenomas and adenocarcinomas. Higher MUC5AC expression differentiated adenocarcinomas
from normal colon tissues. Overall, expression of MUC5AC in colon pathologies, its association
with the adenoma-carcinoma sequence and its secretory nature suggests that MUC5AC combined
with other relevant markers could be a useful marker for early diagnosis of CRC.
Among mucin-associated glycans, the TAG72 epitope is carried by high-molecularweight mucins and identified as Sialyl-Tn. It is overexpressed in several malignancies, including
CRC, and is considered as an early marker for CRC and other dysplastic colonic diseases [42,
43]. The present results regarding TAG72 expression are consistent with those previously
reported studies. Although expression of TAG72 differentiated adenoma and adenocarcinoma
from normal colon, yet it could not emerge as a significant marker during adenoma-carcinoma
sequence.
CA 19-9 identifies the tumor surface marker sialylated Lewis (a). The incidence of
elevated serum CA 19-9 levels in CRCs ranges from 20–40% [44]. However, CA 19-9 is also
expressed in normal colonic mucosa, thus limiting its diagnostic efficacy. We observed
expression of CA 19-9 in 78% of normal colon tissues with weak/mild reactivity. Prominent CA
19-9 expression was observed in 94.4% of ulcerative and 72.4% of Crohn’s colitis tissues
previously [45]. In contrast, we did not observe appreciable alterations in CA 19-9 expression in
inflammatory tissues relative to normal colon tissues. Confounding views regarding the utility
and feasibility of measuring CA 19-9 to differentiate low and high-risk adenomatous polyps have
been published. Despite positivity for CA 19-9 in 60% of adenomas, its utility as a marker of the
adenoma-carcinoma sequence is questionable due to lack of correlation with degree of dysplasia,
size of adenoma and villous component [45, 46]. These results from previous studies are
corroborated by our finding that CA 19-9 was present in 90% of hyperplastic polyps and 67% of
adenomas, but it could not differentiate these lesions from benign or inflammatory conditions.
Although the diagnostic sensitivity and specificity of CA 19-9 for CRC has been estimated to be
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70% and 61%, respectively [47], our results underscore the inability of CA 19-9 assays to
differentiate normal and inflammatory colon from adenocarcinoma, despite its increase in
expression in 75% of tissues. Since the elevated CA 19-9 levels correlate with tumor stage and
with the highest sensitivity in patients with metastases [48], it may serve as a useful marker for
advanced disease.
The Tn and sialyl-Tn epitopes appear to be colon cancer-associated antigens that act as
markers of poorly differentiated adeno- and mucinous carcinomas [49]. Of colon carcinoma
tissues, 82% express Tn antigens, and 73% express STn antigens on mucins in the cytoplasm or
in luminal cell membranes [50]. Malignant effusions from breast, colon, gastric, and ovarian
cancers have Tn antigen on MUC1 [51]. Proximity ligation assays have been applied for
detection of aberrant mucin glycoforms in cancer. Tn/STn-MUC1 glycoforms are the most
frequently expressed cancer biomarkers in the series of mucinous colon carcinomas [52].
Considering the overexpression of MUC1 and associated glycoforms in the adenoma-carcinoma
sequence and their association with increased malignant potential of colon tissues, we
investigated the antigenic expression of MUC1-associated Tn/STn glycans utilizing 5E5 antibody
characterized previously [53]. The antibody 5E5 reacts with all Tn and STn glycoforms of the
MUC1 tandem repeat but shows no reactivity with non-glycosylated MUC1 peptides. Our results
demonstrate the utility of Tn/STn-MUC1 in differentiating hyperplastic polyps (p<0.05),
adenomas (p<0.05), and adenocarcinomas (p<0.005) from normal colon. Of normal colon tissues,
89% did not express Tn/STn-MUC1 while the remaining 11% exhibited focal immunoreactivity.
The incidences of Tn/STn-MUC1 in adenomas and adenocarcinomas were 47% and 63%,
respectively. As Tn/STn-MUC1 is tumor associated antigen, its higher expression was observed
in comparison to MUC1 in certain cases. A further analysis of histologically-defined subtypes of
cancer-associated adenomas and examination of adenocarcinomas and metastatic tissues are
needed to establish its utility as a diagnostic marker in the adenoma-carcinoma sequence.
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In addition to determining the pattern of distribution of mucins and mucin-associated
glycans individually in the adenoma-carcinoma sequence, the present study performed
multivariate regression analyses to identify combinations of mucins and mucin-associated glycans
for predicting colon carcinogenesis at an early stage. The results suggest that a combination of
MUC2, MUC17, and MUC5AC can be utilized to assess the likelihood of adenoma and
adenocarcinoma versus benign hyperplastic polyps.
While this study utilized a comprehensive panel of mucin and associated glycan
antibodies, it is limited by the small sample size. The colon disease array used in this study did
not include mucinous adenocarcinoma and metastatic colon cancer samples, limiting the complete
picture of mucin and mucin-associated glycans expression in malignant tissues (e.g. MUC2 and
MUC5AC which are highly expressed in mucinous adenocarcinomas). Additionally, the lack of
information about the sites in the colon from which the tissues were procured and about
associated mutations limits the interpretations with regard to prediction of malignancy.
Overall, we investigated the signature of mucins and mucin-associated glycans associated
with the adenoma-carcinoma sequence and found significant alterations in expressions of MUC2,
MUC4, MUC5AC, MUC17, and Tn/STn-MUC1. We also explored combinations of mucins and
mucin-associated glycans for early-stage prediction of colon carcinogenesis. The combination of
MUC2, MUC5AC, and MUC17 may indicate the likelihood of a colon lesion being premalignant
and/or malignant versus benign. Future efforts are underway to determine utility of mucin and
mucin-associated glycans profile in risk stratification of different colorectal polyp subtypes to
enhance early stage management of this malignancy.
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Figure 5.1: Expression analysis of transmembrane mucins (MUC1, MUC4, and MUC17) in
colon disease tissue microarrays. Colon tissue microarrays (Cat. # 809a) were probed with
MUC1 (HMFG2), MUC4 (8G7) monoclonal antibodies and MUC17 polyclonal antibody (SN1132) after non-specific blocking with horse serum. All sections were examined under a
microscope and the expression was evaluated on the basis of reddish brown staining by a
pathologist. Representative photomicrographs are shown for MUC1 (A-E), MUC4 (F-J) and
MUC17 (K-O) stained tissues of normal, Inflamed Colon, hyperplastic polyp, adenoma, and
adenocarcinoma respectively. Elevated expression of MUC1 was observed during inflammation
(B), hyperplastic polyp (C), adenoma (D) and adenocarcinoma (E) of the colon in comparison to
normal colon samples (A). Strong expression of MUC4 was observed in normal colon tissues (F)
that were gradually lost during further progression to inflammation (G), hyperplastic polyp (H),
adenoma (I) and adenocarcinoma (J). High immunoreactivity of MUC17 observed in normal
colon (K) was downregulated in colon inflammation cases (L) and was observed to be
significantly upregulated during further progression to a hyperplastic polyp (M), adenoma (N)
and adenocarcinoma (O) cases in comparison to colonic inflammation cases.
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Figure 5.2: Expression analysis of secretory mucins (MUC2, MUC5AC, MUC5B and
MUC6) in colon disease tissue array: Colon tissue microarrays (Cat. # 809a) were probed with
MUC2 (EPR6145), MUC5AC (45M1), MUC5B (19.4E) and MUC6 (CLH5) monoclonal
antibodies after non-specific blocking with horse serum. All sections were examined under a
microscope, and the positive expression was evaluated on the basis of reddish brown staining by a
pathologist. Representative photomicrographs are shown for MUC2 (A-E), MUC5AC (F-J),
MUC5B (K-O) and MUC6 (P-T) stained tissues of normal, inflamed colon, hyperplastic polyp,
adenoma and adenocarcinoma of colon respectively. Strong expression of MUC2 observed in
normal colon tissues (A). Gradual loss of expression was observed during progression to
inflammation (B), hyperplastic polyps (C), adenoma (D) and adenocarcinoma (E). No
immunoreactivity of MUC5AC was observed in normal colon cases (F). Expression was
significantly enhanced in a hyperplastic polyp (H), adenoma (I) and adenocarcinoma (J) of colon
in comparison to normal colon (A) and inflammation cases (G). No MUC5B expression was
observed in normal colon (K) while rare expression was observed during inflammation (L),
hyperplastic polyp (M), adenoma (N) and adenocarcinoma (O). MUC6 expression was rarely
observed in cases of adenoma (S) and adenocarcinoma (T).

172

Figure 5.2:
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Figure 5.3: Expression analysis of mucin-associated glycans (Tn/STn-MUC1, CA 19-9 and
TAG72) in colon disease tissue array. Colon tissue microarrays (Cat. # 809a) were probed with
Tn/STn-MUC1 (5E5), CA 19-9 (NS19.9) and TAG72 (CC49) monoclonal antibodies after nonspecific blocking with horse serum. All sections were examined under a microscope, and the
positive expression was evaluated on the basis of reddish brown staining by a pathologist.
Representative photomicrographs are shown for Tn/STn-MUC1 (A-E), CA 19-9 (F-J) and
TAG72 (K-O) stained tissues of normal or inflamed colon, hyperplastic polyp, adenoma and
adenocarcinoma of the colon. Tn/STn-MUC1 expression was elevated during colonic
inflammation (B) that was further significantly enhanced in a hyperplastic polyp (C), adenoma
(D) and adenocarcinoma (E) cases of the colon when compared to normal colon samples (A). An
increase in CA 19-9 expression was observed in inflammation (G), hyperplastic polyp (H),
adenoma (I) and adenocarcinoma (J) when compared to normal colon cases (F). Low expression
of TAG72 was observed in normal colon cases (K). An increase in its expression was observed in
colon inflammation (L) and hyperplastic polyp (M) cases that was significantly upregulated in
colon adenoma (N) and adenocarcinoma (O) cases in comparison to normal colon (K).
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Supplementary Figure 5.1: Heat map for mucin and mucin-associated glycans expression
analysis in normal colon, colon inflammation, hyperplastic polyps, adenoma and
adenocarcinoma: Higher intensity of color corresponds to higher levels of expression based on
composite score (see Materials and Methods). Statistically significant mucins differentially
expressed during progression to colon cancer are represented by asterisks when compared to
controls.
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Table 5.1: Composite and intensity scores for transmembrane mucins (MUC1, MUC4, and MUC17) expression in normal,

MUC4
MUC17
MUC1
MUC4

Composite Scores
Intensity Scores

Transmembrane mucins

MUC1

inflammation, hyperplastic polyp, adenoma and adenocarcinoma tissues of the colon.

Diagnosis

Normal

Inflammation

Polyp

Adenoma

CAC

Mean ± SE

3.5 ± 0.5

5.2 ± 1.2

3.8 ± 1.1

4.0 ± 0.6

5.8 ± 0.9

Overall
p-value

0.34
Median (Min, Max)

4 (1, 6)

6 (0, 12)

2.5 (0, 12)

2 (0, 12)

5 (0, 12)

Mean ± SE

11.6 ± 0.3 5,8,11,14

7.9 ± 1 2,9,14

4.4 ± 1.5 2,12

4.2 ± 0.7 3,4,13

0.6 ± 0.3 3,6,7,10

Median (Min, Max)

12 (9, 12)

8.5 (0, 12)

3 (0, 12)

3.5 (0, 12)

0 (0, 4)

Mean ± SE

8.5 ± 1

5.6 ± 0.9 10,12

7.7 ± 1.5

9.5 ± 0.6 5

9.0 ± 0.8 4

Median (Min, Max)

8 (4, 12)

6 (1, 9)

9 (1, 12)

12 (0, 12)

8.0 (4, 12)

Mean ± SE

1.7 ± 0.212

1.9 ± 0.3

2.1 ± 0.3

1.9 ± 0.212

2.4 ± 0.2 1,9

Median (Min, Max)

2 (1, 2)

2 (0, 3)

2 (0, 3)

2 (0, 3)

3 (0, 3)

Mean ± SE

3 ± 0 8,4,11

2.5 ± 0.3 7,9,14

1.5 ± 0.4 2,4,12

1.6 ± 0.2 3,4,13

0.5 ± 0.2 3,6,7,10

Median (Min, Max)

3 (3, 3)

3 (0, 3)

2 (0, 3)

2 (0, 3)

0 (0, 2)

<0.0001

0.047

0.057

<0.0001

MUC17
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Mean ± SE

2.4 ± 0.2

2 ± 0.3

2.3 ± 0.3

2.5 ± 0.1

2.4 ± 0.1
0.47

Median (Min, Max)

2 (2, 3)

2 (1, 3)

3 (1, 3)

3 (0, 3)

2 (1, 3)

p<0.05 vs. normal; 2p<0.005 vs. normal; 3p<0.0005 vs. normal; 4p<0.05 vs. inflammation; 5p<0.005 vs. inflammation; 6p<0.0005 vs.

1

inflammation; 7p<0.05 vs. polyp; 8<0.005 vs. polyp; 9p<0.05 vs. adenoma; 10p<0.005 vs. adenoma; 11p<0.0005 vs. adenoma; 12p<0.05 vs.
adenocarcinoma; 13p<0.005 vs. adenocarcinoma; 14p<0.0005 vs. adenocarcinoma
p-value <0.05 has been shown as the bold numbers in last column (overall p-value)
colon adenocarcinoma (CAC); standard error (SE); composite score (CS); intensity score (IS)
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Table 5.2: Composite and intensity scores for secretory mucins (MUC2, MUC5B, MUC5AC, and MUC6) expression in tissues

MUC5B
MUC5AC
MUC
5B

MUC2

MUC6

Composite Scores CS)
Intensity Scores
(IS)

Secretory mucins

MUC2

corresponding to normal, inflammation, polyp, adenoma and adenocarcinoma tissues of the colon.

Diagnosis

Normal

Inflammation

Mean ± SE

12 ± 0 7,11,14

11.4 ± 0.4 11,14

Polyp

Adenoma

CAC

Overall
p-value

9.7±1.1 1,9,13 7.4 ± 0.6 3,6,7,13 3.8 ± 0.9 3,6,8,10
<0.0001

Median (Min, Max)

12 (12, 12)

12 (9, 12)

12 (3, 12)

9 (1, 12)

3 (0, 12)

Mean ± SE

0±0

0.4 ± 0.3

0.8 ± 0.6

2.2 ± 0.7

0.19 ± 0.1
0.34

Median (Min, Max)

0 (0, 0)

0 (0, 3)

0 (0, 6)

0 (0, 12)

0 (0, 2)

Mean ± SE

0 ± 0 7,10,12

0.5 ± 0.3 9

1.8 ± 1 1

3.1 ± 0.6 2,5

1.7 ± 0.7 1
0.01

Median (Min, Max)

0 (0, 0)

0 (0, 2)

0.5 (0, 9)

1.5 (0, 9)

0 (0, 9)

Mean ± SE

0±0

0±0

0±0

0.5 ± 0.4

0.19 ± 0.1

Median (Min, Max)

0 (0, 0)

0 (0, 0)

0 (0, 0)

0 (0, 12)

0 (0, 1)

Mean ± SE

3 ± 012

3 ± 012

2.9 ± 0.1

2.8 ± 0.112

2 ± 0.3 1,4,9

Median (Min, Max)

3 (3, 3)

3 (3, 3)

3 (2, 3)

3 (1, 3)

3 (0, 3)

Mean ± SE

0±0

0.4 ± 0.3

0.4 ± 0.3

0.8 ± 0.2

0.2 ± 0.1

0.29

0.0069

0.34

MUC6

MUC5AC
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Median (Min, Max)

0 (0, 0)

0 (0, 3)

0 (0, 2)

0 (0, 3)

0 (0, 2)

Mean ± SE

0 ± 0 7,10,12

0.5 ± 0.3 9

0.9 ± 0.4 1

1.5 ± 0.2 2,4

1.1 ± 0.3 1
0.013

Median (Min, Max)

0 (0, 0)

0 (0, 2)

0.5 (0, 3)

1 (0, 3)

0 (0, 3)

Mean ± SE

0±0

0±0

0±0

0.2 ± 0.1

0.2 ± 0.1
0.29

Median (Min, Max)

0 (0, 0)

0 (0, 0)

0 (0, 0)

0 (0, 3)

0 (0, 1)

1

p<0.05 vs. normal; 2p<0.005 vs. normal; 3p<0.0005 vs. normal; 4p<0.05 vs. inflammation; 5p<0.005 vs. inflammation; 6p<0.0005 vs.

inflammation; 7p<0.05 vs. polyp; 8<0.005 vs. polyp; 9p<0.05 vs. adenoma; 10p<0.005 vs. adenoma; 11p<0.0005 vs. adenoma; 12p<0.05 vs.
adenocarcinoma; 13p<0.005 vs. adenocarcinoma; 14p<0.0005 vs. adenocarcinoma;
p-value <0.05 has been shown as the bold numbers in last column (overall p-value)
colon adenocarcinoma (CAC); standard error (SE); composite score (CS); intensity score (IS)
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Table 5.3: Composite and intensity scores for mucin-associated glycans (CA 19-9, TAG72, and Tn/STn on MUC1) in tissues

CA 19-9
TAG72
Tn/STn
on MUC1
Tn/STn
on MUC1

TAG72

CA 19-9

Composite Scores
Intensity Scores

Mucins associated Glycans

corresponding to normal, inflammation, hyperplastic polyp, adenoma and adenocarcinoma tissues of the colon.

Diagnosis

Normal

Inflammation

Polyp

Adenoma

CAC

Mean ± SE

2.8 ± 0.9

3 ± 1.0

3.3 ± 0.9

3.2 ± 0.6

6.1 ± 1.2

Overall
p-value

0.3
Median (Min, Max)

3 (0, 6)

2.5 (0, 9)

2.5 (0, 9)

3 (0, 12)

6 (0, 12)

Mean ± SE

1.7 ± 0.3 5,6

3.5 ± 0.3

4.5 ± 0.5

4.5 ± 0.1 2

5.2 ± 0.2 1
0.093

Median (Min, Max)

1(0, 4)

2.5 (1, 9)

4 (0, 9)

4 (0, 12)

6 (0, 12)

Mean ± SE

0.11 ± 0.1 3,4,7

1.3 ± 0.7

2.4 ± 1 1

1.8 ± 0.5 1

3.5 ± 1.0 2
0.077

Median (Min, Max)

0 (0, 1)

0 (0, 6)

1.5 (0, 9)

0 (0, 9)

2 (0, 12)

Mean ± SE

1.9 ± 0.5

1.6 ± 0.5

2.1 ± 0.3

1.8 ± 0.2

2.2 ± 0.3
0.71

Median (Min, Max)

3 (0, 3)

2 (0, 3)

2.5 (0, 3)

2 (0, 3)

3 (0, 3)

Mean ± SE

1.1 ± 0.2 3,5,6

1.7 ± 0.3

2.1 ± 0.3 1

2 ± 0.1 2

2.0 ± 0.2 1
0.043

Median (Min, Max)

1(0, 2)

1.5 (1, 3)

2 (0, 3)

2 (0, 3)

2 (0, 3)

Mean ± SE

0.1 ± 0.1 3,4,6

0.5 ± 0.3

1.2 ± 0.4 1

0.9 ± 0.2 1

1.5 ± 0.3 1
0.036

Median (Min, Max)

0 (0, 1)

0 (0, 2)

1.5 (0, 3)

0 (0, 3)

2 (0, 3)
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1

p<0.05 vs. normal; 2p<0.005 vs. normal; 3p<0.05 vs. hyperplastic polyp; 4p<0.05 vs. adenoma; 5p<0.005 vs. adenoma; 6p<0.05 vs.

adenocarcinoma; 7p<0.005 vs. adenocarcinoma
p-value <0.05 has been shown as the bold numbers in last column (overall p-value)
colon adenocarcinoma (CAC); standard error (SE); composite score (CS); intensity score (IS)
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Table 5.4: Univariate and multivariate analyses: odds of Adenoma/Adenocarcinoma vs. Hyperplastic polyp

Univariate

Multivariate

95% CI

95% CI

Effect

OR

Lower

Upper

p-value

OR

Lower

Upper

p-value

MUC4

0.918

0.779

1.081

0.300

0.837

0.668

1.050

0.120

MUC17

1.128

0.940

1.354

0.200

1.254

0.960

1.638

0.097

MUC2

0.724

0.557

0.942

0.672

0.490

0.921

MUC5AC

1.092

0.861

1.385

0.016
0.470

1.338

0.962

1.859

0.014
0.083

Tn/STn on MUC1

1.003

0.808

1.246

0.980

0.754

0.538

1.057

0.100

p-value <0.05 has been shown as the bold numbers in last column (overall p-value).
Confidence interval (CI); Odds Ratio (OR)
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Chapter VI

Combinatorial assessment of CA 19-9/MUC17/MUC5AC
expression discriminates sessile serrated adenoma/polyps and
tubular adenoma from hyperplastic polyps
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1. Synopsis
Sessile serrated adenoma/polyps (SSA/Ps) are precursors of colorectal cancer. Failure to identify
and remove sessile serrated adenoma/polyps due to their anatomical position, inconsistent
pathological diagnosis, and dearth of the molecular markers to discriminate them from
hyperplastic polyps result in mis-diagnosis, causing suboptimal surveillance and colonoscopy
interval cancers. Owing to the suitability of combined mucins and associated glycan epitopes
expression to discriminate premalignant/malignant lesions of colon from hyperplastic polyps
(HP), this study aimed to determine the individual and combinatorial predictive value of mucins
and associated glycan epitopes expression, for comprehensive stratification of sessile serrated
adenoma/polyp from other colorectal polyp subtypes. This approach as an adjunct to colonoscopy
would help clinicians for accurate diagnosis and management of colorectal polyps. For this we
investigated expression of mucins (MUC1, MUC4, MUC17, MUC2, and MUC5AC) and
associated glycan epitopes (CA 19-9 and Tn/STn-MUC1) by immunohistochemical analysis on
sessile serrated adenoma/polyps (n=39), tubular adenoma (TA) (n=34), and hyperplastic polyp
(n=33). Efficacy of individual and combinatorial panels of mucins and associated glycan epitopes
as biomarkers to discriminate colorectal polyps was investigated further. We observed significant
differential expression of mucins and associated glycan epitopes in SSA/Ps, TA and HP. In
univariate logistic regression analysis, significant markers of SSA/Ps vs. HP were MUC4,
MUC17, and MUC5AC. The significant predictors of SSA/P vs. TA were MUC1, MUC17,
MUC2, MUC5AC, Tn/STn-MUC1, CA 19-9 and the significant predictors of TA vs. HP were
MUC4, MUC2, MUC5AC, and CA 19-9. Further, multivariate logistic regression and ROC curve
analysis demonstrated that a combination of MUC5AC/MUC17 effectively discriminates SSA/Ps
vs. HP (SN/SP=85/82%), MUC1/MUC17/CA 19-9 combination improved prediction of SSA/P
vs. TA (SN/SP=92/97%), and CA19-9 alone effectively predicts TA vs. HP (SN/SP=89/82%).
Effective discrimination of SSA/P from other colorectal polyps, using combinatorial panel of
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mucins and associated glycan epitopes, as an adjunct to colonoscopy can help clinicians for easy
diagnosis and better surveillance strategy to reduce colonoscopy interval cancers.
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2. Background and rationale
Colorectal cancer (CRC) is molecularly and histologically heterogeneous, biologically diverse
public health problem with over one million new cases diagnosed worldwide every year [1]. The
multistep process of colorectal carcinogenesis is associated with accumulation of genetic and
epigenetic alterations in epithelial cells via distinct molecular pathways including the most
common “adenoma–carcinoma” pathway and the recently identified “serrated polyp-neoplasia”
pathway [2-4]. Conventional adenomas (tubular, villous, and tubulovillous) exhibit characteristic
cytological dysplasia and are widely understood to be the premalignant lesions accounting for 6570% of CRCs [5]. In contrast to this, the serrated neoplasia pathway is associated with serrated
polyps. It accounts for 15-30% of CRCs, and potentially the majority of interval cancers with the
characteristics of microsatellite instability along with DNA hypermethylation and BRAF
mutations and predominantly occurring in the right colon [6, 7]. As per the latest World Health
Organization (WHO) recommendations, the heterogeneous group of serrated lesions is classified
pathologically into hyperplastic polyp (HP), sessile serrated adenomas/Polyp (SSA/P) and
traditional serrated adenomas (TSA) [8]. Traditionally, the smaller HPs are considered to be
benign and non-neoplastic [9]. In contrast, large serrated polyps have been significantly
associated with synchronous advanced adenocarcinomas [10]. Evidences suggest that neoplastic
progression with the serrated neoplasia pathway is faster than the classical adenoma-carcinoma
sequence and may take as little as eight months [11-13].
The different cancer risks of HPs and SSA/Ps make their morphological distinction
clinically relevant. However, owing to costly and impractical assessment of genetic events
(KRAS and BRAF mutations) that lack specificity [14], and difficult histologic evaluation due to
shared morphologic features, a diagnostic “gray zone” exists between HP and SSA/P, with a wide
interobserver variability [15-17]. As current surveillance recommendations depend on the
histologic type of the polyp, underdiagnoses of these premalignant precursors may lead to an
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inappropriate follow-up care and therapy thus contributing to interval carcinomas [18]. Therefore,
sensitive and specific markers that could significantly aid in improving the diagnosis of SSA/Ps
from other polyp subtypes are urgently needed.
Secreted and transmembrane mucins forms the most abundant component of colon and
are major building blocks of the dynamic stratified gastrointestinal mucus layer [19]. Alterations
in mucins and their associated carbohydrate structures play a role in various GI disorders
(inflammatory bowel diseases and colorectal cancers) [20]. Recent analyses of combinatorial
panel of mucins core protein and associated glycan epitopes by our group highlighted their
potential to discriminate premalignant and malignant lesions of colon from benign polyps [21].
Further,

a

recent

study

identified

transmenbrane

mucin

MUC17

as

potential

immunohistochemical marker for SSA/Ps [22]. In another study, Bartley et al. found the
relatively high specificity of MUC6 (82%) but low sensitivity (54%) for sessile serrated adenoma
[23], while Renauld et al. observed MUC5AC hypomethylation as an early marker of polyps with
malignant potential [24]. However, most of these studies were conducted on one or few mucins,
did not consider alterations in mucin-associated glycan epitopes, and did not investigate mucins
and associated glycan epitopes as combinatorial panels of biomarkers for stratification of polyp
sub-types. Considering the complexity associated with morphological distinction of various polyp
sub-types and high clinical utility of their appropriate classification, in the present study, we
comprehensively evaluated the potential of most abundant colonic mucins (MUC1, MUC4,
MUC17, MUC2, MUC5AC) and associated glycan epitopes (Tn/STn-MUC1, CA 19-9) for
differentiating pre-neoplastic precursor lesions of colon cancer from benign polyps. Further, we
evaluated their clinical utility as biomarkers to discriminate SSA/Ps from other polyp subtypes.
3. Results
Mucins are the most abundant component of the colon, involved in making and maintaining the
physicochemical barrier of colon. Based on our earlier findings of differential expression of
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mucins and associated glycan epitopes during progression of colon cancer, utility to differentiate
benign lesions from precancerous/cancerous lesions, their emergence as differential marker in the
global studies, in present study, we comprehensively investigated the expression of
transmembrane (MUC1, MUC4, MUC17), secreted (MUC2, MUC5AC) and associated glycan
epitopes (Tn/STn-MUC1 and CA 19-9). The major objective was to identify combinatorial panels
of mucins and associated glycan epitopes that can efficiently discriminate SSA/Ps from other
polyp subtypes.
3.A Expression of mucins and associated glycan expressions in colorectal polyps
An overlap in the expression of transmembrane (MUC1, MUC4, MUC17), secretory mucins
(MUC2, and MUC5AC) and glycan epitopes (CA 19-9 and Tn/STn-MUC1) was observed in
different colorectal polyp subtypes when compared to adjacent normal colon crypts (ANCC).
Expression of MUC1, MUC5AC, Tn/STn-MUC1, and CA 19-9 were significantly upregulated in
all polyp subtypes compared to lesion adjacent normal colon crypts (Figure 6.1A, Table 6.1).
Expression of MUC17 was significantly high in HP and SSA/Ps with non-significant alterations
in TA compared to ANCC (Figure 6.1A, Table 6.1). MUC4 was significantly downregulated in
SSA/Ps, with non-significant alterations in HP and TA (Figure 6.1A, Table 6.1), while MUC2
was significantly downregulated in both SSA/Ps and TA with non-significant alterations
compared to ANCC (Table 6.1). Difference is localization patterns for expression of different
mucins and associated glycan epitopes in ANCC and different polyp groups has been tabulated
(Supplementary table 6.1).
3.B Association of mucins and associated glycan epitopes expression in colorectal polyps
with clinicopathological features
As summarized in (Table 6.2) expression of mucins and associated glycan epitopes were
independent of age, gender, family history of colon cancer, and polyp size of the patient. In
polyps of cases with Caucasian ethnicity significant increase in expression of MUC5AC
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(p=0.027) and CA 19-9 (p=0.021) were observed in comparison to any others ethnicity. MUC4
was the only mucin whose expression altered significantly as per the polyp site (p=0.037),
tobacco consumption (p=0.021), and diagnosis of ≥2 precancerous polyps (p=0.013). Expression
of MUC4 was high in polyps resected from descending colon compared to all other sites, in
patients who used tobacco compared to non-tobacco users and low in cases with diagnosis of ≥2
precancerous polyps compared to <2 precancerous polyps. Interestingly, expression of MUC1
was significantly higher in cases with ≥2 polyps. MUC2 levels were significantly high (p=0.024)
in polyps of cases who had undergone ≥2 prior or subsequent colonoscopies.
3.C Differential expression of mucins and associated glycan epitopes among colorectal polyp
subtypes
Looking at aberrant expression of mucins and associated glycan epitopes in different colorectal
polyps, we next investigated whether mucins and associated glycan epitopes are differentially
expressed between benign (HP) and pre-cancerous lesions of colon (SSA/Ps, TA).
SSA/Ps and HP: SSA/Ps had reduced expression of MUC4 (p=0.0066) and elevated
expression of MUC17 (p=0.0002), and MUC5AC (p<0.0001) in comparison to HP (Figure 6.1B
panel g,h, j,k, p,q; Table 6.1). Interestingly in SSA/Ps, intense reactivity of MUC4 was
restricted to 10% of cases in comparison to 45% of HP cases. While moderate to intense
reactivity of MUC17, MUC5AC was observed in 33% and 62% of SSA/P cases, respectively,
compared to only 6% and 15% of HP cases respectively. Notably, in conjunction with
quantitative expressional changes stark differences were also observed in MUC5AC expression
pattern within the colon crypts among the study groups. Qualitatively, expression of MUC5AC
was absent in normal colon. Among HP cases, it was limited to goblet cells in 61% cases, and
both goblet and cytoplasmic compartments in 39% cases. Interestingly, in SSA/Ps cases goblet
cell only expression of MUC5AC was limited to only 11% cases while in significantly high
number of cases (89%, p<0.0001) aberrantly increased MUC5AC expression was observed in
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both goblet and cytoplasmic compartments (Figure 6.1C, panel a-d). With regard to MUC4
expression, in normal colon MUC4 was localized in cytoplasmic compartments throughout the
crypts. However it was absent from luminal surface epithelium. In HP and TAs, expression of
MUC4 was observed throughout the crypt along with luminal surface epithelium. Interestingly in
approximately 30% SSA/P cases, MUC4 expression was limited to lower one third of the crypts
only, while in rest 70% cases, qualitative expression pattern was similar to HP and TA (Figure
6.1C, panel e-h).
SSA/P vs. TA: TA had elevated expression of MUC1 (p=0.0005), and downregulation of
MUC17 (p=0.0054), MUC2 (p=0.02), MUC5AC (p<0.0001) and CA 19-9 (p<0.0001) as
compared to SSA/Ps (Figure 6.1B-e,f; k,l; n,o; q,r; w,x; Table 6.1). TA had moderate to intense
reactivity of MUC1 in 47% of cases compared to 13% of SSA/Ps cases. Further, moderate to
intense reactivity of MUC17, MUC2, MUC5AC, CA 19-9 was observed in 33%, 100%, 62%,
82% of SSA/P cases respectively compared to 11%, 58%, 8%, none respectively in TA cases.
TA vs. HP: HP had elevated expression of MUC2 (p=0.0018), MUC5AC (p<0.0001)
and CA 19-9 (p<0.0001) compared to TA (Figure 6.1B-m, o; p, r; v, x; Table 6.1). Intense to
moderate immunoreactivity of MUC2 was observed in 94% of HP cases, compared to 58% of TA
polyps. MUC5AC was expressed in all the HP cases, while its incidence was limited to 43% in
TA. Further, 67% of HP cases had moderate to intense CA 19-9 reactivity, compared to none in
TA.
3.D Mucins and associated glycan epitopes: potential molecular marker(s) for
differentiating colon polyps
Considering the significant differences in the level and localization of multiple mucins and
associated glycan epitopes, we next evaluated their statistical power to discriminate polypsubtypes alone or in combination. The univariate logistic regression analysis with receiver-
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operator characteristics (ROC) curves was utilized to investigate discrimination of polyp subtypes.
SSA/Ps vs. HP: MUC4, MUC17 and MUC5AC differentiated SSA/P polyps from HP with the
sensitivity and specificity (SN/SP) of 61.5%/70%, 67%/91% and 77%/73% respectively (Figure
6.2A, Table 6.3). SSA/P vs. TA: MUC1, MUC17, MUC2, MUC5AC, Tn/STn-MUC1 and CA
19-9 differentiated SSA/P from TA with the sensitivity and specificity (SN/SP) of 74.4%/72.2%,
67%/78%, 72%/58.3%, 92.3%/81%, 79.5%/44.4% and 87.2%/100% respectively (Table 6.3). TA
vs. HP: MUC4, MUC2, MUC5AC, Tn/STn-MUC1 and CA 19-9 differentiated TA from HP with
the SN/SP of 78%/54.5%, 50%/91%, 78%/70%, 44.4%/91%, 89%/82% respectively (Table 6.3).
3.E Combinatorial panels of mucins and associated glycan epitopes for differentiating
colorectal polyp sub-types:
Next, we evaluated the combined utility of significantly altered mucins for differential
identification of polyp subtypes. For this multivariate regression models were created, using the
most promising markers from the univariate logistic regression analysis, in conjunction with ROC
curve based analysis.
SSA/P vs. HP: The combination of MUC17/MUC5AC effectively discriminated SSA/P from HP
with SN/SP of 85%/82% (Figure 6.3A, Table 6.4). The optimal cut point derived from the model
[P(SSA/P)

=≥0.49]

suggest

that, if

the

predicted probability from the

combined

MUC17/MUC5AC model is ≥0.49 then the model predicts SSA/P, and if it is <0.49 then model
predicts HP. SSA/P vs. TA: The combination of MUC1/MUC17/CA 19-9 effectively
discriminated SSA/P from TA with SN/SP of 92.3%/97.2% (Figure 6.3B, Table 6.4). Further,
optimal cutpoint [P(SSA/P) ≥0.385] suggests that if the predicted probability from the combined
MUC1/MUC17/CA 19-9 model is ≥0.385 then the model predicts SSA/P and if it is <0.385 then
model predicts TA. TA vs. HP: Multivariate logistic regression analysis demonstrated that CA
19-9 can effectively discriminate TA from HP at optimal cutpoint obtained as a probability of the

198

logistic model of ≤0.3 with SN/SP of 89%/82% (Figure 6.3C, Table 6.4). Overall, if CA19-9 is
≤0.3 then the model predicts TA, and if CA19-9 is >0.3 then model predicts HP.
3.F MUC5AC, MUC17 and CA19.9: a unique biomarker combination for differentiating
polyp subtypes: Next, we evaluated clinical utility of the significant markers obtained from
multivariate logistic regression results utilizing the tree based modeling to predict the diagnostic
group (HP, SSA/P, or TA). The combined utility of three markers (CA 19-9, MUC17 and
MUC5AC in order of preference) was highlighted for differential diagnosis of precancerous
polyps (SSA/P and TA) from benign polyp (HP) (Figure 6.3D). As per model, if observed CA199 levels are <0.525, the polyp under observation is predicted to be TA. If CA19-9 histological
score is ≥0.525 then the next marker considered is MUC17. If MUC17 is ≥0.75, there are higher
chances of SSA/P. However, if MUC17 is <0.75, then next marker considered is MUC5AC. If
levels of MUC5AC is ≥1.05, then SSA/P is predicted and if MUC5AC <1.05, then HP is
predicted. Overall, the tree based model predicts HP, SSA/P and TA with SN/SP of 58%/95%,
79%/90% and 97%/83% respectively.
Overall, we demonstrated the utility of combinatorial panels of differentially expressed
mucins and associated glycan epitopes for effective discrimination of colorectal polyp subtypes.
4. Discussion
A substantial increase in colonoscopy interval CRCs in recent times disputed its effectiveness in
the surveillance of colon cancer [25]. Interestingly, the culprit precursor lesions for the interval
cancers were hypothesized to be SSA/P’s. Despite the increasing recognition that serrated polyps
are significantly associated with CRC [10], the diagnostic criteria for serrated polyps at the
morphological, histopathological, and molecular levels remains enigmatic. This confusion and
inconsistency translates in misdiagnoses of serrated lesions due to interobserver variability and
ultimately inappropriate follow-up care and therapy. In this context, different investigations have
aimed at determining mucin gene expression levels in different colorectal polyp subtypes.
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Unfortunately, most of these studies were either limited to one or few mucins, did not consider
modifications of associated glycan epitopes, focused only to detect expression levels without
emphasizing diagnostic utility, and did not combine mucins and glycan epitopes as a panel of
markers. Looking at utility of mucins and associated glycan epitopes as biomarkers to
discriminate benign polyps from premalignant and malignant lesions [21], this study for the first
time comprehensively investigated expression of all the major mucins and associated glycan
epitopes significantly altered during colon carcinogenesis, for discriminating SSA/Ps from HP
and TA.
Previous studies have highlighted that MUC1 is either absent or is weakly expressed in
normal colonic mucosa [26, 27]. Focal to mild reactivity in HP and its inability to discriminate
them from SSA/Ps has previously been described [26, 28-30]. In contrast, increased MUC1
positivity has been reported in conventional adenomas [26]. Consistent with these studies, we
observed focal to mild immunoreactivity of MUC1 in serrated polyps and significantly higher
expression in TA. Looking at focal to mild MUC1 expression in serrated polyps and a previous
report demonstrating MUC1 expression to be independent of microsatellite status [31], it can be
suggested that MUC1 may not be a prominent player in the serrated pathway of neoplasia.
However, its higher levels in TA’s along with reports of its highest values in colorectal
adenocarcinomas [27], and association with invasion risk [30] argue in favor of the potential
applicability of MUC1 expression as a predictor of malignant transformation in the adenomacarcinoma sequence.
Congruent to previous studies [26], MUC4 appeared to be a prominent mucin gene
expressed in normal colon as evidenced by its expression in polyp adjacent normal colon crypts.
Loss of MUC4 in CRC cases has previously been demonstrated [21, 32]. Interestingly, we
observed a significant loss of MUC4 in SSA/Ps compared to HP, suggesting that loss of MUC4
might play an important role during serrated pathway of neoplasia. Significant utility of MUC4 as
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an independent predictor of precancerous lesions (SSA/P and TA) versus benign lesions (HP) was
also revealed in this study. However, MUC4 did not appear as a significant contributor among
combinatorial panels of biomarkers to discriminate different polyp subtypes. Further, MUC4 was
the only mucin whose expression was significantly altered as per the site of the polyp suggesting
the role of microenvironment in regulation of this mucin. Interestingly, in our analysis, we also
found that MUC4 expression was significantly high in polyps of the patients who consumed
tobacco. Long-term cigarette smoking is associated with colorectal polyps and increased risk of
colorectal cancer mortality in both men and women [33, 34]. Recently it has been reported that
smoke exposure increased Muc4 expression in the distal colon of mice [35]. Cigarette smoke
mediated upregulation of MUC4 has also been reported previously from our lab [36]. Presence of
MUC4 confers worse prognosis to early stage colorectal cancer patients [32, 37] therefore, in
future it would be interesting to investigate role of cigarette smoke mediated upregulation of
MUC4 during colorectal cancer progression.
MUC17 is significantly upregulated in colon adenocarcinoma cases compared to colon
inflammation cases [21]. In this study, we not only conducted comprehensive analysis of MUC17
expression in different colorectal subtypes, but also observed its exceptional utility as a biomarker
to discriminate SSA/Ps from HP and TA. MUC17 has previously been shown to be a top
differentially expressed gene in SSA/P tissue versus TA [38]. RNA-seq analysis has also shown
an 82-fold increase in MUC17 in SSA/Ps compared to adenomatous polyps, uninvolved and
normal colon samples [22]. Interestingly, none of these studies considered hyperplastic polyps to
compare differential expression of genes in SSA/Ps, thus limiting the overall interpretations in
terms of molecular characterization of SSA/Ps for their efficient diagnosis. We observed
significant upregulation of MUC17 expression in HP and SSA/Ps compared to adjacent normal
colon crypts. MUC17 was also significantly overexpressed in SSA/Ps in comparison to both HP
and TA cases, and it turned out to be a significant independent predictor of SSA/P versus HP and
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TA with high specificity. Further, in multivariate models, the combination of MUC17 and
MUC5AC exceptionally improved the diagnostic accuracy of SSA/Ps versus HP with 85%
sensitivity and 82% specificity. Furthermore, MUC17 was a significant contributor to the
combinatorial panel of diagnostic markers that discriminate SSA/P from TA. It has been
demonstrated

that

hypomethylation

near

the

transcriptional

start

site

contributes

to MUC17 expression in LS-174 colon cancer cells [39]. Therefore, we hypothesize that
hypomethylation of MUC17 may contribute to its increased expression in SSA/Ps and
identification of MUC17 hypomethylation in future may be a useful approach to identify serrated
neoplasia pathway-related precursor lesions. Due to the paucity of information regarding the
association of MUC17 with BRAF mutation, CIMP, MSI and MSI-H colon carcinomas,
additional studies addressing these aspects would help establish MUC17 as a marker of neotransformation through the serrated neoplasia pathway.
Numerous different studies have previously reported MUC5AC expression in normal
colon, hyperplastic polyps, sessile serrated adenomas, traditional serrated adenomas, mixed
polyps and all the subtypes of adenomatous polyps. Unfortunately, none of these studies could
establish the diagnostic utility of MUC5AC for differentiating between polyps [26, 27, 40-42].
Conceptually, high positivity of MUC5AC represents an early gain of gastric differentiation in
SSA/Ps and is significantly associated with MSI-H CRCs sporadic tumors (P<0.001) [43].
Consistent with these studies, we also observed significant alterations in the expression of
MUC5AC in HP, SSA/Ps, and TA when compared to the adjacent normal colon. Further,
significant overexpression of MUC5AC was observed in SSA/Ps when compared to HP and TA.
Increased expression of MUC5AC in SSA/Ps has recently been attributed to MUC5AC
hypomethylation. MUC5AC hypomethylation is specifically associated with serrated lesions with
BRAF mutation, CIMP-H or MSI [24]. Therefore, increased expression of MUC5AC in SSA/P
may be reflective of neoplastic biological process. Additionally, our univariate analysis revealed
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that higher expression of MUC5AC significantly discriminates SSA/P from HP, HP from TA and
SSA/P from TA. Further, combination of MUC5AC and MUC17 discriminates SSA/P from HP
with AUC=0.865 and sensitivity and specificity of 86%/82%. Interestingly, MUC5AC was the
only marker which could significantly differentiate SSA/Ps from HP and TA on basis of its
localization pattern. Given these results, IHC for these markers may be helpful to pathologists for
effective discrimination of SSA/Ps from benign HP. Further studies characterizing role of
MUC5AC during the serrated pathway of colon cancer progression would be helpful in
cementing its utility as a predictive marker of neoplastic transformation.
CA 19-9 is a monosialosyl Lewis (a) blood group antigen that has been shown to be
differentially expressed during adenoma-carcinoma sequence [21]. The importance of CA 19-9
serum levels at the beginning of malignant alterations for monitoring colorectal tumors has been
underscored [44] and its diagnostic utility to discriminate premalignant lesions from cancer has
previously been reported [45]. To our knowledge, none of the previous studies considered
evaluation of CA 19-9 in SSA/Ps and attempted an assessment of its diagnostic efficacy to
discriminate colorectal polyps in combination with other mucins. Our study clearly demonstrated
that CA 19-9 expression is significantly increased in all colorectal polyp subtypes. Interestingly,
comparisons between polyp subtypes revealed its highest levels in SSA/Ps, and significant
reduction in TA when compared to HP and SSA/Ps. Diagnostic utility of CA 19-9 was evident
from the fact that CA 19-9 in combination with MUC1 and MUC17 predicts SSA/P from TA
with very high sensitivity and specificity (92.3%/97.2%). Our assessment from multivariate
models was further corroborated in decision tree model where CA 19-9 proved to be a very
effective marker to clearly discriminate adenomatous lesions from serrated polyps at the very first
step.
Looking at the promising results of this study, future studies would focus on further
validation of the combinatorial panels from this study in a larger set of colorectal polyp subtypes
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and to discriminate micro vesicular HP from SSA/Ps, colorectal polyp subtypes with varying
degree of dysplasia, anatomical location, and recurrence after prior polypectomy. Findings from
these studies could help circumvent the current challenges with histopathological classification
and nomenclature of colon polyps that are ambiguous, lack consensus and demonstrate high
interobserver variability.
Recent study on Stool DNA tests offered some promise in the detection of SSA/Ps [46].
Stool methylated maker mBMP3 was noted to have high discriminative power for detection of
SSA/P ≥ 1 cm with significantly greater specificity than fecal immunochemical test (FIT) [46].
Incorporating colorectal adenoma specific combinatory mucin and mucin associated glycan
epitopes to current sensitive and specific stool DNA tests could add incremental value in the
detection of precancerous polyps and CRC.
Cancer associated posttranslational modifications frequently produces aberrant O-linked
truncated glycoproteins. These Aberrant O-linked glycoproteins in combination with protein
backbone induce autoantibodies due to lack of tolerance [47]. One recent study reported cancerassociated autoantibodies to a set of aberrant glycopeptide derived from mucin MUC1 and MUC4
in serum of patients with CRC [47]. Therefore, future research efforts should also focus attention
on identification of CRC specific glycan epitopes on differentially expressed mucins (MUC1,
MUC2, MUC4, MUC5AC and MUC17). This information can be utilized for developing CRC
specific glycopeptide microarrays for seromic profiling of patients with colon polyps with an
objective to identify polyps with malignant potential.
Efforts should continue to further elucidate the currently unexplored roles of mucins
MUC4, MUC17 and MUC5AC in pathogenesis of CRC via different pathways, along with their
association with various genetic and epigenetic mutations in CRC. This will firmly establish their
utility for assessment of malignant potential of polyps. In addition, investigation of molecular
mechanisms associated with upregulation of mucins like MUC17 and MUC5AC in SSA/Ps, may
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further help in devising novel diagnostic markers, and therapies targeting these precancerous
lesions.
Overall, this study is the first critical step addressing the “gray zone” in differentiating SSA/Ps
from other polyp subtypes due to shared morphologic features (leading to the inter-observer
variability among pathologists), and current non-availability of specific and sensitive markers.
The efficient discrimination of different colorectal polyp subtypes utilizing the combinatorial
panel of molecular markers CA 19-9/MUC17/MUC5AC, in conjunction with currently available
tests and colonoscopy, may aid clinicians for devising the personalized colon cancer screening
recommendations.
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Figure 6.1: Immunohistochemical expression of mucins and associated glycan epitopes in
colorectal polyps: (A) Venn diagram showing considerable overlaps in expression of mucins and
associated glycan epitopes in HP, SSA/P and TA when compared to adjacent normal colon crypts
(ANCC). Markers in red were upregulated while markers in green were downregulated in
comparison to ANCC. (B) HP, SSA/P and TA tissue specimens were probed with MUC1
(HMFG2), MUC4 (8G7), MUC17 (SN-1132), MUC2 (EPR6145), MUC5AC (45M1), CA 19-9
(NS 19.9), and Tn/STn-MUC1 (5E5) antibodies after non-specific blocking with horse serum. All
the tissue sections were examined under microscope, and the expression was evaluated on the
basis of reddish brown staining by a pathologist. Representative photomicrographs (20X) of
Hematoxylin & Eosin staining (a-c) and for MUC1 (d-f), MUC4 (g-i), MUC17 (j-l), MUC2 (mo) and MUC5AC (p-r), Tn/STn-MUC1 (s-u), and CA 19-9 (v-x), stained tissues of HP, SSA/Ps
and TA were taken. MUC1 expression was significantly high (p=0.0005) in TA (f) in comparison
to HP (d) and SSA/P (e). Strong expression of MUC4 was observed in adjacent normal colon
crypts. Compared to HP (g), MUC4 expression was significantly reduced (p=0.0066) in SSA/P
(h). Significantly high immunoreactivity of MUC17 was observed in SSA/P lesions (k) compared
to HP (j) and TA (l). Compared to HP (m) and SSA/P (n), MUC2 expression was significantly
reduced in TA (o) (p=0.0018, 0.020 respectively). MUC5AC expression is significantly high in
HP (p) and SSA/P (q) compared to TA (r) (p<0.0001). HP (s), SSA/P (t), and TA (u) expressed
Tn/STn-MUC1 at similar levels. CA 19-9 expression was significantly high in HP (v) (p<0.0001)
and SSA/P (w) (p<0.0001) compared to TA (x). (C) Localization pattern of MUC5AC expression
revealed its absence in normal colon crypts, goblet cell (GC) specific expression in HP, goblet
cell and cytoplasmic pattern (CP) in SSA/Ps and goblet cell specific in TA. MUC4 expression in
normal colon was throughout the colon crypts (CC) excluding luminal surface epithelium (LE).
HP revealed MUC4 expression throughout CC including LE. In 30% SSA/P cases MUC4
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expression was limited to lower one third of CC and in TA, MUC4 expressed throughout CC
including LE.
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Figure 6.2: Diagnostic performances of mucins and associated glycan epitopes from
univariate models for discriminating colorectal polyp subtypes: ROC curves comparing
different mucins and associated glycan epitopes for differentiating (A) SSA/P from HP, (B)
SSA/P from TA and (C) TA from HP. MUC1, MUC17, MUC2, MUC5AC, Tn/STn-MUC1, and
CA 19-9 were the significant predictors of SSA/P from TA. MUC4, MUC17, and MUC5AC were
the significant predictors of SSA/P from HP. MUC4, MUC2, MUC5AC, Tn/STn-MUC1, and
CA 19-9 were the significant predictors of TA from HP.
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Figure 6.2
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Figure 6.3: Diagnostic performances of mucins and associated glycan epitopes in
combination for discriminating colorectal polyp subtypes: ROC curves representing
diagnostic potential of mucins and associated glycan epitopes combinatorial panels for
differentiating (A) SSA/P from HP, (B) SSA/P from TA and (C) TA from HP.
MUC17/MUC5AC combination (AUC=0.87) was the significant predictor of SSA/P from HP
(A). MUC1/MUC17/CA 19-9 (AUC= 0.99) combination efficiently predicts SSA/P from TA. CA
19-9 (AUC 0.89) itself improves diagnosis of TA from HP. (D) Tree based model highlighted CA
19-9/MUC17/MUC5AC combinatorial panel of markers for effective diagnosis of disease group
(HP, SSA/P and TA).
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Table 6.1: Expression of mucins and associated glycans (H-Scores) in different colorectal polyp subtypes and corresponding adjacent normal
colon
ANCC-H

HP

ANCC-S

SSA/P

ANCC-T

TA

Mean ± SE

0.25±0.07 e

0.76 ± 0.09 b

0.09±0.02 l

0.53 ± 0.09 c,h

0.28±0.05 i

1.02 ± 0.09 c,k

Median (Min, Max)

0.1(0,1.4)

0.6(0.1, 2.1)

0.05(0, 0.3)

0.4(0.05, 2.4)

0.2(0, 1)

1(0.1, 2.4)

Mean ± SE

1.87±0.11

1.66 ± 0.12 k

1.63±0.15 l

1.05 ± 0.12 c,e

1.25±0.12

1.21 ± 0.12

Median (Min, Max)

2.1(0.2,
2.55)

1.8(0.3, 2.7)

1.8(0.1, 2.4)

1(0.05, 2.7)

1.2(0.05, 2.4)

1.3(0.1, 2.4)

Mean ± SE

0.11±0.03 f

0.37 ± 0.05 c,l

0.06±0.02 l

0.85 ± 0.08 c,f,g

0.24±0.05

0.47 ± 0.07 j

Median (Min, Max)

0.05(0, 0.7)

0.2(0.05, 1.2)

0(0, 0.3)

1(0.05, 2.1)

0.1(0, 1.2)

0.4(0, 1.4)

Mean ± SE

2.31±0.09

2.09 ± 0.09 h

2.26±0.09 k

1.92 ± 0.08 b,g

2.21±0.06 i

1.35 ± 0.14 c,e,j

Median (Min, Max)

2.4(1.2,
2.7)

2.4(0.75, 2.7)

2.4(0.9, 2.7)

1.8(1.2, 2.7)

2.4(1, 2.7)

1.3(0.1, 2.7)

Mean ± SE

0±0 f

0.65 ± 0.08 c,l,i

0±0 l

1.24 ± 0.09 c,f,i

0.03±0.02 i

0.3 ± 0.08 c,f,l

Median (Min, Max)

0(0, 0)

0.6(0.15, 2.1)

0(0, 0)

1.2(0.15, 2.4)

0(0, 0.6)

0.06(0, 2.1)

Mean ± SE

0.23±0.05 f

1.42 ± 0.07 c

0.17±0.05 l

1.39 ± 0.08 c

0.39±0.05 i

1.13 ± 0.1 c

Median (Min, Max)

0.1(0, 0.8)

1.4(0.6, 2.7)

0(0, 0.8)

1.4(0.3, 2.4)

0.3(0, 1.6)

1.2(0, 2.4)

Mean ± SE

0.1±0.05 f

1.53 ± 0.17 c,i

0.04±0.02 l

1.72 ± 0.13 c,i

0.02±0.01 i

0.1 ± 0.03 c,f,l

Median (Min, Max)

0(0, 1.2)

1.8(0, 2.7)

0(0, 0.4)

2.1(0, 2.7)

0(0, 0.3)

0(0, 0.6)

MUC1

MUC4

MUC17

MUC2

MUC5AC

Tn/STnMUC1

CA 19-9
a

p<0.05 vs. adjacent normal; bp<0.005 vs. adjacent normal; cp<0.0005 vs. adjacent normal; dp<0.05 vs. HP; ep<0.005 vs. HP; fp<0.0005 vs. HP; gp<0.05 vs.
TA; hp<0.005 vs. TA; ip<0.0005 vs. TA; jp<0.05 vs. SSA/P; kp<0.005 vs. SSA/P; lp<0.0005 vs. SSA/P
Abbreviations: ANCC-H, Adjacent normal colon crypts to hyperplastic lesion; ANCC-S, Adjacent normal colon crypts to sessile serrated adenoma;
ANCC-T, Adjacent normal colon crypts to tubular adenoma; HP, Hyperplastic polyps; SSA/P, Sessile serrated adenoma/polyp; TA, Tubular adenoma; SE,
Standard error; Min, Minimum; Max, Maximum
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Table 6.2: Association of mucins and associated glycans expression with clinicopathological characteristics

N

Age

< 60 years

47

>=60 years

50

p-value

Gender

Female

57

Male

40

p-value

Ethnicity

Caucasian

74

Other

13

p-value

Polyp site

MUC4

MUC17

MUC2

MUC5AC

CA 19-9

Mean ±
SE
0.77 ±
0.09
0.72 ±
0.08
0.76
0.74 ±
0.07

Mean ±
SE
1.31 ±
0.11
1.27 ±
0.11
0.79

Mean ±
SE

Mean ±
SE
1.71 ±
0.11

Mean ±
SE
0.88 ±
0.09
0.68 ±
0.09
0.1
0.71 ±
0.08
0.87 ±
0.11
0.32
0.83 ±
0.08

Mean ±
SE
1.21 ±
0.15
0.98 ±
0.14
0.25
1.12 ±
0.14
1.04 ±
0.15
0.41
1.18 ±
0.12
0.45 ±
0.21
0.021
1.19 ±
0.24
1.01 ±
0.28
0.84 ±
0.36
0.95 ±
0.21
1.17 ±
0.22
1.03 ±
0.28
0.93
0.97 ±
0.11
1.44 ±
0.25
0.064

0.75 ± 0.1
0.67
0.73 ±
0.06
0.87 ±
0.18
0.51

0.95

0.75 ± 0.1

1.29 ± 0.1
1.29 ±
0.12
0.96
1.31 ±
0.09
1.31 ± .21

8

0.65 ± 0.1

1.03 ± .14

Ascending

22

0.73 ±
0.12

1.28 ± .22

Transverse

13

0.5 ± 0.15

Descending

12

Sigmoid

21

Rectum

19

no

74

yes

17

p-value

0.68 ±
0.17
0.74 ±
0.12
1.02 ±
0.15
0.16
0.77 ±
0.07
0.62 ±
0.09
0.58

0.5 ± 0.07
0.64±
0.06
0.093
0.57 ±
0.06
0.58 ±
0.08
0.68
0.56 ±
0.05
0.48 ±
0.12
0.58

Cecum

p-value

FH of colon cancer

MUC1

1.11 ±
0.27
1.73 ±
0.19
1.42 ±
0.16
0.93 ± 0.2
0.037
1.27 ±
0.09
1.38 ±
0.14
0.66

0.56 ±
0.19
0.55 ±
0.16
0.55 ± 0.1
0.43 ±
0.09
0.59 ±
0.11
0.33
0.56 ±
0.05
0.49 ± 0.1
0.64

1.8 ± 0.1
0.54
1.7 ± 0.1
1.84 ±
0.12
0.25
1.73 ±
0.09
1.85 ±
0.17
0.79
1.6 ± 0.16
1.96 ±
0.12
1.43 ±
0.32
1.57 ±
0.19
1.98 ±
0.15
1.88 ±
0.19
0.33
1.72 ±
0.09
1.92 ±
0.11
0.65

0.4 ± 0.12
0.027
0.75 ±
0.15
0.93 ±
0.24
0.54 ±
0.25
0.59 ±
0.09
0.79 ±
0.11
1.06 ±
0.24
0.47
0.77 ±
0.08
0.76 ±
0.18
0.9

Tn/STnMUC1
Mean ± SE
1.34 ± 0.07
1.2 ± 0.07
0.37
1.28 ± 0.06
1.25 ± 0.09
0.61
1.22 ± 0.06
1.45 ± 0.15
0.15
1.15 ± 0.1
1.28 ± 0.15
1.05 ± 0.14
1.35 ± 0.13
1.3 ± 0.11
1.39 ± 0.13
0.42
1.28 ± 0.06
1.13 ± 0.1
0.15
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Tobacco

no

29

yes

63

0.63 ±
0.09
0.79 ±
0.08
0.3

p-value

Polyp size

<0.05 cm3

66

>=0.05 cm3

24

Number of polyps

21

>=2

75

<2

23

>=2

49

0.83 ±
0.14
0.51
0.58 ±
0.14
0.79 ±
0.06
0.034
0.73 ±
0.08
0.81 ±
0.08
0.85

1.31 ±
0.16
0.9

p-value
Prior or subsequent
colonoscopies with polyps

<2

45

>=2

21

0.021
1.3 ± 0.09

p-value
Number of precancerous
polyps

1.43 ± 0.1

0.7 ± 0.07

p-value
<2

1.02 ±
0.13

0.7 ± 0.08

p-value
Abbreviations: FH, Family history; SE, Standard error

0.69 ±
0.11
0.94

1.3 ± 0.17
1.29 ±0.09
0.99
1.62 ±
0.18
1.05 ±
0.11
0.013
1.05 ±
0.13
1.25 ±
0.14
0.31

0.51 ±
0.07
0.56 ±
0.06
0.78
0.53 ±
0.06
0.68 ±
0.09
0.11
0.62 ±
0.11
0.57 ±
0.05
0.76
0.5 ± 0.1
0.65 ±
0.07
0.14
0.6 ± 0.08
0.6 ± 0.1
0.78

1.65 ±
0.15
1.8 ± 0.09
0.52
1.78 ±
0.08
1.75 ±
0.17
0.84
1.91 ±
0.12
1.71 ±
0.09
0.44
1.82 ±
0.13
1.58 ±
0.12
0.31
1.48 ±
0.11
1.91 ±
0.14
0.024

0.89 ±
0.14
0.7 ± 0.08
0.27
0.72 ±
0.08
0.98 ±
0.13
0.087
0.97 ±
0.17
0.72 ±
0.07
0.2
0.69 ±
0.11
0.76 ± 0.1
0.88
0.71 ± 0.1
0.84 ±
0.15
0.48

1.1 ± 0.18
1.02 ±
0.13
0.51
0.98 ±
0.12
1.29 ±
0.21
0.17
1.28 ±
0.22
1.02 ±
0.12
0.35
1.36 ±
0.21
0.89 ±
0.14
0.077
0.99 ±
0.15

1.28 ± 0.1
1.24 ± 0.06
0.84
1.25 ± 0.07
1.32 ± 0.08
0.27
1.33 ± 0.13
1.25 ± 0.06
0.41
1.43 ± 0.1
1.23 ± 0.07
0.18
1.19 ± 0.07

0.95 ± 0.2

1.35 ± 0.11

0.83

0.25
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Table 6.3: Univariate logistic regression and ROC curve analysis for mucins and associated glycans as biomarkers to discriminate different
colorectal polyps

Marker

MUC1

MUC4

MUC17

MUC2

MUC5AC

Tn/STnMUC1

CA 19-9

Diagnosis
SSA/P vs.
HP
TA vs. HP
SSA/P vs.
TA
SSA/P vs.
HP
TA vs. HP
SSA/P vs.
TA
SSA/P vs.
HP
TA vs. HP
SSA/P vs.
TA
SSA/P vs.
HP
TA vs. HP
SSA/P vs.
TA
SSA/P vs.
HP
TA vs. HP
SSA/P vs.
TA
SSA/P vs.
HP
TA vs. HP
SSA/P vs.
TA
SSA/P vs.
HP

OR (95% CI)

p-value

AUC (95% CI)

Cutpoint

Sensitivity

Specificity

0.411 (0.156, 1.084)

0.072

0.6772 (0.5531, 0.8012)

<=0.30

0.487

0.848

2.626 (0.987, 6.983)

0.053

0.6515 (0.5201, 0.7830)

>=1.0

0.583

0.727

0.188 (0.069, 0.509)

0.001

0.7639 (0.6545, 0.8733)

<=0.60

0.744

0.722

0.324 (0.160, 0.657)

0.0018

0.7257 (0.6089, 0.8425)

<=1.2

0.615

0.697

0.417 (0.206, 0.842)

0.015

0.6692 (0.5422, 0.7962)

<=1.6

0.778

0.545

0.745 (0.395, 1.405)

0.36

0.5630 (0.4319, 0.6942)

<=1.2

0.615

0.5

14.376 (3.664, 56.41)

0.0001

0.7739 (0.6623, 0.8855)

>=0.8

0.667

0.909

2.292 (0.588, 8.929)

0.23

0.5560 (0.4174, 0.6946)

>=0.4

0.611

0.606

5.990 (1.955, 18.346)

0.0017

0.7222 (0.6047, 0.8397)

>=0.80

0.667

0.778

0.530 (0.210, 1.337)

0.18

0.5960 (0.4640, 0.7279)

<=1.8

0.513

0.727

0.244 (0.111, 0.535)

0.0004

0.7546 (0.6421, 0.8672)

<=1.2

0.5

0.909

3.288 (1.573, 6.873)

0.0016

0.6991 (0.5765, 0.8216)

>=1.60

0.718

0.583

9.112 (2.912, 28.51)

0.0001

0.7995 (0.6947, 0.9043)

>=0.9

0.769

0.727

0.194 (0.057, 0.660)

0.0087

0.8018 (0.6934, 0.9101)

<=0.3

0.778

0.697

21.755 (5.985, 79.078)

<0.0001

0.9081 (0.8320, 0.9842)

>=0.60

0.923

0.806

0.870 (0.317, 2.390)

0.79

0.5085 (0.3756, 0.6415)

<=0.8

0.179

0.939

0.294 (0.100, 0.866)

0.026

0.6620 (0.5337, 0.7904)

<=1.0

0.444

0.909

2.472 (1.016, 6.016)

0.046

0.6353 (0.5095, 0.7611)

>=1.2

0.795

0.444

1.279 (0.746, 2.194)

0.37

0.5287 (0.3907, 0.6668)

>2.1

0.333

0.606

216

TA vs. HP
SP/A vs.
TA

0.014 (<0.001, 0.214)

0.0021

0.8948 (0.8110, 0.9786)

<=0.3

0.888

0.818

54.383 (6.489, 455.7)

0.0002

0.9551 (0.9095, 1.0000)

>=0.80

0.872

1

Abbreviations: HP, Hyperplastic polyps; SSA/P, Sessile serrated adenoma/polyp; TA, Tubular adenoma; OR, Odds ratio;
AUC, Area under curve; CI, Confidence of interval
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Table 6.4: Multivariate logistic regression and ROC curve analysis for mucins and associated glycans as biomarkers to discriminate different
colorectal polyps

Diagnosis
SSA/P vs. HP
TA vs. HP
SSA/P vs. TA

Comparison
MUC17+MUC5AC
CA19-9
MUC1+MUC17+CA19-9

AUC
0.865
0.8948
0.9868

AUC 95% CI
Lower Upper
0.776
0.954
0.811 0.9786
0.97
1

Threshold
P(SP)>= 0.4928
CA19-9<=0.3
P(SPT)>=0.385

Sensitivity
0.846
0.888
0.923

Specificity
0.818
0.818
0.972

To calculate P (SP) uses the formula: P (SP) = 1/(1+exp[-(-2.7740 + 2.2098*MUC17+ 1.7847*MUC5AC)])
To calculate P (SPT) use the formula: P (SPT) = 1/(1+exp[-(-1.1109 -3.6250*MUC1 +2.7928*MUC17+3.6299*CA19-9)])

Abbreviations: HP, Hyperplastic polyps; SSA/P, Sessile serrated adenoma/polyp; TA, Tubular adenoma; OR, Odds ratio; AUC, Area under curve; CI,
Confidence of interval
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Supplementary Table 6.1: Localization pattern of different mucins and associated glycan
epitopes in normal colon and different colorectal polyp subtypes

MUC1

MUC4

Normal
Cytoplasmic

HP
Cytoplasmic

Cytoplasmic,
Throughout the
crypt, absent on
luminal surface
epithelium

Cytoplasmic,
Throughout the
crypt and present on
luminal surface
epithelium

MUC17

Cytoplasmic and
granular

MUC2

Goblet cells

Cytoplasmic and
granular
Goblet cells and
Cytoplasmic

SSA/P
Cytoplasmic
Cytoplasmic,
Throughout the
crypt and on
luminal surface
epithelium (70%
cases), in lower one
third of crypt (30%
cases)
Cytoplasmic and
granular
Goblet cells and
Cytoplasmic

TA
Cytoplasmic

Goblet cells

Cytoplasmic,
Throughout the
crypt and luminal
surface epithelium

Cytoplasmic and
granular
Goblet cells and
Cytoplasmic

MUC5AC

Absent

Goblet cells

Goblet cells and
Cytoplasmic

CA 19-9

Absent

Goblet cells and
Cytoplasmic

Goblet cells and
Cytoplasmic

Goblet cells and
Cytoplasmic

Tn/STnMUC1

Cytoplasmic and
granular

Cytoplasmic and
granular

Cytoplasmic and
granular

Cytoplasmic and
granular

Abbreviations: HP, Hyperplastic polyps; SSA/Ps, Sessile serrated adenoma/Polyps; TA, Tubular
adenoma
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1. Summary and Conclusions
Mucins are the high molecular weight glycoproteins expressed by various epithelial cell types to
protect them from fluctuations in molecular compositions associated with harsh and complex
environments under physiological and pathological conditions [1]. By playing a central role in the
maintenance of homeostasis, mucins promote cell survival under diverse conditions [1]. One such
condition is cancer where dysregulation of mucins is implicated in growth, invasion, and
metastasis by configuring the inhospitable conditions of the tumor microenvironment [2]. Both
the membrane-bound and secretory mucins are differentially expressed and functionally involved
in multiple malignancies [3]. Consequently, mucins have been identified as potential diagnostic
markers and therapeutic targets in cancer [3]. Over the years, our lab has made research efforts to
comprehend the expression profile, regulation, and functional significance of mucins in
pancreatic and colorectal cancer with an objective to exploit their potential in early stage
diagnosis and therapy of these malignancies [4-8]. Previous studies have shown that secretory
mucin MUC5AC is overexpressed in pancreatic cancer (PC) [9] and colorectal cancer (CRC)
[10]. Since MUC5AC was one of the top most differentially expressed gene in PC compared with
normal pancreas [11], we explored the role of MUC5AC during PC onset and progression with an
objective to recognize MUC5AC as a therapeutic target for PC. Further, considering differential
overexpression of MUC5AC in precursor lesions of CRC [12] along with its secretory nature we
were interested in investigating whether differential expression of MUC5AC, other mucins, and
associated glycoepitopes can discriminate premalignant/malignant lesions of the colon from
benign polyps. Hence in this dissertation, we explored the MUC5AC associated functional
implications and their mechanistic basis during the initiation and progression of PC using in vitro
and in vivo models. Further, we comprehensively explored the potential utility of MUC5AC,
other differentially expressed mucins, and associated glycoepitopes to predict premalignant
lesions and colorectal malignancy. Overall, to elucidate the role of MUC5AC in pancreatic and
colorectal cancer the study was divided into four main parts: 1) Functional and mechanistic
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implications of MUC5AC in PC, 2) Impact of loss of Muc5ac expression in onset and
progression of PC utilizing the KrasG12D; Pdx1-Cre; Muc5ac-/- mouse model, 3) Mucins and
associated glycan signatures in colon adenoma-carcinoma sequence: prospective pathological
implication(s) for early diagnosis of colon cancer, 4) Combinatorial assessment of CA 199/MUC17/MUC5AC expression for discriminating sessile serrated adenoma/polyps and tubular
adenoma from hyperplastic polyps.
1) Functional and mechanistic implications of MUC5AC in PC
PC remains the most lethal malignancy despite continuous research efforts over the past decades
[13]. Research studies have continuously focused on identifying and validating different
molecules for the early diagnosis and treatment of PC. However, PC remains to be a devastating
disease underscoring poor understanding and lack of complete knowledge about the biological
and molecular processes involved in the initiation and progression of this deadly malignancy.
Therefore, to develop a more in-depth understanding of the various signaling pathways
deregulated in PC, advancement of studies to elucidate roles of newer molecules is necessitated.
Mucins are universally recognized as key components that are deregulated in cancer and have
been identified as biomarkers or molecular targets for the treatment of PC [3]. Interestingly,
secretory mucin MUC5AC was observed to be one of the top most differentially expressed genes
in PC when compared to the normal pancreas [11]. Overexpression of MUC5AC was reported to
be associated with poor prognosis of PC patients [9]. Few in vitro, in vivo studies also highlighted
the role of MUC5AC in pancreatic tumor growth and metastasis. However, the mechanistic basis
of MUC5AC functioning remained unexplored. In light of these observations, we proposed that
MUC5AC might have a significant role in the progression of PC. We sought to characterize this
mucin in PC with an objective to contribute towards better understanding of the disease and
developing therapeutic modalities.
In this context, I could provide further experimental evidence that MUC5AC is not detected
in the normal pancreas while it is significantly overexpressed in PC. Looking at these
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observations, I could conclude that overexpressed MUC5AC may play an important role in the
progression of PC. For further functional characterization, I identified PC cell lines that
endogenously express MUC5AC. I performed knockdown of MUC5AC in two PC cell lines
(FG/COLO357 and SW1990). My findings using these cell line models show that MUC5AC is a
critical player in facilitating PC cell proliferation, chemoresistance, migration, and angiogenesis.
Decreased expression of MUC5AC resulted in the impaired viability of PC cells, significantly
decreased anchorage-independent growth, and increased apoptosis. The impact of MUC5AC on
cell proliferation was further validated by cell cycle analysis assay. My study emphasizes the
novel role of MUC5AC in significantly faster progression of the cell cycle through G1/S phase.
Mechanistically, I observed increased expression of cell cycle inhibitor p27 and decreased
expression of G1/S phase regulatory proteins Cyclin-D1 and Cyclin-E on knockdown of
MUC5AC.
One of the problems associated with PC is early stage metastasis to distant locations. As
MUC5AC is expressed at early stages of PC, we wanted to explore whether overexpressed
MUC5AC can impact migration and adhesive properties to extracellular matrix proteins. In my
observations, significant reduction in the migratory potential of PC cells was observed on
knockdown of MUC5AC. Interestingly, MUC5AC positive cells revealed a significantly higher
tendency to adhere to Matrigel, advocating the role of MUC5AC in the metastatic process.
Mechanistically, I observed increased expression of epithelial marker E-Cadherin upon
MUC5AC knockdown. As a recent study highlighted the role of MUC5AC in regulating
expression of integrins in lung cancer, I also investigated the impact of MUC5AC on the
expression of integrins. I observed a downregulation of αV-, β5-integrin on knockdown of
MUC5AC. As β5-integrin is known to mediate its effects through Src-FAK signaling, I
investigated the impact of MUC5AC knockdown on phosphorylation of Src kinase. Interestingly,
knockdown of MUC5AC decreases phosphorylation of Src-(Y416). It has been speculated that
that MUC5AC may impact localization of E-Cadherin to cell membrane and by colocalizing with
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E-Cadherin, MUC5AC and MUC1 may modulate E-Cadherin function. In light of these studies, I
hypothesized that MUC5AC may physically interact with E-Cadherin. Interestingly, my
immunoprecipitation experiments revealed the interaction between MUC5AC and E-Cadherin.
Moreover, I could also observe an interaction of MUC5AC with β-Catenin and Src. Looking at
these observations, I conclude that by its interactions with E-Cadherin/β-Catenin complex
MUC5AC may impact PC cell growth and metastasis. However, this conclusion warrants further
comprehensive experimental validation.
Angiogenesis is one of the most important factor associated with growth and metastasis
of different cancers. Previous studies showed MUC5AC mediated impact on phosphorylation of
VEGFR-1. Therefore, impacts of MUC5AC knockdown were explored on angiogenesis process.
Knockdown of MUC5AC decreases mRNA levels of VEGF-A, significantly decreases
endothelial cell viability and endothelial tube formation capacity, quantified as percentage vessels
area and a total number of endothelial tube junctions formed. From these observations, I assume
that MUC5AC assist metastasis of PC cells through increased angiogenesis. To further
investigate the impact of MUC5AC on metastasis in vivo, we utilized an orthotopic model of PC.
In this experiment, I observed a significantly high pancreatic tumor size/weight and number of
metastases to distant organs in mice orthotopically injected with MUC5AC expressing cells. In
conclusion, using various biochemical and functional assays, we report for the first time a novel
cell cycle and metastasis-associated role of MUC5AC in PC.
It has been speculated that polymeric secretory mucins like MUC5AC may form a layer
over cell surface and hinder the effective targeting of therapeutics. In a recent study from our lab,
it was shown that MUC5AC plays a critical role in cisplatin resistance of lung cancer cells.
Looking at my observations of MUC5AC mediated anti-apoptotic impact and above mentioned
studies, I tested the hypothesis that MUC5AC may play an important role in resisting the antiproliferative impact of chemotherapeutic drug-Gemcitabine. Interestingly, I observed that
decreased expression of MUC5AC sensitizes PC cells to Gemcitabine. A dose dependent
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significant decrease in PC cell viability was observed in MUC5AC knockdown cells on treatment
with Gemcitabine. Further, there was a significant increase in apoptosis and necrosis in
Gemcitabine-treated MUC5AC knockdown PC cells. Mechanistically, I observed increased
expression of apoptotic mediators Cyt-c, BAD, cleaved caspase-3 and cleaved caspase-9 in
cytoplasmic extracts form MUC5AC knockdown PC cells. Further, reactivation of Wnt/β-Catenin
signaling in Gemcitabine-resistant cancer-cells has previously been demonstrated. WNT/βCatenin signaling coordinates cancer stem cell state. It has been reported that GLI mediated
increased MUC5AC expression mediates nuclear accumulation of β-Catenin in the nucleus.
Therefore, I tested the hypothesis that MUC5AC mediated increased nuclear translocation of βCatenin may enrich the stem cell population in Gemcitabine-resistant PC cells. Interestingly, I
observed a significant decrease in nuclear translocation of β-Catenin in Gemcitabine treated
MUC5AC knockdown cells. Further evaluation of stem cell markers revealed a significant
reduction in expression of ESA, SHH, SOX2 and OCT3/4 in Gemcitabine-treated MUC5AC
knockdown PC cells.
In totality, the first objective of my dissertation shows that MUC5AC plays a critical role
in PC progression and MUC5AC can be identified as an important therapeutic target. In light of
these observations, I wanted to explore further the tumor enhancing role of MUC5AC PC
spontaneous mouse model.
2) Impact of loss of Muc5ac expression in onset and progression of PC utilizing the
KrasG12D; Pdx1-Cre; Muc5ac-/- mouse model
Development of genetically engineered mouse models (GEMM) of PC has been one of the most
progressive steps taken towards a better understanding of the pancreatic carcinogenesis process
and the underlying mechanisms. As early identification remains the key to effective management
of PC, the mice models provide a system to study the role of differentially expressed genes during
initiation and progression of PC. Similar to humans, where MUC5AC is overexpressed during PC
progression, a recent study in our lab demonstrated expression of mucins Muc1, Muc4 and
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Muc5ac in KRasG12D; Pdx1-Cre (KC) mouse model of PC. Expression of Muc5ac in the pancreas
of KC mice was observed as early as 10 weeks of age, and it further increased with progression.
Therefore, for functional and mechanistic characterization of Muc5ac under in vivo conditions,
we acquired the Muc5ac knockout mice, and I developed the KRasG12D; Pdx1-Cre; Muc5ac-/- mice
model by breeding Muc5ac-/- mice with KC mice.
Interestingly, I observed a consistent decrease in pancreas weight and a high percentage
of the normal pancreas in KCMuc5ac-/- mice compared to KCMuc5ac+/+ mice. Further, on
individual analysis of pancreatic intraepithelial neoplasia (PanIN) lesions, I observed reduced
number of PanIN-1 (p<0.01) and PanIN-2 lesions at the 10th week of age in KCMuc5ac-/- mice
compared to KCMuc5ac+/+ mice, suggesting the critical role of Muc5ac in the onset of PC.
Additionally, decreased number of high-grade PanIN-3 lesions at 20th, 30th, 40th (p<0.01) and 50th
(p<0.01) weeks of age in KCMuc5ac-/- mice and a significant reduction in the number of nuclei
staining positive for Ki-67 in KCMuc5ac-/- mice pancreas clearly established an important role of
Muc5ac in the progression of PC. Therefore, I provide the first evidence that Kras mutation
mediated upregulation of Muc5ac during PC, plays a critical role in the onset and progression of
PC, and loss of Muc5ac may provide a survival benefit to PC patients.
3) Mucins and associated glycan signatures in colon adenoma-carcinoma sequence:
prospective pathological implication(s) for early diagnosis of colon cancer
CRC is the third most common cancer in both men and women and the second leading cause of
cancer deaths in the US. The advanced stages of CRC have a worst outcome with 5-year survival
being 13%. Ironically, only 40% of CRCs are diagnosed at early stages, due to the underuse of
screening modalities. Thus, development of biomarkers that detect early stage resectable
premalignant lesions of the colon can provide critical aid in the prevention of this malignancy. In
this context, various inflammatory, benign (hyperplastic polyps), premalignant (adenomas), and
malignant conditions of the colon are associated with alterations in mucin expression,
organization, and glycosylation. Some previous evidence advocated the utility of differential
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mucin expression to predict malignant transformation of colon pre-neoplastic lesions. Therefore,
in this study, I investigated the combined expression of various mucins and mucin-associated
glycans during the adenoma-carcinoma sequence of colon cancer progression with my objective
being evaluation of the applicability of mucins and associated glycoepitopes as markers for
differentiating adenomas/adenocarcinomas from benign hyperplastic polyps.
Interestingly, by immunohistochemical analysis on colon disease array having samples of
normal colon, inflammed colon, hyperplastic polyps, different adenomas and colon
adenocarcinoma, I found significant alterations in expressions of mucins MUC2, MUC4,
MUC5AC, MUC17, and glycan epitope Tn/STn-MUC1 during adenoma-carcinoma sequential
progression. After analyzing the individual efficacy of these differentially expressed mucins and
glycans for early-stage prediction of colon carcinogenesis, I also explored the combinatorial
efficacy of these markers for early-stage prediction of colon carcinogenesis. I could demonstrate
that a combination of MUC2, MUC5AC, and MUC17 may indicate the likelihood of a colon
lesion being premalignant and/or malignant versus benign hyperplastic polyp. Looking at the
promising results from this study, we further extended our work to determine the expression
profile of mucin and associated glycans in colon cancer precursor lesions-sessile serrated
adenomas/polyp (SSA/P) and tubular adenoma (TA) and evaluated their efficacy to discriminate
from benign hyperplastic polyps (HP).
4) Combinatorial assessment of CA 19-9/MUC17/MUC5AC expression discriminates sessile
serrated adenoma/polyps and tubular adenoma from hyperplastic polyps
The multistep process of histologically and molecularly heterogeneous colorectal carcinogenesis
is known to proceed via the most common “adenoma–carcinoma” pathway and the recently
identified “serrated polyp-neoplasia” pathway. Evidence suggests that neoplastic progression with
the serrated neoplasia pathway is faster than the classical adenoma-carcinoma sequence. Failure
to identify sessile serrated adenoma/polyp (SSA/P), due to inconsistent pathological diagnosis
and dearth of the molecular markers to discriminate them from hyperplastic polyp (HP), results in

231

misdiagnosis causing suboptimal surveillance and colonoscopy interval cancers. My previous
study established the combinatorial efficacy of mucins and associated glycoepitopes to
discriminate premalignant/malignant lesions of the colon from benign polyps (HP). Further, in
this study, I aimed to address the “gray zone” in differentiating SSA/Ps from other polyp subtypes
due to shared morphologic features (leading to the inter-observer variability among pathologists),
and current non-availability of specific and sensitive markers.
I could demonstrate that a combinatorial panel of molecular markers CA 199/MUC17/MUC5AC could discriminate SSA/P, TA and HP with high sensitivity and specificity.
My findings hold immense translational relevance as when employed in conjunction with gold
standard colonoscopy; it would help clinicians for accurate diagnosis, management of colorectal
polyps and may aid them in devising the personalized colon cancer screening recommendations.
2. Future directions
1. Elucidate the factors responsible for the upregulation of MUC5AC at early stage of PC
A better understanding of the etiology and early developmental events of PC requires serious
attention. Recurrent pancreatic injuries due to multiple factors induce a pro-inflammatory milieu.
The various types of immune cells release different cytokines, chemokines, and growth factors
leading to prolonged/chronic inflammatory conditions. Extensive studies conducted in last decade
highlighted the role of different cytokines, chemokines, and growth factors in the regulation of
MUC5AC expression specifically in the context of inflammatory airway diseases. It has been
shown that de novo expression of MUC5AC is an early event in PC progression. Further, I
showed that MUC5AC plays a significant role in PC cell growth, migration, angiogenesis, and
resistance to Gemcitabine. Therefore, to devise strategies for early stage modulation of MUC5AC
overexpression during PC, it is important to elucidate different inflammatory factors at an early
stage of PC that might be responsible for increased MUC5AC expression. A better understanding
of the inflammatory factors regulating MUC5AC expression in PC would help to identify novel
molecular targets and better therapeutic intervention for this lethal malignancy.
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2. Elucidation of MUC5AC domain that interacts with E-Cadherin and β-Catenin
It has been speculated that GLI1 mediated upregulation of MUC5AC may interfere with
membrane localization of E-Cadherin resulting in increased nuclear translocation of β-Catenin
mediated enhanced migration and proliferation of PC cells. Besides this, colocalization of MUC1
and MUC5AC with E-Cadherin was assumed to be related to loss of E-Cadherin function. On the
basis of these studies, we hypothesized that MUC5AC may physically interact with E-Cadherin
and β-Catenin to modulate its functions. In this dissertation, I have shown that by physically
interacting with E-Cadherin and β-Catenin MUC5AC may impact PC cell growth and metastasis.
By deciphering the exact domain of MUC5AC that interacts with E-Cadherin and β-Catenin,
strategies can be devised to hinder this association therapeutically for modulation of PC cell
growth and metastasis. I anticipate that MUC5AC hinders stabilization of E-Cadherin on plasma
membrane due to the formation of polymeric gel layer on the cell surface. Therefore, strategies to
break these polymeric gels might prove beneficial for proper assembly of E-Cadherin on plasma
membrane, inhibiting nuclear localization of β-Catenin, thus inhibiting growth and migratory
properties of PC cells.
3. To elucidate the impact of Muc5ac on pancreatitis and acinar to ductal metaplasia
Lack of early stage diagnostic markers and metastasis to distant locations by the time of diagnosis
makes PC one of the most lethal malignancies. The current research efforts in PC field are trying
to identify markers that can be utilized for early stage diagnosis and can simultaneously be
targeted to combat this disease. Pancreatitis is considered one of the most prominent risk factor of
PC. Previous studies have shown strong expression of MUC5AC in pancreatitis cases. Recent
studies identified production of Muc5ac along with enhanced BrdU incorporation in pancreatic
duct glands in a mice model of diabetes and pancreatitis. Data from our lab suggests increased
Muc5ac expression in cerulein-induced KC mice model of pancreatitis. In this dissertation, I have
shown that Muc5ac plays a major role in the initiation of PC. Therefore, based on above
mentioned studies, I anticipate that pancreatitis patients with increased MUC5AC expression may
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progress faster to PC. Hence, I propose a future investigation of Muc5ac roles in pancreatitis
along with the onset of acinar to ductal metaplasia and thus PC, utilizing the cerulein-induced KC
mice model of pancreatitis in presence and absence of Muc5ac.
4. To elucidate the impact of Muc5ac on neutrophil infiltration during PC progression
A hallmark of pancreatic ductal adenocarcinoma is the fibro-inflammatory microenvironment that
consists of extracellular matrix proteins, activated pancreatic stellate cells, and a variety of
inflammatory cells, such as T-cells, macrophages, or neutrophils [14]. The interaction between
cancer cells and inflammatory cells plays a critical role in the initiation and progression of cancer;
however, this interaction has not been systematically investigated in pancreatic neoplasia [15].
Infiltration of neutrophils has been associated with the promotion of aggressive tumor growth and
increased metastatic potential [16]. A recent meta-analysis suggests that PC patients with
elevated neutrophil to lymphocyte ratio (NLR) have shorter overall survival [17]. In this
dissertation, I showed that knockout of Muc5ac in PC progression mice model delays the
initiation and progression of PC. Several factors may impact the tumor-infiltrating neutrophils
within the tumor. Interestingly, previous studies utilizing Muc5ac-/- mice model in the context of
airway pathologies, have demonstrated impact of Muc5ac on the infiltration of inflammatory
mediators such as neutrophils. Based on these studies, and my observations in this dissertation,
I propose further investigation of Muc5ac mediated impact on neutrophils and T-lymphocytes
infiltration along with underlying mechanistic basis, utilizing the KCMuc5ac+/+ and
KCMuc5ac-/- PC mice models.
5. Validation of the CA 19-9/MUC17/MUC5AC panel in a diverse set of colorectal polyp
subtypes
From our study, we could clearly establish that expression of mucins and associated
glycoepitopes can be utilized for efficient discrimination of SSA/P and TA from HP. However,
our study was limited by a smaller sample size, lack of further subtypes in each polyp category,
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lack of adenomas with different grades of dysplasia, and lack of information regarding mutational
profiles of these samples. A subtype of HP- microvesicular hyperplastic polyps that have similar
histologic and molecular features to SSA/P has been pointed out to be the potential colorectal
carcinoma precursor [18]. This necessitates immediate attention as to date malignant potential of
HP was not indicated. Therefore, future studies should first focus on employing the combinatorial
panels from our study, on a larger set of colorectal polyp subtypes in a blinded manner so that a
validation of current findings can be made. Further efforts should also focus to elucidate markers
that can discriminate micro-vesicular HP from SSA/Ps, colorectal polyp subtypes with varying
degree of dysplasia, anatomical location, and recurrence after prior polypectomy. Findings from
these future studies could help circumvent the current challenges with histopathological
classification and nomenclature of colon polyps that are ambiguous, lack consensus and
demonstrate high interobserver variability.
6. Development of CRC-specific glycopeptide microarrays with an objective to identify
polyps with malignant potential
Diagnosis of a polyp type that would progress to cancer is one of the biggest challenges faced by
pathologists. This necessitates identification of highly specific and sensitive markers that can
efficiently discriminate the early stage precursor lesions of colon cancer from benign polyps.
Cancer-associated posttranslational modifications frequently produce aberrant O-linked
glycoproteins and these aberrant O-linked glycoproteins in combination with protein backbone
induce autoantibodies [19]. Mucins are known to be aberrantly glycosylated during cancer. One
recent study reported cancer-associated autoantibodies to a set of aberrant glycopeptide derived
from mucin MUC1 and MUC4 in the serum of patients with CRC [19]. Looking at this, future
research efforts could focus on identification of CRC-specific glycan epitopes on differentially
expressed mucins (MUC1, MUC2, MUC4, MUC5AC, and MUC17). The information gained can
be utilized for developing CRC-specific glycopeptide microarrays for seromic profiling of
patients with colon polyps with an objective to identify polyps with malignant potential. This can
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also be utilized for effective monitoring of the patients during colonoscopy interval period.
7. Elucidate the mechanisms associated with upregulation of MUC5AC and its role in
pathogenesis of CRC
Expression of MUC5AC is not detected in the normal colon while it is significantly
overexpressed during adenoma-carcinoma sequence [20]. Interestingly, expression of MUC5AC
was strongly associated with carcinogenic features via the serrated neoplasia pathway, including
CIMP positivity, BRAFp.V600E mutation and increased tumor-stage [12, 21]. Despite all these
information, none of the studies to date explored the role of MUC5AC and associated
mechanisms in CRC. Therefore, future efforts should focus to elucidate the currently unexplored
roles of secretory mucin MUC5AC in the pathogenesis of CRC. This will firmly establish the
utility of MUC5AC as a marker for assessment of the malignant potential of polyps. Also,
investigation of molecular mechanisms associated with upregulation of MUC5AC in SSA/P may
further help in devising novel therapies targeting these precancerous lesions.
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